

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Macrophage polarization by potential nutraceutical compounds: A strategic approach to counteract inflammation in atherosclerosis

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1849904> since 2023-07-25T10:07:56Z

Published version:

DOI:10.1016/j.freeradbiomed.2022.02.010

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Free Radical Biology and Medicine

Macrophage polarization by potential nutraceutical compounds: a strategic approach to counteract inflammation in atherosclerosis.

--Manuscript Draft--

Manuscript Number:	FRBM-D-21-01901R1
Article Type:	Review Article
Section/Category:	Review Article
Keywords:	atherosclerosis, inflammation, oxidative stress, macrophage polarization, nutraceuticals, lipid homeostasis
Corresponding Author:	Gabriella Leonarduzzi University Orbassano, Italy
First Author:	Barbara Sottero
Order of Authors:	Barbara Sottero Gabriella Testa Paola Gamba Erica Staurengi Serena Giannelli Gabriella Leonarduzzi
Abstract:	<p>Chronic inflammation represents a main event in the onset and progression of atherosclerosis and is closely associated with oxidative stress in a sort of vicious circle that amplifies and sustains all stages of the disease. Key players of atherosclerosis are monocytes/macrophages. According to their pro- or anti-inflammatory phenotype and biological function, lesional macrophages can release various mediators and enzymes, which in turn contribute to plaque progression and destabilization or, alternatively, lead to its resolution. Among the factors connected to atherosclerotic disease, lipid species carried by low density lipoproteins and pro-oxidant stimuli strongly promote inflammatory events in the vasculature, also by modulating the macrophage phenotyping. Therapies specifically aimed to balance macrophage inflammatory state are increasingly considered as powerful tools to counteract plaque formation and destabilization. In this connection, several molecules of natural origin have been recognized to be active mediators of diverse metabolic and signaling pathways regulating lipid homeostasis, redox state, and inflammation; they are, thus, considered as promising candidates to modulate macrophage responsiveness to pro-atherogenic stimuli. The current knowledge of the capability of nutraceuticals to target macrophage polarization and to counteract atherosclerotic lesion progression, based mainly on <i>in vitro</i> investigation, is summarized in the present review.</p>
Suggested Reviewers:	Gerard Lizard gerard.lizard@u-bourgogne.fr Giuseppe Valacchi giuseppe.valacchi@unife.it Monica Deiana mdeiana@unica.it Cesar Fraga cfraga@ffyb.uba.ar
Response to Reviewers:	

Prof Giovanni Mann
Editor
Free Radical Biology and Medicine

FRBM-D-21-01901: “Macrophage polarization by potential nutraceutical compounds: a strategic approach to counteract inflammation in atherosclerosis” (Sottero et al.)

Turin, January 27, 2022

Dear Prof Giovanni Mann,
we finally provide you with the revised version of the quoted manuscript, that includes the implements suggested by the referees.

Hereafter please find our point to point answers to the reviewer queries.

We thank the reviewers for the thoughtful review and helpful comments, which have guided the revision of the manuscript.

Reviewer #1:

1. The first part summarizing the mechanisms involved in macrophage polarization, is clearly presented and well-documented.

We thank the reviewer for his/her appreciation.

2. The second part focused on nutraceuticals is very interesting, but a bit messy in view of the large number of works related to the subject. Note however that the authors nicely summarize the effects of the compounds in Figure 2, which is of great help. It is preferable if the authors restructure the text by separating data observed in vitro (in cultured cells) and in vivo, in animal models for atherosclerosis.

We agree with the reviewer that usually, to improve the readability of a manuscript, it would be preferable to separate in different specific sections evidences arising from “in vitro” and from “in vivo” studies. Nevertheless, in our manuscript, data from animal model are very few compared to data from cultured cells (as highlighted at the end of “Introduction”), for this reason we have preferred to keep them together in the same section in order to harmonize as a whole the text.

3. Observations of nutraceutical effect on macrophage polarization in humans though discussed in the conclusion, could be highlighted in more detail with insights for future research.

We are aware that, as regards research that evaluates nutraceutical interventions on humans, the manuscript is not exhaustive. On the other hand, and considering the abundance of the relative literature, an in-depth overview of data about it goes beyond the purpose of our manuscript, which mainly focuses on biomolecular evidence arising from pre-clinical studies (as we have specified in the abstract and at the end of the Introduction.

Nevertheless, we agree with the reviewer that an improvement in this part can be informative, therefore we have added a new section (4. Nutraceutical approaches to the treatment of atherosclerosis: outcomes from human studies), in which we have considered those studies in humans that we think more interesting and pertinent to the topic of our review, and have furtherly commented them in the “Conclusions”.

Reviewer #2:

Specific points:

1. Ref. n. 1 (1993) is outdated, please substitute with a more recent ones

We have substituted this reference with a more recent one (O. Soehnlein, P. Libby, Targeting inflammation in atherosclerosis-from experimental insights to the clinic, Nat. Rev. Drug Discov. 20(8) (2021) 589-610).

2. Chapter 1 / Sections 1.1, 1.2: to improve readability, the general aspects of macrophage differentiation reported here could be usefully condensed and included (as introductory remarks) in the corresponding Chapter 2 / Sections 2.1, 2.2, thus helping to maintain the focus on the atherosclerotic process

Although this is a share opinion, the other reviewers have appreciated chapter 1 as it was in the original manuscript and for this reason we have preferred not to change it.

3. Chapter 3: a clearer title would be: “Modulation of ... by nutraceuticals”

As suggested by the reviewer, we have changed the title.

4. Conclusions: as this section is quite lengthy in its present form, may I suggest to change its title to “Concluding remarks and future perspectives

As suggested by the reviewer, we have changed the title.

Reviewer #3:

Specific comments:

1. Overall the scope of the review is appropriate and the thorough evaluation of the various and sometimes conflicting findings regarding the ability of micronutrients to alter macrophage inflammation and metabolism is commendable.

We thank the reviewer for his/her appreciation.

2. Figures and tables are clearly organized, readable, and appropriate to content of the review.

We thank the reviewer for his/her appreciation.

3. At times, the organization of the sections of the review was hard to follow, in particular the introduction of some (but not all) of the micronutrients/nutraceuticals in section 3, and the further mention of additional/different compounds in the following sections. Could the authors revise section 3 to ensure that all the compounds to be discussed in later sections are introduced?

In the present version all the compounds mentioned in section 3 have been included in its introductory part.

4. Likewise, it may strengthen the manuscript to reorganize the sections on 3.1 inflammation and 3.2 inflammasome/autophagy to bring observations/impact on similar pathways by different compounds together in one paragraph, to better compare/contrast the roles of these compounds in modulating these pathways. (Ex. in 3.2, discuss all inflammasome-related studies first, then the autophagy-related findings).

Undoubtedly, section 3 organization suggested by the reviewer is a reasonable alternative to our organization. However, since the main subject of the manuscript are micronutrients, we have preferred to organize the subsections according to the different class of compounds rather than to the different signaling pathways, for this reason we have kept the structure of the original manuscript.

5. Could the authors expand further in section 3.3 on the potential for micronutrients/nutraceuticals to exert atheroprotective effects through activation of NRF2-mediated oxidative stress pathways?

In all the section 3. we have further improved the data concerning the effects of micronutrients/nutraceuticals on NRF2 pathways and Fig. 2 was modified accordingly to it.

6. Sulforaphane from broccoli as Nrf2 activator is mentioned in the text but missing from tables, please add with relevant references.

We have added in the manuscript new references about sulforaphane and Fig. 1 and table 1 were modified accordingly to that.

7. Are there any studies that have evaluated the potential for any of the mentioned compounds to be atheroprotective in humans - i.e., are there any correlative studies that have identified specific compounds associated with atheroprotection in clinical trials?

We are aware that, as regards studies on humans, the manuscript is not exhaustive considering the abundance of literature about this topic. However, a more extensive overview goes beyond the purpose of our manuscript, that mainly focuses on pre-clinical studies (as we have specified in the abstract and at the end of the introduction).

Nevertheless, we have added a new section (4. Nutraceutical approaches to the treatment of atherosclerosis: outcomes from human studies) in which we have considered some human studies that can make more informative our manuscript. We have also improved the "Conclusion" by commenting them.

Minor comments:

In several places, RAW264.2 macrophages are referenced instead of RAW264.7 cell line.

We have checked the cell name in all manuscript and corrected it.

Readability could benefit from revision to improve syntax/flow- some sentences are overly long with multiple clauses joined together.

As suggested by the reviewer, we have modified some sentences to improve the readability of the manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Macrophage polarization by potential nutraceutical compounds: a strategic approach to counteract inflammation in atherosclerosis.

Barbara Sottero*, Gabriella Testa*, Paola Gamba, Erica Staurenghi, Serena Giannelli, Gabriella Leonarduzzi[§]

Department of Clinical and Biological Sciences, School of Medicine, University of Turin, Orbassano, Torino

*These authors contributed equally to this work.

§ Corresponding author: Department of Clinical and Biological Sciences, School of Medicine, University of Turin, San Luigi Hospital, 10043 Orbassano, Torino, Italy.

E-mail address: gabriella.leonarduzzi@unito.it (G. Leonarduzzi)

ABSTRACT: Chronic inflammation represents a main event in the onset and progression of atherosclerosis and is closely associated with oxidative stress in a sort of vicious circle that amplifies and sustains all stages of the disease. Key players of atherosclerosis are monocytes/macrophages. According to their pro- or anti-inflammatory phenotype and biological function, lesional macrophages can release various mediators and enzymes, which in turn contribute to plaque progression and destabilization or, alternatively, lead to its resolution. Among the factors connected to atherosclerotic disease, lipid species carried by low density lipoproteins and pro-oxidant stimuli strongly promote inflammatory events in the vasculature, also by modulating the macrophage phenotyping. Therapies specifically aimed to balance macrophage inflammatory state are increasingly considered as powerful tools to counteract plaque formation and destabilization. In this connection, several molecules of natural origin have been recognized to be active mediators of diverse metabolic and signaling pathways regulating lipid homeostasis, redox state, and inflammation; they are, thus, considered as promising candidates to modulate macrophage responsiveness to pro-atherogenic stimuli. The current knowledge of the capability of nutraceuticals to target macrophage polarization and to counteract atherosclerotic lesion progression, based mainly on *in vitro* investigation, is summarized in the present review.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

KEYWORDS: atherosclerosis, inflammation, oxidative stress, macrophage polarization, nutraceuticals, lipid homeostasis

Abbreviations

ABC: ATP-binding cassette transporter

AMPK: adenosine 5'-monophosphate-activated protein kinase

AP-1: activator protein-1

ASC: apoptosis-associated speck-like protein containing a CARD

ATF: AMP-dependent transcription factor-1

Atg: autophagy-related gene

CLA: conjugated linoleic acid

CK2: casein kinase 2

COX: cyclooxygenase

CREB: cAMP-responsive element-binding

CRP: C-reactive protein

CVD: cardiovascular disease

DHA: docosahexanoic acid

EGCG: epigallocatechin gallate

EPA: eicosapentenoic acid

ER: endoplasmic reticulum

ERK: extracellular signal-regulated kinase

FA: fatty acid

FOX: Forkhead box protein

GPR: G protein-coupled receptor

GSH: glutathione

Hb: hemoglobin

HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A

HIF1 α : hypoxia inducible factor 1 α

HO-1: heme oxygenase-1

IFN: interferon

IL: interleukin

1 iNOS: inducible nitric oxide synthase
2 IRF: interferon regulatory factor
3 JAK: Janus kinase
4 JNK: c-Jun N-terminal kinase
5 KLF: Kruppel-like factor
6 LA: linoleic acid
7 LDL: low density lipoprotein
8 LOX-1: lectin-like low-density lipoprotein receptor-1
9 LPS: lipopolysaccharides
10 LXR: liver X receptor
11 MAPK: mitogen-activated protein kinase
12 MCP1: monocyte chemotactic protein 1
13 miR: microRNA
14 MKP-1: MAPK phosphatase-1 NOX
15 MMP: metalloprotease
16 mTOR: mammalian target of rapamycin
17 MUFA: monounsaturated fatty acid
18 MyD88: myeloid differentiation 88
19 NF-κB: nuclear factor-κB
20 NLRP3: nucleotide-binding domain (NOD)-like receptor protein 3
21 NO: nitric oxide
22 NOX: NADPH oxidase
23 Nrf2: nuclear factor E2-related factor 2
24 oxLDL: oxidized LDL
25 PAMP: pathogen-associated molecular pattern
26 PBMC: peripheral blood monocyte
27 PGC: PPARγ-coactivator
28 PG: prostaglandin
29 PI3K: phosphoinositide 3-kinase
30 PMA: phorbol myristate acetate
31 PPAR: peroxisome proliferator-activated receptor
32 PPP: pentose phosphate pathway
33 PRR: pattern recognition receptor
34 PUFA: polyunsaturated fatty acid
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 ROS: reactive oxygen species
2 Rv: resolvin
3 RXR: retinoid X receptor
4
5 SIRT: sirtuin
6
7 SOCS: suppressor of the cytokine signaling
8
9 SOD: superoxide dismutase
10
11 SPM: specialized pro-resolving mediator
12
13 SREBP: sterol regulatory element binding protein
14
15 STAT: signal transducer and activator of transcription
16
17 TCA: tricarboxylic acid
18
19 TERT: telomerase reverse transcriptase
20
21 TGF β : transforming growth factor β
22
23 Th: T-helper lymphocyte
24
25 TLR: Toll-like receptor
26
27 TNF α : tumor necrosis factor α
28
29 UFA: unsaturated fatty acid
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

Atherosclerosis is a chronic inflammatory disorder affecting large and medium-sized arteries and is characterized by the subendothelial accumulation of lipid species carried by low density lipoproteins (LDLs) together with fibrotic tissue and cell debris. The formation of these deposits is the consequence of endothelial cell dysfunction that triggers a cascade of inflammatory reactions characterized by the continuous and uncontrollable transmigration of circulating immune cells into the vessel wall, giving rise to the atherosclerotic plaque. Key players of atherosclerosis are monocytes/macrophages that are provided with several tasks such as lipid and cellular debris clearance, orchestration of inflammatory response, and tissue repairing. As disease progresses, plaque macrophages engulf more and more lipids, transforming themselves into foam cells able to secrete inflammatory molecules and proteolytic factors, and to release reactive oxygen species (ROS). If the insult to the vasculature persists, the inflammatory response becomes chronic and plaque macrophages start displaying perturbed capability to migrate and phagocytize. As a consequence the

1 number of apoptotic/necrotic cells in the lesion core increases, leading to advanced plaque
2 vulnerability and, eventually, rupture. On the contrary, when noxious materials, including lipids and
3 necrotic debris, are efficiently removed, the inflammatory response can be reversed under the
4 modulation of protective factors and lesion regression occurs. Resident macrophages can, thus,
5 strongly participate to the resolution process by acquiring anti-inflammatory features and functions
6 [1,2].
7
8
9

10 Lipid accumulation represents a preeminent event in the atheroma development.
11 Hypercholesterolemia associated to high levels of the cholesterol-carrier LDLs is in fact a well-
12 recognized risk factor for atherosclerosis. In particular, oxidative modifications of these lipoproteins
13 favor their uptake by macrophages via specific scavenger receptors (e.g., SR-A, CD-36) and confer
14 pro-inflammatory properties on these particles, contributing significantly to the lesion lipid-rich
15 necrotic core expansion [3].
16
17
18
19

20 Macrophages are the most abundant immune cell type in atherosclerotic lesions whose expansion
21 they significantly contribute during all stages of the disease. In fact, they play prominent roles in
22 oxidized LDL (oxLDL) uptake and cholesterol accumulation, lesion matrix remodeling, cytokine
23 release, and clearance of dead cell debris [1,2].
24
25
26
27
28

29 Most recent advances regarding the macrophage dynamics in atherosclerosis point out the
30 complexity of lesional macrophage phenotype: it has been recognized that rather than a few distinct
31 populations, a broad spectrum of cell subsets could be present depending on the environmental
32 signals, including lipid and cholesterol loading, and that the balance among all these cell populations
33 directs plaque evolution [4]. According to this view, a growing consideration is being given to
34 therapeutic strategies specifically aimed at targeting the atherosclerotic macrophage phenotype, thus
35 promoting disease regression [5,6]. In this context, various molecules of natural origin may represent
36 an important opportunity. Thanks to their multiple activities as antioxidants, lipid-lowering agents,
37 and cell signaling modulators, they can likely be effective in counteracting lesion development and,
38 in particular, in regulating the macrophage inflammatory response [7,8].
39
40
41
42
43
44
45
46

47 The purpose of the present review is to provide the major current insights on the applicability of
48 natural compounds in the prevention and treatment of atherosclerosis, taking advantage of their
49 capability to affect macrophage polarization. In particular, we focus on basic research evidence that
50 elucidates the molecular mechanisms in support of beneficial effects of micronutrients as
51 nutraceuticals, principally focusing on macrophage cell models.
52
53
54
55
56
57

58 **1. Macrophage polarization: a general overview**

59
60
61
62
63
64
65

1 Macrophages are highly versatile cells able to adopt different functional programs in response to
2 the surrounding microenvironmental stimuli, a process known as macrophage polarization.
3 Classically, they are classified into two main cell phenotypes according to their state of activation: in
4 the presence of harmful stimuli they acquire the so-called M1 phenotype, which is able to promote
5 inflammation; conversely, they assume the alternative inflammation suppressing and reparative
6 phenotype M2 when the inflammatory response is no longer needed [9].

7
8
9
10 Although initially well accepted, more extensive *in vitro* and *ex vivo* studies have shown that this
11 bipolar M1/M2 classification does not accurately represent the macrophage diversity. In fact, M1 and
12 M2 are only the extremes of a broader spectrum of cell subpopulations, overlapping with each other
13 in terms of metabolic adaptation, gene expression, and function associated with a variety of
14 inflammatory, anti-inflammatory, and remodeling gene program. Noteworthy, these phenotypes are
15 transient and reversible consistently with milieu changes [9]. For instance, M2 macrophages have
16 been further classified into M2a, M2b, M2c, and M2d subgroups, according to the different stimuli
17 that activate them and to their protein production. Among them, M2a subgroup contributes to tissue
18 repair, M2b stands out for the production of both pro- and anti-inflammatory cytokines that regulate
19 immune cell functions, M2c exerts the strongest anti-inflammatory activity and is responsible for
20 phagocytosis and apoptotic cell clearance, and finally M2d has angiogenic properties [10].

31 32 33 *1.1. Cell signaling involved in macrophage polarization*

34
35
36 The inflammatory orientation of macrophages is under strict control by a variety of transcription
37 factors and coregulatory molecules.

38
39 Cytokines released by T-helper 1 (Th1) lymphocytes, such as interferon γ (IFN γ), interleukin-1 β
40 (IL-1 β), and tumor necrosis factor α (TNF α), but also pathogen-associated molecular patterns
41 (PAMPs) detected by pattern recognition receptors (PRRs), lipopolysaccharides (LPS) and
42 lipoproteins activate the M1 phenotype, or classically-activated macrophages, via involvement of the
43 signal transducer and activator of transcription (STAT) family member STAT1/2 [9,11,12]. Among
44 the inflammatory factors pointed to promote M1 differentiation rather than M2 is also included C-
45 reactive protein (CRP) [13]. Conversely, alternatively-activated M2 macrophages are activated by the
46 Th2-derived cytokines IL-4 and IL-13, or by other anti-inflammatory stimuli through STAT3 or
47 STAT6 modulation [9,12]. Nuclear transcription factors involved in lipid homeostasis, namely
48 peroxisome proliferator-activated receptor (PPAR)- γ and liver X receptors (LXRs), are also identified
49 as mediators in M2 anti-inflammatory phenotyping [14]. More in detail, M2a macrophages express
50 high levels of mannose receptors and respond to IL-4 and IL-13, M2b macrophages are activated by
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 immune complexes and Toll-like receptor (TLR) ligands or IL-1 receptor agonists, M2c macrophages
2 by IL-10 and glucocorticoids [15], and M2d macrophages by TLR-signals through the adenosine
3 receptor [16].
4

5 In response to their activation, M1 macrophages release ROS, nitric oxide (NO) via inducible
6 nitric oxide synthase (iNOS), as well as pro-inflammatory cytokines such as TNF α , IL-1 β , IL-12, and
7 IL-23, while all types of M2 macrophages produce anti-inflammatory cytokines and growth factors,
8 such as IL-10, IL-4 and transforming growth factor β (TGF β), and are angiogenic and pro-fibrotic
9 [10,12,17].
10
11
12
13
14
15

16 *1.2. Metabolic requirements associated to macrophage polarization*

17
18
19

20 Macrophages with M1 and M2 phenotypes significantly differ also for the metabolic
21 requirements necessary to sustain their specific activity: while M1 macrophages depend almost on
22 glucose uptake, glycolysis, and pentose phosphate pathway (PPP), bioenergetic supply in M2
23 macrophages is ensured mainly by oxidative phosphorylation and fatty acid (FA) oxidation [18,19].
24 On the other hand, metabolic shifts switched on by growth factors and nutrient availability can
25 themselves be the up-stream signals that control macrophage polarization. Overall, polarizing and
26 metabolic cues finely communicate with each other to coordinate the induction of different phenotype
27 activities and the metabolic processes needed to sustain them [17].
28
29
30
31
32
33

34 Metabolic signaling pathways activated by polarizing signals include Akt, mammalian target of
35 rapamycin (mTOR), and adenosine 5'-monophosphate-activated protein kinase (AMPK) [18]. **In fact,**
36 activation of the TANK-binding kinase/inhibitor of nuclear factor- κ B kinase/Akt pathway or of the
37 mTOR/Akt pathway drives to different glucose utilization in LPS- and IL-4-activated macrophages
38 [20,21]. The transcription factor hypoxia-inducible factor 1 α (HIF1 α) mediates the M1
39 reprogramming by LPS and hypoxia through up-regulation of genes involved in glycolysis [22],
40 whose metabolites **in turn** stabilize HIF1 α protein itself [23]. Induction of HIF1 α by mTOR also can
41 be responsible for shifts towards glycolytic reactions [24]. Conversely, the oxidative metabolism
42 typical for the anti-inflammatory phenotype is prompted by STAT6 and PPAR γ -coactivator (PGC)-
43 1 β in response to IL-4 [25], and by AMPK in response to IL-10 [26]. The tricarboxylic acid (TCA)
44 cycle and oxidative phosphorylation are enhanced by IL-4 macrophage activation by up-regulation
45 of genes linked to these routes too, as for example the sedoheptulose kinase carbohydrate kinase-like
46 protein (CARKL), which restricts the glucose flux through the PPP [27]. As a consequence, also
47 mitochondrial metabolism adjustment is associated to macrophage polarization [28]. By perturbing
48 the electron transport chain in mitochondria, both NO and ROS affect energetic supply and metabolic
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 profile of macrophages, accounting for the suppression of the oxidative phosphorylation and for the
2 switching to glycolytic commitments [18,29,30]. In particular, NO regulates the amount of the
3 catalytic Complex I subunits in murine macrophages and, besides that, the balance of succinate and
4 citrate, the key metabolites of TCA cycle [31]. In addition, ROS overproduction is promoted in
5 mitochondria of inflammatory macrophages by excessive glucose utilization and leads to
6 dimerization of the glycolytic enzyme pyruvate kinase M2 (PKM2), further sustaining glycolysis and
7 the PPP pathway [32]. Activation of NOTCH represents another mechanism to reprogram
8 mitochondrial metabolism in favor of glycolysis and glucose flux to the TCA cycle, thus contributing
9 to mitochondrial ROS generation and ROS-dependent induction of nuclear and mitochondrial M1
10 genes [33].
11
12
13
14
15
16
17
18
19

20 **2. Macrophage polarization in the atherosclerotic plaque**

21
22

23 Macrophage heterogeneity has been recognized in the context of atherosclerosis. Different
24 macrophage populations can originate in response to systemic factors circulating in the blood and to
25 local plaque-specific stimuli; the prevalence of some cell subsets on others can drive plaque evolution
26 and atherosclerosis outcome [34,10]. It has been observed that plaques from symptomatic patients
27 suffering from acute ischemic attack have indeed a greater concentration of M1 macrophages, while
28 M2 macrophages prevail in plaques from asymptomatic patients [35]. At least in mice models, M2
29 cells are more numerous in early lesions but they shift toward a M1 phenotype as lesion progresses
30 [36]. Moreover, pro-inflammatory macrophages are preferentially located on the rupture-prone
31 shoulders of the plaque, while there are no significant differences between cell subsets in the fibrous
32 caps [37].
33
34
35
36
37
38
39
40
41

42 In addition to the typical M1 and M2 classes, other macrophage subsets have been specifically
43 recognized in the atheroma (Fig. 1), whose proportion and distribution might reflect plaque
44 vulnerability [5,17].
45
46

47 Oxidative stress is undoubtedly one of the main promoter of atherosclerotic macrophage
48 polarization towards more inflammatory phenotypes: overproduction of oxidant species by
49 macrophages is not only a hallmark of their inflammatory adaptation, but it is also responsible for
50 LDL modification in more pro-atherogenic particles that can in turn trigger and sustain the
51 inflammatory response by the cells. Indeed, in mouse models of atherosclerosis, oxidized
52 phospholipids present in oxLDLs have been established to induce a subtype of macrophages with a
53 Mox phenotype. Compared to M1 and M2, Mox macrophages display reduced phagocytic and
54 chemotactic properties but express antioxidative and detoxifying genes, mainly regulated by the
55
56
57
58
59
60
61
62
63
64
65

1 nuclear factor E2-related factor 2 (Nrf2), which are fundamental for intracellular redox balance
2 maintenance [38].

3
4 A non-foam cell type of macrophages, termed as hemoglobin (Hb)-stimulated macrophage,
5 or M(Hb), was identified at hemorrhagic sites of human atherosclerotic lesions. Besides an enhanced
6 cholesterol efflux, they are characterized by a decrease in ROS production and by the expression of
7 anti-inflammatory factors such as IL-10 [39]. Heme also polarizes macrophages towards an
8 atheroprotective hemorrhage-mitigating phenotype, the Mhem subtype, which, by expressing heme
9 oxygenase-1 (HO-1), contributes to cholesterol efflux, Hb clearance via erythrocyte phagocytosis,
10 and oxidative stress reduction [40]. Finally, a very recent publication reported the macrophage
11 polarization towards a pro-atherogenic phenotype after cell exposure to ferrylHb, an oxidized form
12 of Hb commonly present in hemorrhagic atheromas as a consequence of damaged erythrocyte
13 accumulation. FerrylHb internalization by macrophages seems to lead to HO-1 up-regulation and iron
14 overloading within lysosomes. The event induces a transcriptome profile, distinct from that of native
15 Hb and overlapping with gene expression found in human complicated lesions; this gene profile is
16 associated with macrophage activation, inflammation, iron metabolism, apoptosis, and lipid transport,
17 and appears to be driven by activation of the phosphoinositide 3-kinase (PI3K)/HIF1 α pathway [41].

18
19 A further macrophage state, completely distinct from all the other known phenotypes, namely
20 M4, was described to be induced by the platelet chemokine CXCL4 and to lack phagocytosis capacity
21 but to possess pro-atherogenic properties, including the secretion of metalloprotease (MMP)-7 and
22 MMP-12 [42]. This subtype is predominantly present in the tunica adventitia and intima of coronary
23 arteries of patients with severe coronary artery disease [43].

2.1. *Cell signaling and metabolic requirements driving atherosclerotic macrophage polarization*

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Intra-plaque macrophages, in particular macrophage-derived foam cells, express several PRRs, including TLRs and scavenger receptors (e.g. CD36), and the intracellular PRR inflammasomes [44]. As M1-promoters, PRRs are implicated in the onset and progression of lesions: upon their activation by binding to a multitude of ligands, they trigger diverse signaling cascades in macrophages, resulting in the expression of pro-inflammatory proteins. Ligands of PRRs are PAMPs present in atherosclerotic plaques such as bacterial nucleic acids, peptidoglycans, and exogenous heat shock proteins (HSPs). Beside them, damage-associated molecular patterns (DAMPs), which include cholesterol crystals, oxLDLs, necrotic cell debris, and extracellular matrix components accumulating in growing lesions, also interact with PRRs [11,12]. In response to them, myeloid differentiation 88 (MyD88)-dependent and/or TIR-domain-containing adaptor protein inducing IFN β (TRIF)-

1 dependent pathways are triggered leading to TLR activation and final induction of transcription
2 factors such as interferon regulatory factors (IRFs), nuclear factor- κ B (NF- κ B), c-Jun, Forkhead Box
3 (FOX) O3a, and p53 [11,12]. For example, TLR4 is stimulated by saturated FAs and by minimally
4 modified LDLs via either MyD88-dependent or MyD88-independent/ROS-dependent mechanisms,
5 while oxLDLs stimulate TLR4/6 after binding to the scavenger receptor CD36 [11]; macrophage
6 activation by lysosomal damaging cholesterol crystals requires the involvement of the intracellular
7 nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome [45]; other factors
8 able to induce NLRP3 are ROS, oxLDLs, mitochondrial dysfunction, and endoplasmic reticulum
9 (ER) stress [46-48]. Upon NLRP3 activation, both apoptosis and pyroptosis, a caspase-dependent
10 form of cell death characterized by plasma membrane pore formation and intracellular content release
11 [49], occur contributing to the necrotic core formation [50].

12 Furthermore, the on-off switch of inflammasome can depend on autophagy, a process aimed
13 at eliminating intracellular macromolecules and aged/damaged organelles, and essential to maintain
14 cellular energy balance and nutritional status, including lipid availability. In particular, lipophagy,
15 namely the autophagic clearance of intracellular lipid materials, regulates cholesterol efflux from
16 macrophages by modulating the lysosomal acid lipase, which is responsible for the hydrolysis of
17 cholesteryl esters stored in the lipid droplets [51]. Autophagy is relevant in determining the
18 macrophage inflammatory state; indeed, its loss promotes systemic inflammation by polarizing
19 macrophages towards M1 cells at the expense of M2 cells [52], thus it is reasonable that it acts in the
20 same way in the plaque. In support of this, in ApoE-null mice macrophages autophagy was seen to
21 become dysfunctional with plaque progression, triggering inflammasome hyper-activation and IL-1 β
22 overproduction [53]. *In vitro* and *in vivo* studies pointed to the metabolic anti-inflammatory
23 PI3K/Akt/mTOR pathway being critical for autophagy execution by atherosclerotic macrophages
24 and, ultimately, for determining their differentiation [54,55]. Certain sirtuins (SIRTs), a class of
25 deacetylases involved in various physiological processes, including cell metabolism and cellular
26 response to stress, have also been reported to promote autophagy. This occurs through deacetylation
27 of autophagy-related nuclear and cytosolic factors, such as FOXO1, FOXO3, and autophagy-related
28 genes (Atgs), through involvement in rapamycin complex 1 (mTORC1)- and AMPK-dependent
29 signals, counteracting foam cell formation [56].

30 In addition, dysregulation of lipophagy accounts for inefficient removal of apoptotic cells by
31 efferocytosis, contributing to accumulation of toxic cell debris in the lesion core [57]. One of the main
32 regulators of the efferocytic machinery, which appears to be compromised in the lipid engulfed
33 macrophages, is Mer tyrosine kinase (MerTK). Activation of this kinase depends on NADPH oxidase
34 (NOX)-derived ROS and TLR4, and is promoted by oxidized polyunsaturated fatty acids (PUFAs)

1 [58,59]. Of note, efferocytosis presumably addresses macrophages to an anti-inflammatory
2 phenotype since its inhibition promotes IL-1 β , IL-6, and TNF α expression, but decreases IL-10 and
3 TGF β levels [60]. In addition, LXR signaling has been shown to be critical for a functional efferocytic
4 process [61]. A close relationship exists also between efferocytosis and the lipid mediators lipoxins,
5 resolvins (Rvs), protectins, and maresins; all these molecules favor a correct efferocytosis execution
6 contributing to pro-resolving macrophage skewing and quelling of inflammation [62]. In this
7 connection, biosynthesis of these lipid mediators appears higher in M2 compared to M1 macrophages,
8 where biosynthesis of pro-inflammatory autocooids prevails, demonstrating that different macrophage
9 subtypes are also characterized by a specific profile of endogenous lipid mediators [63].
10

11 Besides PRRs, other signal cascades have been suggested to drive macrophage polarization.
12 For example, NOTCH pathway promotes the activation of M1 macrophages in atherosclerotic
13 plaques [64], whereas its inhibition raises the secretion of IL-10 by M2-like population [65]. Members
14 of the transcription factor Kruppel-like factor (KLF) family can also underlie macrophage
15 differentiation: KLF4 promotes M2 polarization by inhibiting NF- κ B signaling, and likely cooperates
16 with STAT6 and PPAR γ , constituting an alternative axis for the anti-inflammatory transition [66].
17 Conversely, exposure to oxLDLs switches M2 macrophages to a pro-inflammatory M1 profile by
18 preventing the expression of KLF2 [67].
19

20 As regards the macrophage classes specifically present in the atherosclerotic plaque, Mox
21 differentiation by oxidized phospholipids depends on Nrf2 activation [38], M(Hb) differentiation
22 depends on haptoglobin-Hb complex formation [39], while Mhem differentiation occurs through
23 induction of activating cyclic AMP-dependent transcription factor-1 (ATF-1), which subsequently
24 induces both HO-1 and LXR β [40].
25

26 Moreover, polarization of atherosclerotic macrophages can be affected by dysfunctional
27 metabolism. Limited oxygen supply in the lesion leads to HIF1 α -dependent suppression of FA
28 oxidation and favors, instead, glucose metabolism and lipid accumulation, likely contributing to the
29 inflammatory activation of macrophages [68-70]. Furthermore, ROS overproduction through the
30 mitochondrial oxidative metabolism of foam cells causes mitochondrial damage and blockage of
31 oxidative phosphorylation, and consequently directs to M1 polarization [71].
32

33 **3. Modulation of atherosclerotic macrophage polarization by nutraceuticals**

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

to counteract the inflammatory boost that drives plaque progression, are gaining increasing consideration by the clinical community.

Given the importance of dietary habits for health, constituents of foods can offer a reliable support. It is well recognized that the consumption of fruits, vegetables, spices, nuts, fish, and olive oil is able to decrease atherosclerosis incidence, not only by regulating lipid levels but likely also by regulating other processes that contribute to atheroma development [8]. Indeed, the majority of these foods have a high content of bioactive compounds with proven antioxidant, cell signaling, and metabolic activity, which are thus strong candidates for the inhibition of the pro-inflammatory activation of immune cells and consequently for plaque stabilization and even regression [8]. Noteworthy, some advantages derive for the long-term use of natural origin molecules compared to synthetic drugs due to their more relative safety, fewer side effects, and greater efficacy. The list of potentially anti-atherogenic micronutrients includes polyphenols, carotenoids, terpenoids, unsaturated fatty acids (UFAs), and vitamins (Table 1).

Polyphenols are undoubtedly the most important and abundant phytochemicals in the human diet. They are classified in different subclasses, among which are flavonoids, phenolic acids, phenolic alcohols, stilbenes, and lignans; they are chemically characterized by the presence of one or more benzene rings joined to hydroxyl groups, which confers them with antioxidant capacity [72]. Among them are curcumin, isolated from the rhizomes of turmeric and present in the spice curcuma, resveratrol, the main polyphenol in wine, and the olive oil derivatives oleuropein, tyrosol and hydroxytyrosol, all of which have been extensively investigated in the contest of vascular pathology [8].

Other antioxidants of plant origin are carotenoids, a class of lipophilic pigments that comprises carotenes and xanthophylls, according to the presence or absence of oxygen groups, respectively. Lycopene, abundant in tomato, and β -carotene, present in green leafy vegetables, and in orange and yellow fruits and vegetables, are the most widespread carotenes in nature, whereas lutein, from crucifers and egg yolk, is the most common xanthophyll; all of them have been considered for their positive health outcomes. Noteworthy, carotenoids cannot be synthesized by most animals where they are substrates of the enzymatic cleavage that gives rise to vitamin A. The latter, in its active form (i.e. retinoic acid), is the ligand of the transcriptional factors retinoid X receptors (RXRs), fundamental for immune system differentiation and function, as well as for energy metabolism [73].

Olive oil and other vegetable oils provide monounsaturated fatty acids (MUFAs), also recognized to be beneficial for cardiovascular health [74].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Certain organosulfur compounds, such as allicin from garlic and sulforaphane from cruciferous vegetables and mustard, appear beneficial against cardiovascular diseases (CVD) by improving lipid metabolism and modulating crucial redox sensitive pathways [8,75].

Phytosterols are steroid compounds found in vegetable sources such as oils, nuts, fruits, and cereals. The family includes β -sitosterol, stigmasterol, campesterol, and brassicasterol. Thanks to their structure similarity to cholesterol, they have been considered to correct aberrations in cholesterol homeostasis [76].

Ginseng is another world-wide used herbal medicine potentially effective in the treatment of cardiovascular and, more generally, of metabolic diseases. Its anti-inflammatory activity relies principally on members of the saponin family, ginsenosides [77]. Another saponin of interest is diosgenin from fenugreek seeds and soy beans [78].

Berberine, an alkaloid extracted from the root, rhizome, and stem bark of many medicinally important plants, such as *Hydrastis canadensis* (goldenseal), *Coptis chinensis Franch* (Coptis orgoldentthread), *Berberis aquifolium* (Oregon grape), *Berberis vulgaris* (barberry), and *Berberis aristata* (tree turmeric), has been found to regulate lipid metabolism and homeostasis [79].

More recently, research attention focused on iridoids, which are secondary metabolites of alkaloid biosynthesis occurring in several plants and some animals. These monoterpenes are provided with anti-inflammatory and antioxidant properties [80].

Another promising natural compound is the diterpene tanshinone IIA, the main fat-soluble monomer component of the root of Danshen (*Salvia miltiorrhiza*), extensively used in traditional folk medicine for the treatment of cerebrovascular disease and CVD [81]

Although fruits and vegetables are preferentially recommended for healthy diets, foodstuffs of animal origin can be sources of bioactive molecules as well. Indeed, not only nuts and vegetable oils but also fish, fish oil, and animal fats are supplies of UFAs, which might be taken into account as potential valuable micronutrients. It is worth to be underlined, however, that ω -6 PUFAs also possess pro-inflammatory features, thus their consumption should be carefully considered [8,82]. Dietary intake of ω -3 and ω -6 PUFAs, many of which cannot be synthesized *in vivo* and therefore are called essential FAs, is determinant for the endogenous production of eicosanoid molecules involved in the inflammatory response. The major examples are the ω -3 eicosapentenoic acid (EPA) and its metabolite docosahexanoic acid (DHA). Besides the intake from fish such as salmon, herring, cod, and bluefish, minimal amount of EPA can also be provided by conversion in the body of the other essential ω -3 PUFA α -linolenic acid [82].

The carotenoid astaxanthin too is commonly found in seafood such as salmon, trout, fish eggs, and crustaceans, to which it confers the typical pink or red color [83].

1 In addition, eggs, fish, meat, and milk fat are sources of the lipophilic cholesterol-based vitamin
2 D (vit D). Of note, although vit D is commonly considered an essential micronutrient, its content in
3 foods is very low; thus, additional provision by means of supplements might be necessary to reach
4 the effective dose. Vit D, initially identified as a crucial hormone in the metabolism of bone calcium,
5 is now gaining growing consideration for its role in other physiopathological processes, including
6 lipid metabolism, oxidative stress, immune and inflammatory responses. For this reason, it has been
7 suggested as a coadjuvant in atherosclerosis treatment, but its real benefit is still questionable, since
8 pro-atherogenic consequences have also been reported for oral vit D intake over time, at least in
9 animal models [84,85].

10
11
12
13
14
15
16 The nervous system and skeletal muscles of mammals and poultry also store carnosine, a natural
17 histidine-containing dipeptide known as a metal chelator as well as scavenger of ROS and reactive
18 aldehydes [86]. Thanks to these properties, carnosine is recognized to be beneficial against
19 atherogenesis, in particular against foam cell formation [87,88].
20
21
22
23
24

25 *3.1. Nutraceuticals as modulators of inflammation: direct effects on inflammatory pathways*

26
27
28
29 Almost all the transcription factors and up/down-stream effectors of the signaling pathways,
30 accounted for macrophage pro- or anti-inflammatory polarization, appeared sensitive to the
31 intervention of micronutrients.
32
33

34
35 In human peripheral blood mononuclear cells, quercetin lessened the oxLDL-induced TLR2
36 and TLR4 mRNA levels and modulated the TLR/NF- κ B signaling pathway, thereby inhibiting cell
37 inflammatory response [89]. In both murine and human macrophages, the flavonoid apigenin
38 counterbalanced the LPS-induced increase of crucial pro-inflammatory cytokines, partly through
39 mRNA destabilization, thus favoring IL-10 expression. Apigenin was also found to block NF- κ B and
40 extracellular signal-regulated kinase (ERK)1/2 activation, as well as to interfere with inflammasome
41 assembly [90]. Hydroxytyrosol, a main polyphenol of olive oil, attenuated the expression of pro-
42 inflammatory molecules, including various cytokines and MMPs, in different macrophage models,
43 principally interfering with NF- κ B and protein kinase C (PKC) α and PKC β 1 signaling [91,92], but
44 also with STAT1 α and IRF-2, through ROS generation [93]. Epigallocatechin gallate (EGCG), the
45 most abundant flavonoid in green tea, markedly attenuated the cyclooxygenase-2 (COX-
46 2)/membrane-bound prostaglandin (PG) E synthases-1 (PGES-1)/PGE₂ pathway in U937 cells
47 activated by oxidized lipids; also in this case, the flavonoid reduced secretion of inflammatory
48 cytokines and MMP-9, which are responsible for plaque instability [94]. Alternative M2 polarization
49 was promoted by a bacterial metabolite of antocyanins, namely protocatechuic acid, which is present
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 in black olives, mushrooms, and chicory; in J774 macrophages the protocatechuic acid was able to
2 abolish the PI3K/Akt/NF- κ B cascade in favor of the STAT6/PPAR γ pathway [95]. Deep
3 consideration has been paid to curcumin as an agent employable to polarize macrophage
4 inflammatory state. Originally recognized as an NF- κ B suppressor in myeloid cells [96], this
5 polyphenol has been further demonstrated to abolish NF- κ B/mitogen-activated protein kinase
6 (MAPK) activation and to contrast M1 polarization of LPS/IFN γ -primed THP1 differentiated cells
7 by inhibiting TLR4 expression [97]. It appears to switch M0 non-activated and RAW264.7 M1
8 activated macrophages to M2 phenotype too, via activation of the inhibitor of NF- κ B α (I κ B α) and
9 PPAR γ , respectively [98]. Nevertheless, whether curcumin can act as a natural agonist of PPAR γ [99]
10 or not [100], regulating it indirectly by other mechanisms, is still debated. In addition, in RAW264.7
11 macrophages curcumin appeared to inhibit LPS-induced IL-6, TNF α , and COX-2 expression, as well
12 as p38 MAPK activity, and to restore, instead, the expression and synthesis of two members of the
13 suppressor of the cytokine signaling (SOCS) family, namely SOCS-1 and SOCS-3 [101]. Of note,
14 curcumin ability to affect arachidonic acid metabolism in the same cell model has already been
15 reported: it inhibited the formation of PGE₂ by blocking cytosolic phospholipase A2 (cPLA2)
16 phosphorylation, decreasing COX-2 expression, and inhibiting the catalytic activities of 5-
17 lipoyxygenase [102]. Resveratrol was able to prevent the NF- κ B-dependent macrophage switching to
18 M1 phenotype limiting the production of inflammatory cytokines and MMPs [103]. In murine
19 macrophages, resveratrol **was able** down-regulated LPS-induced TNF α and IL-6 production by
20 limiting p38 MAPK phosphorylation and, through inhibition of the small noncoding microRNA
21 (miR) immune response regulator miR-155, by promoting the expression of SOCS-1, a STAT
22 inhibitor [104]. Previously, in the same cells **resveratrol** has demonstrated to reverse LPS effects in
23 terms of inflammatory species' generation, by negatively regulating the cAMP-responsive element-
24 binding protein (CREB) and MAPK pathways, and by activating the PI3K/Akt signaling [105].

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 Incubation with the ω -3 PUFA DHA was proven to elicit, in the murine macrophage-like
45 lineage RAW264.7, the activation of PPAR γ and, consequently, M2 macrophage polarization and
46 efferocytosis of apoptotic cells [106]. Moreover, DHA diminished the responsiveness of human
47 monocytic THP1 cells to TNF α in terms of ROS production and foam cell formation, in a PI3K-
48 dependent manner [107]. To further support the pleiotropic activity of PUFAs as signaling
49 modulators, LPS-stimulated RAW264.7 macrophages exhibited a lower expression of inflammatory
50 cytokines after supplementation with high doses of DHA alone or DHA plus EPA. In this case,
51 suppression of LPS-induced TLR4 expression in the lipid rafts of cell membrane has been suggested
52 to underlie, at least in part, ω -3 PUFAs action, which resulted in the decrease and stabilization of
53 aorta plaques of Western-diet fed ApoE-deficient mice [108]. Anti-inflammatory activity of DHA
54
55
56
57
58
59
60
61
62
63
64
65

1 might also rely on its interaction with the free fatty acid receptor 4 (FFA4). Acting as an FFA4 agonist,
2 DHA limited COX-2 expression and thereby prostanoid synthesis by LPS-stimulated RAW264.7
3 cells, independently of COX-1 regulation. Presumably, activation by DHA would promote FFA4
4 coupling to β -arrestin 2; as a consequence, it would suppress TLR4-dependent Akt/c-Jun N-terminal
5 kinase (JNK) phosphorylation and, finally, p65 nuclear translocation and binding to NF- κ B response
6 elements in the COX-2 promoter [109]. *An in vitro model consisting of human THP-1-derived
7 macrophages treated with chylomicron remnants was used to elucidate the properties of diverse
8 dietary fats. The chylomicron remnants were enriched in saturated FA, MUFAs, ω -6 PUFAs, or ω -3
9 PUFAs, respectively derived from palm, olive, corn or fish oil. All FAs suppressed NF- κ B
10 transcriptional activity, with fish oil FAs causing the strongest inhibition followed by corn oil, palm
11 oil, and then olive oil FAs. With a similar trend, they also enhanced cholesterol removal by the cells,
12 suggesting that NF- κ B inhibition might play a role in this modulation [110].*

13
14 Interestingly, DHA and the flavonoid quercetin used in combination potentiated the anti-
15 inflammatory effects of the single compounds, as observed in LPS-stimulated RAW264.7 cells.
16 Indeed, they synergistically inhibited the expression and activity of NF- κ B/MAPK signaling
17 mediators [111]. *In human macrophages, DHA, the flavonoid procyanidins B1, B2 and C1, and the
18 combination of DHA with any of the procyanidins, at concentrations typical of the Mediterranean
19 diet, all attenuated NF- κ B signaling. These compounds inhibited I κ B α phosphorylation, induced the
20 cytoplasmic retention of NF- κ B complex through p105 (NF- κ B1) overexpression, and inhibited p65
21 nuclear translocation and DNA binding [112].*

22
23 Naturally occurring isomers of ω -6 linoleic acid (LA), identified in milk, dairy products, and
24 meat of ruminants, and named conjugated LA (CLA), were originally recognized as ligands for
25 PPAR γ and thus able to exert anti-inflammatory effects on murine macrophages [113]; **but** more
26 recent data indicated a PPAR γ suppressive regulation by these compounds, at least in human
27 macrophages, due to diminished ERK1/2 and p38 phosphorylation [114]. In this connection, it was
28 demonstrated that in RAW 264.7 cells CLA isomers regulate LPS-induced inflammatory cytokine
29 gene expression in an isomer-specific manner that likely implies a selective modulation of the
30 PPAR/RXR heterodimer. Among the tested CLA isomers, 9-trans,11-trans-CLA was the most
31 effective, while 9-cis,11-trans-CLA did not significantly affect immune cell activation [115].
32 Subsequently, CLA was reported to prime mouse bone marrow-derived macrophages to an M2
33 phenotype secreting IL-10, likely as a consequence of IL-10 receptor overexpression and STAT3
34 phosphorylation [116].

35
36 Furthermore, ω -3 PUFAs give rise to specialized pro-resolving mediators (SPMs), such as E-
37 series resolvins (Rvs) from EPA and D-series Rvs protectins and maresins from DHA; SPMs provide
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 an additional contribution to M2 phenotyping and to inflammation resolution [63]. Noteworthy,
2 thanks to SPM production, ω -3 PUFAs might direct macrophage activity towards plaque resolution
3 independently from induction of cytokines. For example, RvD1 protects murine macrophages from
4 apoptosis through anti-apoptotic protein up-regulation and also by attenuating oxidative stress
5 through PKA-mediated inactivation of NOX [117].
6
7

8
9 As regards the ω -6 PUFA arachidonic acid, its role is multifaceted: although its modification
10 by 5-lipoxygenase gives rise to the pro-inflammatory autocooids leukotrienes and PGs, a shift to the
11 12-lipoxygenase or 15-lipoxygenase enzymatic pathways promotes the synthesis of the SPM lipoxins
12 [118,119]. Among them, lipoxin A₄ inhibited foam cell formation, inflammation, and apoptosis
13 occurrence induced by oxLDL in macrophages [120].
14
15
16

17
18 Down-regulation of MMPs and of the extracellular matrix MMP inducer (EMMPRIN),
19 subsequent to NF- κ B inhibition, was observed in oxLDL-stimulated macrophages after incubation
20 with the alkaloid berberine [121]. This modulation might depend on miR150-5p increase that leads
21 to the purinergic receptor P2X7 repression and consequently to AMPK α and MAPK inactivation, as
22 newly brought to light in human and murine oxLDL-induced macrophages [122].
23
24
25

26
27 In a rat model, crocin, the carotenoid responsible for saffron yellow color, favored the M2
28 macrophage polarization and balanced the levels of inflammatory cytokines by limiting NF- κ B p65
29 expression and nuclear translocation [123]. Similarly, lycopene and astaxanthin were proven to
30 diminish, in activated M1 macrophages, the secretion of inflammatory mediators such as TNF α or
31 ILs by inhibiting NF- κ B [124,125]. In particular, astaxanthin could be effective in preserving Src
32 homology phosphatase 2 (SPH2), a negative regulator of NF- κ B activity [125].
33
34
35
36

37
38 NF- κ B binding activity has been reported to be inhibited also by the iridoid scopolioside A
39 that reduced PGE₂ and COX-2 production in LPS-stimulated murine RAW264.7 macrophages [126].
40
41

42 Anti-inflammatory properties have been ascribed to the steroidal compound vit D. In LPS-
43 activated macrophages, vit D biologically active form, namely 1,25-dihydroxyvitamin D
44 (1,25(OH)₂D₃), up-regulated MAPK phosphatase-1 (MKP-1) turning off the p38 signaling
45 responsible for cytokine production [127]. To further confirm the anti-inflammatory effect of vit D,
46 *in vitro* incubation with 1,25(OH)₂D₃ decreased TLR4 expression on cell membranes of differentiated
47 M1 macrophages and increased vit D receptor, the latter likely representing a negative feedback loop
48 mechanism to contain the pro-inflammatory M1 response [128]. Of note, vit D receptor has been
49 recently implied in the restoration of functional autophagy and consequently of lipid removal in both
50 mice and human macrophages. The interaction between vit D and its receptor would indeed trigger a
51 protein tyrosine phosphatase non-receptor type (6PTPN6)/SHP-1 dependent signaling underlying
52 autophagy activation [129].
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Ajoene isomers and their oxidized sulfonyl derivatives from garlic showed efficacy in
2 attenuating LPS-induced inflammatory response of macrophages in terms of COX-2, PGE₂, and
3 cytokine production. Inhibition of NF-κB transcriptional activity and decreased phosphorylation of
4 p38 and ERK MAPKs accounted for these effects [130].
5
6

7 Among saponins, ginsenoside 20(S)-Rg3 could promote M1 to M2 polarization within
8 atherosclerotic plaques of diabetic mice, a switch which likely results from PPAR γ activation [131];
9 the enhancement of STAT6 phosphorylation could account for the improvement of M2 polarization
10 of RAW264.7 macrophages by ginsenoside Rb1 [132]. In addition, the deactivation of the NOTCH
11 signaling pathway, in particular the prevention of NOTCH intracellular domain nuclear translocation,
12 could account for the suppression of oxLDL-loaded THP1 differentiation by diosgenin, another
13 saponin [133]. Moreover, the last compound was previously reported to reduce the production of
14 ROS and pro-inflammatory mediators by LPS/IFN γ -stimulated macrophages blocking the signaling
15 of NF-κB and activator protein-1 (AP-1), and of their down-stream mediators casein kinase 2 (CK2)
16 and JNK [134].
17
18
19
20
21
22
23
24
25
26

27 *3.2. Nutraceutical effects on inflammasome and autophagy*

28
29
30

31 Several polyphenols were demonstrated to be effective in hindering autophagy impairment,
32 among which luteolin [135], a flavonoid extract [136], proanthocyanidins, and EGCG [137].
33 Resveratrol has been recognized as a SIRT1 activator able to sustain macrophagic functional
34 autophagy and ultimately apoptotic cell efferocytosis [138]. Another investigation reported that, in
35 murine macrophages submitted to mitochondrial oxidative stress, autophagy was promoted by
36 resveratrol through a SIRT3/AMPK positive feedback loop [139]. In oxLDL-induced RAW264.7
37 foam cells, the flavonoid quercetin restored autophagic process, thus reducing lipid accumulation and
38 cell senescence, by abrogation of mammalian Ste20-like kinase 1 (MST1) expression [140].
39 Similarly, both EGCG and a mixture of oligomeric proanthocyanidins favored lipid disposal in
40 oxLDL-induced foam cells by coordinated activation of autophagy and lysosomal acid lipase, and
41 induction of the cholesterol transporters ATP-binding cassette transporter (ABC) A1 and ABCG1. In
42 this case, autophagosome formation was triggered by activation of the Class PI3K/Beclin1 complex
43 followed by assembly of the Atg12-Atg5-Atg16L and Atg8/LC3 complexes; interestingly, the same
44 results were observed also by treatment with β -sitosterol [137]. Anti-atherogenic and anti-
45 inflammatory properties of curcumin might rely on its capacity to reduce NLRP3 inflammasome
46 expression, caspase-1 cleavage, and IL-1 β secretion, as observed in phorbol myristate acetate (PMA)-
47 induced human macrophages. All these actions seem to depend not only on the down-regulation of
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 TLR4/MyD88/NF- κ B signal cascade but also on the deactivation of the purinergic 2X7 receptor
2 (P2X7R), another up-stream factor for NLRP3 assembly induction [141]. To further support that
3 polyphenols are effective in interfering with NLRP3 inflammasome signal switch on, there is the
4 evidence that a red wine extract or, to a lesser extent, resveratrol alone negatively affected LPS-
5 priming of murine macrophages necessary for NLRP3 synthesis and IL-1 β secretion; in addition, the
6 wine extract preserved from activation of NLRP3 by complexation with the adaptor protein apoptosis-
7 associated speck-like protein containing a CARD (ASC), whose expression was lessened by wine
8 polyphenols [142]. Similarly, luteolin inhibited the expression of NLRP3, ASC, caspase-1, IL-18,
9 and IL-1 β in LPS-stimulated RAW264.7 cells, thus promoting their polarization toward an M2
10 macrophage type, as confirmed by the induction of the M2 markers arginase-1 and IL-10. In addition,
11 the polyphenol was also confirmed to limit ROS production [143].

12
13
14
15
16
17
18
19
20 Berberine might be considered for autophagy promotion too. In fact, this alkaloid was proven
21 to reduce the inflammatory response of both human and murine oxLDL-loaded macrophages by
22 stimulation of autophagy through intervention on Akt/mTOR or AMPK/mTOR signaling pathways
23 [144,145].

24
25
26
27 Furthermore, the saponin araloside promoted M2 polarization of murine macrophages exposed
28 to oxLDL reducing foam cell formation; also in this case, autophagy induction, mediated by SIRT1
29 up-regulation, was recognized as the driving force [146]. Another saponin, namely ginsenoside Rb1,
30 improved autophagy in macrophage foam cells via AMPK phosphorylation that subsequently led to
31 higher microtubule-associated protein light chain 3 (LC3)II and Atg5 levels [147]. Ginsenosides
32 might also rescue cells from inflammasome activation, and likely from pro-inflammatory IL-1 β
33 maturation and secretion, as demonstrated in mouse and human macrophages, in which both NLRP3
34 and AIM2 inflammasomes were inhibited by a red ginseng extract [148]. Moreover, ginseng is rich
35 in ursolic acid, a triterpene that could additionally contribute to macrophage autophagy by increasing
36 the expression of Atg5, Atg16l1, and LC3, thereby suppressing IL-1 β secretion and promoting
37 cholesterol efflux [149].

38
39
40
41
42
43
44
45
46
47 Another natural compound acting on autophagy is tanshinone IIA. It resulted to activate KLF4
48 and to enhance autophagy and M2 polarization of oxLDL-induced macrophages by inhibiting miR-
49 375 [150].

50
51
52
53 Scopolioside B, an iridoid, decreased expression and synthesis of NLRP3, pro-IL-1 β , and IL-
54 1 β in LPS-induced THP1 cells [151].

55
56
57
58
59
60
61
62
63
64
65 As regards PUFAs, macrophages, isolated from mice fed on a diet supplemented with both
fish or botanical ω -3 and ω -6 PUFAs, exhibited NLRP3 inflammasome suppression, and reduced IL-
1 β secretion as a consequence of improved autophagy and mitochondrial function. Of note, botanical

1 ω -3 and ω -6 PUFAs action seemed independent of mitochondrial ROS production [152].
2 Administration of EPA, DHA, and other ω -3 PUFAs to bone-marrow derived macrophages prevented
3 LPS-induced NLRP3 and NLRPb1 inflammasome activation and IL- β 1 secretion. At least for
4 NLRP3, ω -3 PUFAs might signal through activation of FFA4 and GPR40 [153].
5
6
7

8 3.3. *Nutraceuticals as modulators of cell redox equilibrium*

9

10
11
12 Micronutrients might be helpful in alleviating disease exacerbation caused by imbalances in
13 the redox equilibrium. According to their chemical structure, many of these substances work as
14 classical antioxidants provided with ROS scavenging, chain-reaction quenching, and metal-chelating
15 activities. Besides that or alternatively, they have been proven to affect the principal signal cascades
16 that rule redox equilibrium inside and outside cells [8,72,75].
17
18
19

20
21 Polyphenols seem to act primarily through involvement of the transcription factor Nrf2,
22 critical for the cells to carry out the antioxidant response against oxidative damage. For example, both
23 hydroxytyrosol and resveratrol quenched the oxidative and inflammatory burst triggered by LPS in
24 macrophages, reducing PGE₂ production likely through the negative regulation of the immune
25 response regulator miR-146a and the promotion of Nrf2 nuclear translocation [154]. A polyphenolic
26 extract from Tarocco citrus reduced iNOS and COX-2 expression and ROS/NO release by murine
27 macrophages, reducing PGE₂ production likely through the negative regulation of the immune
28 response regulator miR-146a and the promotion of Nrf2 nuclear translocation [154]. A polyphenolic
29 extract from Tarocco citrus reduced iNOS and COX-2 expression and ROS/NO release by murine
30 macrophages under inflammatory condition. Inhibition of NF- κ B and activation of Nrf2 would
31 account for the extract anti-inflammatory and antioxidant activities, respectively [155].
32 Protocatechuic acid potentiated the glutathione (GSH) antioxidant system of J774A.1 cells by
33 inducing JNK-mediated Nrf2 phosphorylation [156]. Conversely, an extract of the flavonoids
34 anthocyanins appeared to suppress Nrf2 expression and consequently ROS production and expression
35 of inflammatory cytokines, iNOS, and COX-2 that were induced in RAW264.7 macrophages by
36 LPS [157].
37
38
39
40
41
42
43
44

45 Other micronutrients, besides polyphenols, could improve redox balance in macrophages
46 primarily by Nrf2 modulation. For example, the isothiocyanate sulforaphane from broccoli is a well-
47 established inducer of Nrf2 and, in response to primary oxidative stress, it favors the expression of
48 endogenous phase II and antioxidant enzymes, including GSH related enzymes [158]. Interestingly,
49 Keap1/Nrf2 induction by sulforaphane was proven to promote, at least in non-macrophagic cells, the
50 expression of most of the 20S proteasome subunits involved in the degradation of oxidized proteins,
51 thus representing a strategy to prevent long-term oxidative damage and possibly ER stress [158,159].
52 As regards macrophages, in RAW264.7 cells sulforaphane inhibited the NLRP1b, NLRP3,
53 NAIP/NLRC4, and AIM2 inflammasomes through an Nrf2-independent pathway. The down-stream
54
55
56
57
58
59
60
61
62
63
64
65

1 results were the deactivation of caspase-1, together with the repression of IL-1 β processing and
2 secretion, and of macrophage pyroptosis [160]. Likely through Nrf2 activation and NF- κ B inhibition,
3 sulforaphane elicited the M1 to M2 phenotypic change in PMA-differentiated THP1-derived
4 macrophages, assessed in terms of expression levels of M1 (IL-1 β , IL-6, TNF- α , IL-23, CCR7) and
5 M2 (IL-10, PPAR γ , MRC1, CCL22) marker genes [161]. Nrf2-mediated anti-inflammatory activity
6 of sulforaphane, including down-regulation of iNOS, was reported also in RAW264.7 cells
7 challenged with LPS [162]. Considering all these evidences, it would be of interest to investigate the
8 possible involvement of Nrf2 and proteasome in the sulforaphane antioxidant activity also in the
9 context of atherosclerosis.

10
11
12
13
14
15
16 Another isothiocyanate, namely allyl-isothiocyanate from brassica species, counteracted
17 inflammation in LPS-stimulated RAW264.7 macrophages through Nrf2/HO-1 activation. In this case,
18 although not verified, the immune response regulator miR-155 was pointed to as the mediator of the
19 signaling triggered by allyl-isothiocyanate [163].

20
21
22
23 In addition to Nrf2, other redox sensitive pathways can undergo modulation by natural
24 compounds. Resveratrol counterbalanced PMA-induced intracellular GSH depletion and
25 consequently pro-inflammatory differentiation of THP1 cells via AMPK α activation [164]. Geraniin
26 interrupted, through a SOCS-1/NF- κ B-dependent mechanism, the M1 inflammatory response due to
27 ROS and iNOS-derived NO in THP1 cells stimulated with LPS [165]. Myricitrin has been suggested
28 to attenuate the inflammatory activation of murine macrophages by inhibiting the assembly of NOX
29 components. Indeed, the decrease of intracellular ROS resulting by myricitrin administration could
30 account for the abolition of both Janus kinases (JAKs) and STAT1 phosphorylation, induced by LPS,
31 and consequently for the suppression of DNA-binding activity of STAT1 [166]. The antioxidant
32 properties of punicalagin and gallic acid, two polyphenols typical of pomegranate juice, could rely
33 on the stimulation of macrophage paraoxonase-2 expression which, in turn, could depend on the
34 activation of PPAR γ and AP-1 [167].

35
36
37
38
39
40
41
42
43
44
45 Siphonaxanthin, a xanthophyll present in green algae, but not other carotenoids such as lutein
46 and fucoxanthin, attenuated ER stress and the subsequent NF- κ B activation, pro-inflammatory
47 cytokine expression, and NO generation induced by the pro-atherogenic advanced glycation end
48 products in RAW264.7 macrophages. In particular, high doses of siphonaxanthin increased the
49 expression of some antioxidant genes that contribute to ER stress mitigation [168].

50
51
52
53
54
55 In oxLDL-treated macrophages, DNA damage, telomere shortening, cell senescence, and
56 apoptosis due to ROS overproduction have been reversed by the iridoid catalpol, acting on the PGC-
57 1 α /telomerase reverse transcriptase (TERT) pathway [169]. Alternatively, this iridoid might attenuate
58 M1 polarization, inflammatory response, and oxidative stress elicited by IFN γ in J774.A1
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

macrophages through induction of estrogen receptor α . The effect could depend on iNOS suppression and on promotion of endothelial NOS instead [170].

Berberine has been shown to reduce macrophage superoxide anion concentration by inhibiting the expression of its source NOX subunit gp91phox, and by recovering superoxide dismutase (SOD) activity [171]. Moreover, β -sitosterol, a molecule which does not show significant ROS scavenger activity, might protect against oxidative stress because of manganese SOD and GSH peroxidase activation in PMA-stimulated RAW264.7 macrophages, likely through mediation of estrogen receptors and PI3K [172].

3.4. *Nutraceuticals as modulators of cell metabolism: effects on lipid homeostasis and other metabolic routes*

A large number of polyphenols has been reported to reduce foam cell development. EGCG restored ABCA1-mediated reverse cholesterol transport by inhibition in macrophages of the NF- κ B activity induced by TNF α . The entire process appeared to depend on the Nrf2-Kelch-like ECH-associated protein 1 (Keap1) signaling, which controls NF- κ B function [173]. Transformation of human macrophages into foam cells was also prevented by the citrus flavonoids naringenin and hesperitin by up-regulation of LXR α and its target genes ABCA1 and ABCG1 in an AMPK or PPAR γ dependent manner, respectively [174,175]. Other polyphenols effective against lipid-laden cell development are quercetin [176], dihydromyricetin [177], kaempferol [178], resveratrol [179], pomegranate ellagic acid and punicalagin, [180], coffee phenolic acids [181], and curcumin [182]; they act by improving LXR α , PPAR γ , and/or ABC-transporters, and eventually by regulating scavenger receptor expression. More in detail, in THP-1 cells LXR α /ABCA1 up-regulation by curcumin might derive from AMPK-SIRT1 signaling activation [183]. On the other hand, it was evidenced that curcumin treatment of M1 subtype RAW264.7 cells led to PPAR γ overexpression and, in turn, to ABCA1 and CD36 induction. These effects, together with improved intracellular cholesterol esterification, have been deemed as mechanisms efficient to favor noxious lipid handling by atherosclerotic macrophages and to attenuate their inflammatory response [184]. In contrast with the aforementioned data, the flavonoid gossypetin isolated from the flowers of Hibiscus species limited foam cell formation by PPAR γ blockage, promoting the PPAR α /LXR α /ABCA1 signal with down-regulation of the CD36-dependent oxLDL uptake by J774.A1 murine macrophages [185]. Similarly, resveratrol was reported to down-regulate PPAR γ , but also PPAR α , without affecting PPAR β / δ , thus reducing the conversion of THP1 PMA-differentiated cells into foam cells, pointing to AMPK and SIRT1 overexpression as the causative mechanism [186]. A novel mechanism has

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

been recently discovered to explain the protective action of the flavonoid fisetin against lipid accumulation in oxLDL-exposed macrophages. It comprises the induction of CK2-interacting protein-1 (CKIP-1), a protection factor for the cardiovascular system, and of REGγ (11S regulatory particles, 28 kDa proteasome activator, proteasome activator subunit 3), a member of the 11S proteasome activators already recognized as a therapeutic target for lipid metabolism disorders; indeed, REGγ limits organic cation transporter-1 (Oct-1) transcriptional activity, with the subsequent down-regulation of lectin-like LDL receptor-1 (LOX-1), a scavenger receptor responsible for oxLDL uptake [187]. Very recently, fisetin was demonstrated to regulate lipid homeostasis of oxLDL-induced U937 macrophages also by reducing the sterol regulatory element binding protein 1 (SREBP-1)-dependent expression of the liposynthesis genes 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and FA synthase. The process was shown to depend on the antioxidant properties of the flavonoid that, by quenching ROS production, abolished up-stream NLRP3 activation by oxLDLs [188]. In this connection, FA synthase has been recently suggested to be essential for the TLR-mediated macrophage pro-inflammatory activation and its activity was associated to the promotion of cholesterol biosynthesis [189]. The addition of the pomegranate polyphenols punicalagin and/or β-sitosterol to simvastatin raised the drug efficacy against foam cell formation. Punicalagin and/or β-sitosterol appeared to inhibit cholesterol biosynthesis in J774.A1 macrophages and, in combination with simvastatin, significantly reduced ROS production [190].

Phytosterols are well-known to reduce plasma LDL levels by competitive exclusion of cholesterol from micellar space in the intestinal lumen and modulation of enterocyte cholesterol trafficking. In addition, they might have a direct effect on cholesterol homeostasis in macrophage-derived foam cells; stigmasterol, but not campesterol and sitosterol, positively regulated the expression of ABCA1 and ABCG1. Surprisingly, while stigmasterol attenuated the inflammatory response and campesterol was almost inert, sitosterol exacerbated it [191].

A nutritional mixture of flavanol rich cocoa extract and ω-3 PUFA-rich fish oil, with or without phytosterols, increased ApoA-I mediated cholesterol outflow, possibly reversing foam cell formation, and delayed M1 polarization of a monocyte derived THP-1 macrophage model of atherosclerosis [192]. Nevertheless, the potentiality of UFAs to offset against aberrant lipid homeostasis in atherosclerotic macrophages is controversial. Attenuating the ER stress, both the monounsaturated FA oleic acid and the ω-6 PUFA LA were proven to suppress LOX-1 expression, which was induced by palmitic acid in macrophage-like cells [193]. Apparently, this evidence conflicts with a more recent investigation reporting that LA and its natural source soy oil are pro-atherogenic since, by exacerbation of oxidative stress and modulation of the redox-sensitive p38 MAPK, they favor triglyceride biosynthesis and accumulation in J774.A1 cells [194]. In agreement

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

to that, the UFAs palmitoleate, oleate, linoleate, and arachidonate had been previously implicated in atherogenesis since their supply impaired cholesterol release by macrophages by enhancing ABCA1 degradation [195]. In particular, the action of oleate and linoleate appears to be mediated by their acyl-CoA derivatives and could depend on acyl-CoA synthetase 1 up-regulation [196]. In addition, palmitic, oleic, linoleic, linolenic, or eicosapentaenoic acids significantly reduced both ABCA1 and ABCG1 macrophage content by altering, at a transcriptional level, the LXR/histone deacetylase signaling and possibly, in a LXR-independent manner, by inhibiting post-transcriptional pathways [197]. In human macrophage-derived foam cells also CLA seemed to reduce intracellular cholesterol content by up-regulation of ABCA1 through both PPAR γ - and LXR α -dependent pathways. This occurred although the expression of CD36 was increased by CLA [198]. This is consistent with inhibition by CLA of PGC-1 α -mediated macrophage transition to foam cells [199], but contrasts with cholesterol accumulation observed in CD36-overexpressing human macrophages exposed to CLA [200]. It is possible that different CLA isomers have distinct features; in fact, trans-9,trans-11-CLA, but not cis-9,trans-11 and trans-10,cis-12-CLA, activated the cholesterol transporter ABCG1 in murine macrophages by a SREBP1c-dependent mechanism [201].

Among carotenoids, lycopene might be helpful against foam cell formation by affecting cholesterol metabolism of human macrophages. The signal machinery triggered by this compound consisted in an initial inhibition of the cholesterol synthesis key enzyme HMG-CoA reductase followed by small GTPase RhoA inactivation, subsequent increase in PPAR γ and LXR activities, and final enhancement of ABCA1 expression [202]. Cholesterol efflux from murine macrophages to high density lipoproteins (HDLs) was accelerated by all-trans-retinoic acid and by its precursor 9-cis- β -carotene. Both compounds increased ApoE protein level but only 9-cis- β -carotene was effective in the induction of ABCA1, ABCG1, and ApoE genes [203]. A novel mechanism was recently suggested to underlie ABCA1, ABCG1, and scavenger receptor class B type I (SR-BI) overexpression, as well as cholesterol outflow promoted by astaxanthin in oxLDL-overloaded macrophages. This mechanism identified noncoding circular RNAs as key players of the process induced by the carotenoid [204].

In PMA-differentiated THP-1 monocytes, the steroidal saponin diosgenin was proven to induce ABCA1 protein and ABCA1-mediated cholesterol outflow without affecting LXR but suppressing miR-19b, a post-transcriptional regulator of ABCA1 [205].

PPAR α and LXR α are likely the target of the anti-atherogenic action of the garlic derived allicin too, resulting in improved cholesterol exchange by ABCA1 overexpressing macrophages [206].

1 Cholesterol efflux associated to M2 polarization was favored by 1,25(OH)₂D₃ in THP-1-
2 derived foam cells. In this case, LXR-dependent ABCA1 and ABCG1 overexpression was the
3 consequence of the induction of CYP27A1, the enzyme responsible for the synthesis of the LXR
4 agonist 27-hydroxycholesterol [207].
5

6
7 Macrophage differentiation into foam cells has been prevented by berberine too, but through
8 other mechanisms: in oxLDL-stimulated THP1 cells this alkaloid down-regulated the expression of
9 CD36 and LOX-1, and increased the expression of adipocyte enhancer-binding protein 1 (AEBP1),
10 a key regulator of genes associated with intracellular cholesterol homeostasis, including PPAR γ ,
11 LXR α , and ABC-transporters [208]. In addition, cholesterol-lowering effects of berberine were
12 exerted by activation of Nrf2/HO-1, which accounted for ABC-transporter overexpression, and by
13 inhibition of AP-1, which suppressed scavenger receptor expression [209]. Berberine has also been
14 demonstrated to act by up-regulating AMPK and SIRT1 and by down-regulating PPAR γ [210].
15 Berberine as well as ω -3 the PUFAs DHA and EPA were proven to reduce modified LDL uptake by
16 human macrophages, in a scavenger receptor-independent manner, likely as the result of diminished
17 macropinocytosis [211,212].
18

19
20 A preventive effect of tanshinone II on foam cell formation was observed in human monocyte-
21 derived THP-1 cells challenged with oxLDL. This compound markedly down-regulated SR-A and
22 up-regulated ABCA1 and ABCG1 expression. This was the consequence of ERK activation, Nrf2
23 phosphorylation and nuclear translocation, and final HO-1 overexpression [213].
24

25
26 All these observations point to metabolism and cell homeostasis of lipids, in particular of
27 cholesterol, as the main processes that can be affected by bioactive micronutrients, but other
28 metabolic cycles can be affected as well. A flavonoid-rich cocoa extract has prompted M2
29 polarization of active THP-1 derived macrophages which was shown by the reduction of
30 inflammatory cytokine secretion and the increase of IL-10 and IL-12 release. The conversion
31 from M1 to M2 phenotype was accompanied with enhanced oxygen consumption and ATP production
32 through the mitochondrial oxidative phosphorylation, suggesting that flavonoids could act principally
33 as antioxidants that favor the switch towards the oxidative metabolism [214].
34

35
36 Rescue of mitochondrial functions and of the anti-inflammatory metabolism and phenotype
37 might be promoted in M1 macrophages also by carnosine. Indeed, this molecule was recently proven
38 to restore ATP/ADP and NAD(P)⁺/NAD(P)H balance in activated RAW264.7 macrophages, the last
39 effect being indicative of a strong inhibition of the main reactions responsible for cell ROS
40 production. Furthermore, carnosine antioxidant efficacy appeared to be strengthened by its ability to
41 improve the antioxidant defense through up-regulation of Nrf2, HO-1, and ROS scavenger enzymes,
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 and simultaneously to decrease NOX-2 and COX-2 expression, reactive nitrogen species formation,
2 and lipid peroxidation [215,216].
3
4

5 **4. Nutraceutical approaches to the treatment of atherosclerosis: outcomes from human studies**

6
7

8
9 The evidence, at a molecular level, of the antiatherogenic potential of many natural derivatives has
10 prompted to evaluate their efficacy also in humans. Literature in this field, from small observational
11 or interventional studies to larger epidemiological or clinical trials, has been continuously growing [8,
12 74,217,218]. In some cases, as exemplified by some relevant studies hereinafter reported, the
13 micronutrient impact on vascular events was assessed together with inflammatory and oxidative state
14 indices; this provides some information about the correlation between nutraceutical intake and the
15 mechanisms that mainly contribute to atherosclerosis progression. Of note, although the last
16 parameters are usually measured in the circulation and not specifically in the lesions or in the
17 atherosclerotic macrophages, it is conceivable that the systemic condition could reflect what occurs
18 in the plaque cells, among which macrophages.
19
20
21
22
23
24
25
26

27 Polyphenols, UFAs, and carotenoids are the bioactive compounds probably most widespread
28 in nature and abundant in food, thus they are the most investigated for nutritional and pharmacological
29 applications. The PREDIMED trial is undoubtedly one of the most extensive study carried out to
30 analyze the contribute of the Mediterranean nutritional pattern (i.e. increased intake of vegetables,
31 fruits, legumes, fish or seafood, moderate red wine consumption, and reduced intake of red meat),
32 characterized by a high content of polyphenols and PUFAs, on the primary prevention of CVD.
33 Almost 7500 high-risk participants were submitted to two Mediterranean diet regimens supplemented
34 with either virgin olive oil or nuts, or to a control low-fat diet. Intervention with both the enriched
35 diets brought to short-term and long-term decreases in the circulation of inflammatory cytokines, and
36 to an increase of plaque stability markers, together with an improvement of the classical
37 cardiovascular risk factors, including the lipid profile. Of note, the total polyphenol intake, measured
38 as urinary polyphenol excretion, inversely correlated with the levels of inflammatory markers,
39 suggesting a dose-dependent anti-inflammatory efficacy of polyphenols. In spite of that, no
40 significant changes were observed for the expression of genes involved in the atherosclerosis-related
41 inflammation [219-223].
42
43
44
45
46
47
48
49
50
51
52
53

54 A meta-analysis of human nutrigenomic studies highlighted the capacity of acute or sustained
55 interventions with a Mediterranean dietary regimen to down-regulate, in peripheral blood monocytes
56 (PBMCs), the expression of inflammatory and pro-oxidant mediators involved in atherosclerosis.
57 Olive oil appeared the main responsible for gene modulation, thanks to its high content of MUFAs,
58
59
60
61
62
63
64
65

1 carotenoids and, in particular, of polyphenols; in fact, some genes, such as TNF α and monocyte
2 chemotactic protein 1 (MCP1), have been affected by olive oil and its polyphenols, within and out of
3 the context of the Mediterranean diet [224].
4

5 Other dietary sources of polyphenols have been considered for preventive purposes too.
6 Several epidemiological studies have demonstrated the positive association between cocoa and its
7 products and lower CVD risk and mortality, pointing to a pivotal role played by cocoa flavanols.
8 Indeed, systemic levels of inflammatory markers such as ILs and C-reactive protein (CRP) appeared
9 reduced, mainly in studies considering healthy subjects, after short- and medium-term consumption
10 of cocoa derivatives. Nevertheless, a neutral effect on CRP, ILs, and on other inflammatory proteins
11 (TNF α , MCP1) has also been reported, either in healthy subjects and in individuals at cardiovascular
12 risk [225]. Furthermore, cocoa powder supplementation to high-cardiovascular risk volunteers
13 significantly lowered monocyte CD36 expression [226]. As regards polyphenolic compounds present
14 in green and black tea, both case-control studies and meta-analysis data are in support of an inverse
15 association between tea consumption and the risk of coronary artery disease and its fatal outcomes
16 [227].
17

18 Resveratrol and its sources grape and wine were taken into consideration for secondary
19 cardiovascular prevention [228,229]. One-year daily consumption of a grape-extract of the
20 phytochemical was able to modulate, in PBMCs of stable coronary artery disease patients, the
21 expression of inflammation-related transcription factors, including KLF2, NF- κ B, AP-1, c-Jun, ATF-
22 2, and CREB-binding protein. In the cells the expression of IL-1 β and TNF- α was also significantly
23 reduced, but no significant changes of inflammatory markers were observed in the serum, except the
24 reduction of IL-6 levels. Of note, lower expression of the inflammatory cytokines in PBMCs was
25 concomitant with increased levels of miR-21, miR-181b, miR-663, and miR-30c2, and with lower
26 levels of miR-155 and miR-34a, all involved in monocyte and macrophage inflammatory pathways
27 such as TLR and NF- κ B signaling. However, the authors could not detect circulating resveratrol or
28 other grape-derived metabolites, thus the direct relation between resveratrol and the effects observed
29 might be only speculative [230,231].
30

31 An anti-inflammatory activity was also ascribed to UFAs, which characterize some dietary
32 patterns, such as the Mediterranean and the Greenland ones, proven to be health promoting [228,
33 229]. In elderly healthy people, consumption of a Mediterranean diet enriched in MUFAs limited the
34 postprandial inflammatory response in mononuclear cells compared to a saturated FA-rich diet,
35 reducing the expression of TNF α , IL-6 and MCP1, and of MMP-9, thus suggesting a plaque
36 stabilizing efficacy. Of note, MUFA-diet appeared able to act directly on the up-stream NF- κ B
37 signaling, by lowering p65 subunit expression [232]. Very recently, outcomes from the ongoing
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

CORDIOPREV randomized trial further suggest the anti-atherogenic potential of a Mediterranean diet at high virgin olive oil content. It emerged that, compared to a low-fat diet, 5 and 7 years adherence to an olive oil-rich pattern reduced the arterial intima-media thickness of subjects with coronary heart disease at baseline. One might presume that MUFAs present in olive oil largely contribute to vascular protection, although no data about the actual intake of bioactive species, in terms of compound concentration in the plasma and/or urine of participants, were provided to confirm that [233,234].

As precursors of the pro-resolving mediators SPMs, ω -3 PUFA have been explored for atherosclerosis treatment as well, but to date observations from clinical trials did not give conclusive results [235]. On one hand, ω -3 PUFAs, including EPA and DHA, did not significantly reduce cardiovascular events in humans [236]. In this connection, ω -3 PUFAs did not seem to affect SPM levels in urine and plasma of healthy volunteers after fish oil dietary consumption [237]. Conversely, in patients with chronic inflammation, high doses of purified EPA and DHA affected plasma levels of intermediates of SPM biosynthesis and attenuated the expression of pro-inflammatory cytokines in LPS-stimulated PBMCs isolated from study's participants [238].

Moreover, EPA, DHA, docosapentaenoic acid (DPA), and monohydroxylated SPM precursors down-regulated M1 and up-regulated M2 genes of LPS-stimulated monocyte-derived macrophages that were isolated from patients with peripheral artery disease after a short-term intake of marine oil enriched with these FAs and SPM precursors. The phenotypic changes strongly correlated with the plasma SPMs/PGs ratio [239].

More generally, ω -3 PUFAs were demonstrated to promote plaque stabilization: the lipid core of coronary plaques of patients under statin therapy was significantly reduced by EPA co-administration, while fibrous cap formation was favored. It decreased also plasma MCP1 [240]. The OCEAN trial, which enrolled patients awaiting carotid endoarterectomy, reported that interventions with ω -3 PUFA ethyl ester capsules decreased plaque foam cell number and mRNA levels of MMP-7, MMP-9, MMP-12, and IL-6, in association with a higher plaque EPA content [241]. These observations are consistent with an earlier study showing that ω -3 PUFAs-enriched fish oil supplementation to patients with advanced lesions were readily incorporated in the carotid plaque, and were able to limit macrophage infiltration and to enhance atheroma stability. By contrast, the same results were not observed for increased consumption of ω -6 PUFAs [242]. Overall, the latest results are consistent with the outcomes of meta-analysis of clinical trials, including the DART, the GISSI-Prevenzione, and the Jelis trials, from which it emerged that marine ω -3 PUFA supplementation lowered the risk for the major vascular diseases [235].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Among carotenoids, most attention was given to β -carotene and lycopene, while other carotenoids were less investigated. In consideration of data variability, employment of β -carotene for the reduction of vascular morbidity is still debated and should be considered carefully [243]. On one hand, a prospective quantification of β -carotene in the serum of more than 29.000 men, enrolled for the ATBC study, provided evidence for an inverse correlation between β -carotene levels and the occurrence of CVD, heart disease, and stroke during the 31-years follow-up period [244]. On the other hand, according to the Cochrane Database review, β -carotene and vitamin A could increase all-cause mortality [245], and in agreement with that β -carotene was not recommended for prevention of CVD by the US Preventive Task Force [246].

As regards lycopene, interventional studies indicated that its consumption by means of tomato-based foods might be vasoprotective and reduce cardiovascular risk [247]. In addition, in subjects with subclinical atherosclerosis, 1-year treatment with lycopene, alone or in combination with luteolin, induced a decrease in the intima-media thickness that was inversely associated to plasma levels of both carotenoids [248]. These effects might be ascribed to lycopene antioxidant and anti-inflammatory properties; indeed, in individuals at high cardiovascular risk, a daily tomato-juice intake led to a plasmatic trans-lycopene increase that correlated with lessening of plasma IL-8 [249]. However, other studies did not sustain lycopene anti-atherogenic activity. In fact, a relatively high daily consumption of tomato-based products or lycopene supplements were ineffective at reducing vascular disease-related inflammatory markers in moderately overweight, healthy, middle-aged individuals, in spite of the lycopene increase in plasma [250], or at lowering CRP serum levels both in healthy volunteers and in CVD patients [251].

A saffron extract and its main carotenoid, crocin, have also been evaluated for the treatment of CVD patients; crocin, in particular, was able to promote SIRT1 and AMPK expression in the PMBCs of patients and to decrease NF- κ B. These effects were accompanied to the reduction of MCP1 and oxLDL levels in the serum [251].

As regards other less common natural bioactive compounds, literature is still limited and certainly less exhaustive, also in consideration of the few number of participants included in the studies presently available [8, 218]. Phytosterols have been considered mainly as cholesterol-lowering agents [218], while their application as atherosclerosis-related anti-inflammatory substances was less investigated. It has been reported that orange juice and orange juice fortified with phytosterols lessened IL levels in healthy human volunteers [252]; however, this evidence does not seem furtherly corroborated since a following meta-analysis of trials on humans did not report anti-inflammatory efficacy for phytosterol-enriched foods, at least in terms of CRP content [253]. Also for vit D evidence about benefits of its supplementation for atherosclerosis treatment is still scarce,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

although its deficiency is increasingly referred to as a risk factor for vascular diseases, [85]. Of note, a trial is presently going on to explore the anti-inflammatory effects of the injection of a Danshen extract containing tanshinone II in patients with stable coronary artery disease [254].

Conclusions and future perspectives.

Atherosclerosis is a multifaceted pathological process in which macrophages play a pivotal role. Their orientation towards a more or less inflammatory phenotype can affect plaque evolution towards vulnerable lesions, which ultimately leads to fatal adverse outcomes such as ischemic stroke and myocardial infarction, or, conversely, towards atherosclerotic process resolution. In this connection, inflammatory state, redox balance, and metabolic regulation represent a unique complex network that in a coordinated manner drives macrophage polarization and is, in turn, orchestrated by macrophages themselves according to their phenotype. By operating on this network, several substances of natural origin, including extra-nutritional constituents in foods or micronutrients, have shown efficacy to direct macrophage polarization; for this reason, these compounds have been considered as adjuvants in the prevention and treatment of atherosclerosis

The body of evidence available shows that nutraceutical bioactivity mainly relies upon their capability to operate on the diverse signaling cascades that regulate macrophage functions (Fig. 2). Of note, the most widespread compounds in dietary sources, such as polyphenols, UFAs, and carotenoids, act on several pathways (e.g. NF- κ B, MAPKs, TLRs, Nrf2, and PPARs), involved in multiple fundamental macrophage metabolic cycles and immune responses. In some cases, molecules less common in natural sources or present at very low concentrations seem to target more selectively biochemical factors with more specific roles. Examples of that include the modulation of estrogen receptors by β -sitosterol [172], of inflammasomes by saponins [148], of noncoding RNA by berberine, tanshinone II, and diosgenin [122,150,205], or of TERT by the iridoid catalpol [169].

Considering that, the integration of specific compounds through concentrated forms, including non-food matrices like pills, extracts, or powders [255], might represent a promising tool for therapeutical approaches aimed to direct the inflammatory network in atherosclerotic macrophages. In particular, this could be the case of substances such as saponins, iridoids, and berberin, that not only show more peculiar bioactivities but whose uptake through foodstuffs is limited. Noteworthy, administration of molecules targeting machineries with a selective activity might limit perturbations of signaling pathways with a broad impact on important processes shared by vascular and extra-vascular cells, thus avoiding potentially harmful interferences. Other advantages of nutritional

1 supplements are their less sensitivity to those alterations brought about food storage and cooking that
2 can change molecule biochemical reactivity, and eventually a major bioavailability due to the absence
3 of complex foodstuff matrices.
4

5 Nevertheless, definitive and unanimous data about the atherosclerosis-related properties of
6 certain nutraceuticals are still few, as well as information about their bioavailability or potential
7 toxicity due to their overconsumption. This is likely the result of the great variability of the
8 experimental models utilized for their investigation, especially as regards dose and duration of
9 treatments. In particular, as regards studies on humans, the molecule anti-atherogenic efficacy is
10 usually verified by means of clinical parameters, such as the intima-media thickness or the frequency
11 and seriousness of cerebro- and cardiovascular events, while inflammatory and oxidative markers are
12 less frequently observed. Moreover, only few investigations have evaluated the actual uptake of the
13 administered substances, for example by measuring plasma, urine or other tissue levels of the
14 presumed bioactive principle and of its metabolites. In the absence of these data, it is difficult to infer
15 a conclusive correlation between a defined nutraceutical and the observed outcomes in humans. For
16 this reason, further *in vitro* and *in vivo* studies on animals and humans, including extensive clinical
17 trials, are necessary to confirm the effectiveness of natural compounds to induce anti-atherogenic
18 polarization in macrophages and to establish the most suitable guide lines for their administration
19 [256,257].
20
21
22
23
24
25
26
27
28
29
30
31

32 Consequently, the application of micronutrients for atherosclerosis treatment in fully
33 replacement of current pharmacological therapies is not reliable yet. In spite of that, a balanced diet
34 which comprises a variety of nutraceutical-containing foods, such as the Mediterranean diet, likely
35 provides bioactive molecules in amounts adequate to counterbalance atheroma formation. Of note,
36 the copresence in the same foodstuff or meal of more micronutrients could ensure even more efficacy,
37 as highlighted by investigations reporting a synergistic action of them in mixtures [111,112,192].
38 Functional foods enriched with beneficial species could be also considered [255], in particular to
39 enhance provision of essential micronutrients or when the everyday diet is not sufficient for their
40 supplementation.
41
42
43
44
45
46
47
48

49 In conclusion, diets rich in bioactive species, fortified foods, and micronutrient supplements
50 can be employed for early prevention and possibly to improve patient response to drugs [258], as
51 emerged from the study of Rosenblat and collaborators about the combined effect of pomegranate
52 micronutrients and simvastatin [179]. Of note, this could allow lower drug doses reducing their side-
53 effects. For these reasons, nutraceuticals may represent a valid coadjuvant against atherosclerosis
54 evolution and their consumption should become fundamental in daily nutrition.
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments

The work was supported by the University of Turin (Italy) (grant ID: LEOG_RILO_20_01).

Conflict of interest

Authors declare not to have conflicts of interest.

References

- [1] O. Soehnlein, P. Libby, Targeting inflammation in atherosclerosis—from experimental insights to the clinic, *Nat. Rev. Drug Discov.* 20(8) (2021) 589-610. <https://doi.org/10.1038/s41573-021-00198-1>.
- [2] K.J. Moore, S. Koplev, E.A. Fisher, I. Tabas, J.L.M. Björkegren, A.C. Doran, J.C. Kovacic, Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2), *J. Am. Coll. Cardiol.* 72(18) (2018) 2181-2197. <https://doi.org/10.1016/j.jacc.2018.08.2147>.
- [3] S. Adamson, N. Leitinger, Phenotypic modulation of macrophages in response to plaque lipids, *Curr. Opin. Lipidol.* 22(5) (2011) 335-342. <https://doi.org/10.1097/MOL.0b013e32834a97e4>.
- [4] M.S. Gibson, N. Domingues, O.V. Vieira, 2018. Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis. *Front. Physiol.* 9, 654. <https://doi.org/10.3389/fphys.2018.00654>.
- [5] E.A.L. Biessen, K. Wouters, Macrophage complexity in human atherosclerosis: opportunities for treatment? *Curr. Opin. Lipidol.* 28(5) (2017) 419-426. <https://doi.org/10.1097/MOL.0000000000000447>.
- [6] A. Solanki, L.K. Bhatt, T.P. Johnston, Evolving targets for the treatment of atherosclerosis, *Pharmacol. Ther.* 187 (2018) 1-12. <https://doi.org/10.1016/j.pharmthera.2018.02.002>.
- [7] T.V. Kirichenko, V.N. Sukhorukov, A.M. Markin, N.G. Nikiforov, P.Y. Liu, I.A. Sobenin, V.V. Tarasov, A.N. Orekhov, G. Aliev, 2020. Medicinal Plants as a Potential and Successful Treatment Option in the Context of Atherosclerosis. *Front. Pharmacol.* 11, 403. <https://doi.org/10.3389/fphar.2020.00403>.
- [8] J.W. Moss, D.P. Ramji, Nutraceutical therapies for atherosclerosis, *Nat. Rev. Cardiol.* 13(9) (2016) 513-532. <https://doi.org/10.1038/nrcardio.2016.103>.

- 1
2 [9] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation, *Nat. Rev. Immunol.* 2008 Dec;8(12):958-69. <https://doi.org/10.1038/nri2448>.
- 3
4 [10] Y.V. Bobryshev, E.A. Ivanova, D.A. Chistiakov, N.G. Nikiforov, A.N. Orekhov, 2016. *Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis. Biomed. Res. Int.* 2016, 9582430. <https://doi.org/10.1155/2016/9582430>.
- 5
6 [11] A.N. Seneviratne, B. Sivagurunathan, C. Monaco, Toll-like receptors and macrophage activation in atherosclerosis, *Clin. Chim. Acta* 413(1-2) (2012) 3-14. <https://doi.org/10.1016/j.cca.2011.08.021>.
- 7
8 [12] M.P. Wolf, P. Hunziker, Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments, *J. Cardiovasc. Transl. Res.* 13(5) (2020) 744-757. <https://doi.org/10.1007/s12265-020-09961-y>.
- 9
10 [13] S. Devaraj, I. Jialal, C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype, *Arterioscler. Thromb. Vasc. Biol.* 31(6) (2011) 1397-1402. <https://doi.org/10.1161/ATVBAHA.111.225508>.
- 11
12 [14] A. Szanto, T. Roszer, Nuclear receptors in macrophages: a link between metabolism and inflammation, *FEBS Lett.* 582(1) (2008) 106-116. <https://doi.org/10.1016/j.febslet.2007.11.020>.
- 13
14 [15] H. Jinnouchi, L. Guo, A. Sakamoto, S. Torii, Y. Sato, A. Cornelissen, S. Kuntz, K.H. Paek, R. Fernandez, D. Fuller, N. Gadhoke, D. Surve, M. Romero, F.D. Kolodgie, R. Virmani, A.V. Finn, Diversity of macrophage phenotypes and responses in atherosclerosis, *Cell. Mol. Life Sci.* 77(10) (2020) 1919-1932. <https://doi.org/10.1007/s00018-019-03371-3>.
- 15
16 [16] C.J. Ferrante, S.J. Leibovich, Regulation of Macrophage Polarization and Wound Healing, *Adv. Wound Care (New Rochelle)* 1(1) (2012) 10-16. <https://doi.org/10.1089/wound.2011.0307>.
- 17
18 [17] I. Tabas, K.E. Bornfeldt, Macrophage Phenotype and Function in Different Stages of Atherosclerosis, *Circ. Res.* 118(4) (2016) 653-667. <https://doi.org/10.1161/CIRCRESAHA.115.306256>.
- 19
20 [18] G.F.P. Bories, N. Leitinger, Macrophage metabolism in atherosclerosis, *FEBS Lett.* 591(19) (2017) 3042-3060. <https://doi.org/10.1002/1873-3468.12786>.
- 21
22 [19] G.J. Koelwyn, E.M. Corr, E. Erbay, K.J. Moore, Regulation of macrophage immunometabolism in atherosclerosis, *Nat. Immunol.* 19(6) (2018) 526-537. <https://doi.org/10.1038/s41590-018-0113-3>.
- 23
24 [20] A.J. Covarrubias, H. I. Aksoylar, T. Horng, Control of macrophage metabolism and activation by mTOR and Akt signaling, *Semin. Immunol.* 27(4) (2015) 286-296. <https://doi.org/10.1016/j.smim.2015.08.001>.
- 25
26 [21] A. Arranz, C. Doxaki, E. Vergadi, Y. Martinez de la Torre, K. Vaporidi, E.D. Lagoudaki, E. Ieronymaki, A. Androulidaki, M. Venihaki, A.N. Margioris, E.N. Stathopoulos, P.N. Tsihliis, C.
- 27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Tsatsanis, Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization, Proc.
2 Natl. Acad. Sci. USA 109(24) (2012) 9517-9522. <https://doi.org/10.1073/pnas.1119038109>.

3 [22] T. Cramer, Y. Yamanishi, B.E. Clausen, I. Förster, R. Pawlinski, N. Mackman, V.H. Haase, R.
4 Jaenisch, M. Corr, V. Nizet, G.S. Firestein, H.P. Gerber, N. Ferrara, R.S. Johnson, HIF-1 α is
5 essential for myeloid cell-mediated inflammation, Cell 112(5) (2003) 645-657.
6 [https://doi.org/10.1016/s0092-8674\(03\)00154-5](https://doi.org/10.1016/s0092-8674(03)00154-5).

7 [23] G.M. Tannahill, A.M. Curtis, J. Adamik, E.M. Palsson-McDermott, A.F. McGettrick, G. Goel,
8 C. Frezza, N.J. Bernard, B. Kelly, N.H. Foley, L. Zheng, A. Gardet, Z. Tong, S.S. Jany, S.C. Corr,
9 M. Haneklaus, B.E. Caffrey, K. Pierce, S. Walmsley, F.C. Beasley, E. Cummins, V. Nizet, M. Whyte,
10 C.T. Taylor, H. Lin, S.L. Masters, E. Gottlieb, V.P. Kelly, C. Clish, P.E. Auron, R.J. Xavier, L.A.J.
11 O'Neill, Succinate is an inflammatory signal that induces IL-1 β through HIF-1 α , Nature 496 (7444)
12 (2013) 238-242. <https://doi.org/10.1038/nature11986>.

13 [24] S.C. Cheng, J. Quintin, R.A. Cramer, K.M. Shephardson, S. Saeed, V. Kumar, E.J. Giamarellos-
14 Bourboulis, J.H. Martens, N.A. Rao, A. Aghajani-Refah, G.R. Manjari, Y. Li, D.C. Ifrim, R.J. Arts,
15 B.M. van der Veer, P.M. Deen, C. Logie, L.A. O'Neill, P. Willems, F.L. van de Veerdonk, J.W. van
16 der Meer, A. Ng, L.A. Joosten, C. Wijmenga, H.G. Stunnenberg, R.J. Xavier, M.G. Netea, 2014.
17 mTOR- and HIF-1 α -mediated aerobic glycolysis as metabolic basis for trained immunity. Science
18 345(6204), 1250684. <https://doi.org/10.1126/science.1250684>.

19 [25] D. Vats, L. Mukundan, J.I. Odegaard, L. Zhang, K.L. Smith, C.R. Morel, R.A. Wagner, D.R.
20 Greaves, P.J. Murray, A. Chawla, Oxidative metabolism and PGC-1 β attenuate macrophage-
21 mediated inflammation, Cell Metab. 4(1) (2006) 13-24. <https://doi.org/10.1016/j.cmet.2006.05.011>.

22 [26] D. Sag, D. Carling, R.D. Stout, J. Suttles, Adenosine 5'-monophosphate-activated protein kinase
23 promotes macrophage polarization to an anti-inflammatory functional phenotype, J. Immunol.
24 181(12) (2008) 8633-8641. <https://doi.org/10.4049/jimmunol.181.12.8633>.

25 [27] A. Haschemi, P. Kosma, L. Gille, C.R. Evans, C.F. Burant, P. Starkl, B. Knapp, R. Haas, J.A.
26 Schmid, C. Jandl, S. Amir, G. Lubec, J. Park, H. Esterbauer, M. Bilban, L. Brizuela, J.A. Pospisilik,
27 L.E. Otterbein, O. Wagner, The sedoheptulose kinase CARKL directs macrophage polarization
28 through control of glucose metabolism, Cell Metab. 15(6) (2012) 813-826.
29 <https://doi.org/10.1016/j.cmet.2012.04.023>.

30 [28] E.L. Mills, L.A. O'Neill, Reprogramming mitochondrial metabolism in macrophages as an anti-
31 inflammatory signal, Eur. J. Immunol. 46(1) (2016) 13-21. <https://doi.org/10.1002/eji.201445427>.

32 [29] J. Van den Bossche, J. Baardman, N.A. Otto, S. van der Velden, A.E. Neele, S.M. van den Berg,
33 R. Luque-Martin, H.J. Chen, M.C. Boshuizen, M. Ahmed, M.A. Hoeksema, A.F. de Vos, M.P. de
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Winther, Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages, Cell
2 Rep. 17(3) (2016) 684-696. <https://doi.org/10.1016/j.celrep.2016.09.008>.

3 [30] W.A. Baseler, L.C. Davies, L. Quigley, L.A. Ridnour, J.M. Weiss, S.P. Hussain, D.A. Wink,
4 D.W. McVicar, Autocrine IL-10 functions as a rheostat for M1 macrophage glycolytic commitment
5 by tuning nitric oxide production, Redox Biol. 10 (2016) 12-23.
6 <https://doi.org/10.1016/j.redox.2016.09.005>.

7 [31] J.D. Bailey, M. Diotallevi, T. Nicol, E. McNeill, A. Shaw, S. Chuaiphichai, A. Hale, A. Starr,
8 M. Nandi, E. Stylianou, H. McShane, S. Davis, R. Fischer, B.M. Kessler, J. McCullagh, K.M.
9 Channon, M.J. Crabtree, Nitric Oxide Modulates Metabolic Remodeling in Inflammatory
10 Macrophages through TCA Cycle Regulation and Itaconate Accumulation, Cell Rep. 28(1) (2019)
11 218-230. <https://doi.org/10.1016/j.celrep.2019.06.018>.

12 [32] T. Shirai, R.R. Nazarewicz, B.B. Wallis, R.E. Yanes, R. Watanabe, M. Hilhorst, L. Tian, D.G.
13 Harrison, J.C. Giacomini, T.L. Assimes, J.J. Goronzy, C.M. Weyand, The glycolytic enzyme PKM2
14 bridges metabolic and inflammatory dysfunction in coronary artery disease, J. Exp. Med. 213(3)
15 (2016) 337-354. <https://doi.org/10.1084/jem.20150900>.

16 [33] J. Xu, F. Chi, T. Guo, V. Punj, W.N. Lee, S.W. French, H. Tsukamoto, NOTCH reprograms
17 mitochondrial metabolism for proinflammatory macrophage activation, J. Clin. Invest. 125 (2015)
18 1579-1590. <https://doi.org/10.1172/JCI76468>.

19 [34] G. Chinetti-Gbaguidi, S. Colin, B. Staels, Macrophage subsets in atherosclerosis, Nat. Rev.
20 Cardiol. 12(1) (2015) 10-17. <https://doi.org/10.1038/nrcardio.2014.173>.

21 [35] K.Y. Cho, H. Miyoshi, S. Kuroda, H. Yasuda, K. Kamiyama, J. Nakagawara, M. Takigami, T.
22 Kondo, T. Atsumi, The phenotype of infiltrating macrophages influences arteriosclerotic plaque
23 vulnerability in the carotid artery, J. Stroke Cerebrovasc. Dis. 22(7) (2013) 910-918.
24 <https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.11.020>.

25 [36] J. Khallou-Laschet, A. Varthaman, G. Fornasa, C. Compain, A.T. Gaston, M. Clement, M.
26 Dussiot, O. Levillain, S. Graff-Dubois, A. Nicoletti, G. Caligiuri, 2010. Macrophage plasticity in
27 experimental atherosclerosis, PLoS One 5(1), e8852. <https://doi.org/10.1371/journal.pone.0008852>.

28 [37] J.L. Stöger, M.J. Gijbels, S. van der Velden, M. Manca, C.M. van der Loos, E.A. Biessen, M.J.
29 Daemen, E. Lutgens, M.P. de Winther, Distribution of macrophage polarization markers in human
30 atherosclerosis, Atherosclerosis 225(2) (2012) 461-468.
31 <https://doi.org/10.1016/j.atherosclerosis.2012.09.013>.

32 [38] A. Kadl, A.K. Meher, P.R. Sharma, M.Y. Lee, A.C. Doran, S.R. Johnstone, M.R. Elliott, F.
33 Gruber, J. Han, W. Chen, T. Kensler, K.S. Ravichandran, B.E. Isakson, B.R. Wamhoff, N. Leitinger,
34 Identification of a novel macrophage phenotype that develops in response to atherogenic
35

phospholipids via Nrf2, *Circ. Res.* 107(6) (2010) 737-746.

<https://doi.org/10.1161/CIRCRESAHA.109.215715>.

[39] A.V. Finn, M. Nakano, R. Polavarapu, V. Karmali, O. Saeed, X. Zhao, S. Yazdani, F. Otsuka, T. Davis, A. Habib, J. Narula, F.D. Kolodgie, R. Virmani, Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques, *J. Am. Coll. Cardiol.* 59(2) (2012) 166-177. <https://doi.org/10.1016/j.jacc.2011.10.852>.

[40] J.J. Boyle, M. Johns, T. Kampfer, A.T. Nguyen, L. Game, D.J. Schaer, J.C. Mason, D.O. Haskard, Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection, *Circ. Res.* 110(1) (2012) 20-33. <https://doi.org/10.1161/CIRCRESAHA.111.247577>.

[41] L. Potor, Z. Hendrik, A. Patsalos, É. Katona, G. Méhes, S. Póliska, É. Csősz, G. Kalló, I. Komáromi, Z. Combi, N. Posta, K.É. Sikura, D. Pethő, M. Oros, G. Vereb, C. Tóth, P. Gergely, L. Nagy, G. Balla, J. Balla, Oxidation of Hemoglobin Drives a Proatherogenic Polarization of Macrophages in Human Atherosclerosis, *Antioxid. Redox Signal.* 35(12) (2021) 917-950. <https://doi.org/10.1089/ars.2020.8234>.

[42] C.A. Gleissner, Macrophage Phenotype Modulation by CXCL4 in Atherosclerosis, 2012. *Front. Physiol.* 3, 1. <https://doi.org/10.3389/fphys.2012.00001>.

[43] C. Erbel, A. Wolf, F. Lasitschka, F. Linden, G. Domschke, M. Akhavanpoor, A.O. Doesch, H.A. Katus, C.A. Gleissner, Prevalence of M4 macrophages within human coronary atherosclerotic plaques is associated with features of plaque instability, *Int. J. Cardiol.* 186 (2015) 219-225. <https://doi.org/10.1016/j.ijcard.2015.03.151>.

[44] M. Kloc, A. Uosef, J.Z. Kubiak, R.M. Ghobrial, 2020. Role of Macrophages and RhoA Pathway in Atherosclerosis, *Int. J. Mol. Sci.* 22(1), 216. <https://doi.org/10.3390/ijms22010216>.

[45] K. Rajamäki, J. Lappalainen, K. Oörni, E. Välimäki, S. Matikainen, P.T. Kovanen, K.K. Eklund, 2010. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. *PLoS One* 5(7), e11765. <https://doi.org/10.1371/journal.pone.0011765>.

[46] Z. Hoseini, F. Sepahvand, B. Rashidi, A. Sahebkar, A. Masoudifar, H. Mirzaei, NLRP3 inflammasome: Its regulation and involvement in atherosclerosis, *J. Cell. Physiol.* 233(3) (2018) 2116-2132. <https://doi.org/10.1002/jcp.25930>.

[47] F.J. Sheedy, A. Grebe, K.J. Rayner, P. Kalantari, B. Ramkhelawon, S.B. Carpenter, C.E. Becker, H.N. Ediriweera, A.E. Mullick, D.T. Golenbock, L.M. Stuart, E. Latz, K.A. Fitzgerald, K.J. Moore, CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble

ligands into particulate ligands in sterile inflammation, *Nat. Immunol.* 14(8) (2013) 812-820.
<https://doi.org/10.1038/ni.2639>.

[48] X. Chen, X. Guo, Q. Ge, Y. Zhao, H. Mu, J. Zhang ER, 2019. Stress Activates the NLRP3 Inflammasome: A Novel Mechanism of Atherosclerosis. *Oxid. Med. Cell. Longev.* 2019, 3462530.
<https://doi.org/10.1155/2019/3462530>.

[49] J. Shi, Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, Y. Zhuang, T. Cai, F. Wang, F. Shao, Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death, *Nature* 526(7575) (2015) 660-665. <https://doi.org/10.1038/nature15514>.

[50] R. Emanuel, I. Sergin, S. Bhattacharya, J. Turner, S. Epelman, C. Settembre, A. Diwan, A. Ballabio, B. Razani, Induction of lysosomal biogenesis in atherosclerotic macrophages can rescue lipid-induced lysosomal dysfunction and downstream sequelae, *Arterioscler. Thromb. Vasc. Biol.* 34(9) (2014) 1942-1952. <https://doi.org/10.1161/ATVBAHA.114.303342>.

[51] R. Singh, A.M. Cuervo, 2012. Lipophagy: connecting autophagy and lipid metabolism. *Int. J. Cell Biol.* 2012, 282041. <https://doi.org/10.1155/2012/282041>.

[52] K. Liu, E. Zhao, G. Ilyas, G. Lalazar, Y. Lin, M. Haseeb, K.E. Tanaka, M.J. Czaja, Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization, *Autophagy* 11(2) (2015) 271-284.
<https://doi.org/10.1080/15548627.2015.1009787>.

[53] B. Razani, C. Feng, T. Coleman, R. Emanuel, H. Wen, S. Hwang, J.P. Ting, H.W. Virgin, M.B. Kastan, C.F. Semenkovich, Autophagy links inflammasomes to atherosclerotic progression, *Cell Metab.* 15(4) (2012) 534-544. <https://doi.org/10.1016/j.cmet.2012.02.011>.

[54] C. Zhai, J. Cheng, H. Mujahid, H. Wang, J. Kong, Y. Yin, J. Li, Y. Zhang, X. Ji, W. Chen, 2014. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque. *PLoS One* 9(3), e90563.
<https://doi.org/10.1371/journal.pone.0090563>.

[55] F. Tian, B.L. Yu, J.R. Hu, mTOR mediates the cross-talk of macrophage polarization and autophagy in atherosclerosis, *Int. J. Cardiol.* 177(1) (2014) 144-145.
<https://doi.org/10.1016/j.ijcard.2014.09.035>.

[56] M. Kitada, Y. Ogura, D. Koya, The protective role of Sirt1 in vascular tissue: its relationship to vascular aging and atherosclerosis, *Aging (Albany NY)* 8(10) (2016) 2290-2307.
<https://doi.org/10.18632/aging.101068>.

[57] X. Liao, J.C. Sluimer, Y. Wang, M. Subramanian, K. Brown, J.S. Pattison, J. Robbins, J. Martinez, I. Tabas, Macrophage autophagy plays a protective role in advanced atherosclerosis, *Cell Metab.* 15 (2012) 545-553. <https://doi.org/10.1016/j.cmet.2012.01.022>.

- 1 [58] E. Thorp, T. Vaisar, M. Subramanian, L. Mautner, C. Blobel, I. Tabas, Shedding of the Mer
2 tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive
3 oxygen species, protein kinase C δ , and p38 mitogen-activated protein kinase (MAPK), *J. Biol. Chem.*
4 286(38) (2011) 33335-33344. <https://doi.org/10.1074/jbc.M111.263020>.
- 5 [59] U. Garbin, E. Baggio, C. Stranieri, A. Pasini, S. Manfro, C. Mozzini, P. Vallerio, G. Lipari, F.
6 Merigo, G. Guidi, L. Cominacini, A. Fratta Pasini, Expansion of necrotic core and shedding of Mertk
7 receptor in human carotid plaques: a role for oxidized polyunsaturated fatty acids? *Cardiovasc. Res.*
8 97(1) (2013) 125-133. <https://doi.org/10.1093/cvr/cvs301>.
- 9 [60] H. Tao, P.G. Yancey, V.R. Babaev, J.L. Blakemore, Y. Zhang, L. Ding, S. Fazio, M.F. Linton,
10 Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic
11 lesion necrosis, *J. Lipid Res.* 56(8) (2015) 1449-1460. <https://doi.org/10.1194/jlr.M056689>.
- 12 [61] N. A-Gonzalez, S.J. Bensinger, C. Hong, S. Beceiro, M.N. Bradley, N. Zelcer, J. Deniz, C.
13 Ramirez, M. Díaz, G. Gallardo, C.R. de Galarreta, J. Salazar, F. Lopez, P. Edwards, J. Parks, M.
14 Andujar, P. Tontonoz, A. Castrillo, Apoptotic cells promote their own clearance and immune
15 tolerance through activation of the nuclear receptor LXR, *Immunity* 31(2) (2009) 245-258. doi:
16 <https://doi.org/10.1016/j.immuni.2009.06.018>.
- 17 [62] C. Kasikara, A.C. Doran, B. Cai, I. Tabas, The role of non-resolving inflammation in
18 atherosclerosis, *J. Clin. Invest.* 128(7) (2018) 2713-2723. <https://doi.org/10.1172/JCI97950>.
- 19 [63] J. Dalli, C. Serhan, 2016. Macrophage Proresolving Mediators-the When and Where. *Microbiol.*
20 *Spectr.* 4(3), 10.1128/microbiolspec.MCHD-0001-2014.
21 <https://doi.org/10.1128/microbiolspec.MCHD-0001-2014>.
- 22 [64] E. Fung, S.M. Tang, J.P. Canner, K. Morishige, J.F. Arboleda-Velasquez, A.A. Cardoso, N.
23 Carlesso, J.C. Aster, M. Aikawa, Delta-like 4 induces notch signaling in macrophages: implications
24 for inflammation, *Circulation* 115(23) (2007) 2948-2956.
25 <https://doi.org/10.1161/CIRCULATIONAHA.106.675462>.
- 26 [65] D.K. Singla, J. Wang, R. Singla, Primary human monocytes differentiate into M2 macrophages
27 and involve Notch-1 pathway, *Can. J. Physiol. Pharmacol.* 95(3) (2017) 288-294.
28 <https://doi.org/10.1139/cjpp-2016-0319>.
- 29 [66] C. Yang, X. Xiao, L. Huang, F. Zhou, L.H. Chen, Y.Y. Zhao, S.L. Qu, C. Zhang, Role of
30 Kruppel-like factor 4 in atherosclerosis, *Clin. Chim. Acta* 512 (2021) 135-141.
31 <https://doi.org/10.1016/j.cca.2020.11.002>.
- 32 [67] L.J. van Tits, R. Stienstra, P.L. van Lent, M.G. Netea, L.A. Joosten, A.F. Stalenhoef, Oxidized
33 LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

for Krüppel-like factor 2, *Atherosclerosis* 214(2) (2011) 345-349.
<https://doi.org/10.1016/j.atherosclerosis.2010.11.018>.

[68] E.J. Folco, Y. Sheikine, V.Z. Rocha, T. Christen, E. Shvartz, G.K. Sukhova, M.F. Di Carli, P. Libby, Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography, *J. Am. Coll. Cardiol.* 58(6) (2011) 603-614. <https://doi.org/10.1016/j.jacc.2011.03.044>.

[69] M. Terasaki, M. Hiromura, Y. Mori, K. Kohashi, M. Nagashima, H. Kushima, T. Watanabe, T. Hirano, 2015. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice. *PLoS One* 10(11), e0143396. <https://doi.org/10.1371/journal.pone.0143396>.

[70] A. Tawakol, P. Singh, M. Mojena, M. Pimentel-Santillana, H. Emami, M. MacNabb, J.H. Rudd, J. Narula, J.A. Enriquez, P.G. Través, M. Fernández-Velasco, R. Bartrons, P. Martín-Sanz, Z.A. Fayad, A. Tejedor, L. Boscá, HIF-1 α and PFKFB3 Mediate a Tight Relationship Between Proinflammatory Activation and Anerobic Metabolism in Atherosclerotic Macrophages, *Arterioscler. Thromb. Vasc. Biol.* 35(6) (2015) 1463-1471. <https://doi.org/10.1161/ATVBAHA.115.305551>.

[71] Y. Chen, M. Yang, W. Huang, W. Chen, Y. Zhao, M.L. Schulte, P. Volberding, Z. Gerbec, M.T. Zimmermann, A. Zeighami, W. Demos, J. Zhang, D.A. Knaack, B.C. Smith, W. Cui, S. Malarkannan, K. Sodhi, J.I. Shapiro, Z. Xie, D. Sahoo, R.L. Silverstein, Mitochondrial Metabolic Reprogramming by CD36 Signaling Drives Macrophage Inflammatory Responses, *Circ. Res.* 125(12) (2019) 1087-1102. <https://doi.org/10.1161/CIRCRESAHA.119.315833>.

[72] A.B. Santhakumar, M. Battino, J.M. Alvarez-Suarez, Dietary polyphenols: Structures, bioavailability and protective effects against atherosclerosis, *Food Chem. Toxicol.* 113 (2018) 49-65. <https://doi.org/10.1016/j.fct.2018.01.022>.

[73] A.P. Miller, J. Coronel, J. Amengual, 2020. The role of β -carotene and vitamin A in atherogenesis: Evidences from preclinical and clinical studies. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids.* 1865(11), 158635. <https://doi.org/10.1016/j.bbalip.2020.158635>.

[74] I. Balta, L. Stef, I. Pet, T. Iancu, D. Stef, N. Corcionivoschi, Essential Fatty Acids as Biomedicines in Cardiac Health, *Biomedicines.* 9(10) (2021) 1466. [https://doi: 10.3390/biomedicines9101466](https://doi.org/10.3390/biomedicines9101466). PMID: 34680583; PMCID: PMC8533423.

[75] Y. Bai, X. Wang, S. Zhao, C. Ma, J. Cui, Y. Zheng, 2015. Sulforaphane protects against cardiovascular disease via Nrf2 activation. *Oxid. Med. Cell. Longev.* 2015, 407580.

[76] Y. Chen, Y. She, R. Kaur, N. Guo, X. Zhang, R. Zhang, X. Gou, Is Plant Sterols a Good Strategy to Lower Cholesterol? *J. Oleo Sci.* 68(9) (2019) 811-816. <https://doi.org/10.5650/jos.ess19116>.

- 1
2 [77] J.H. Kim, Y.S. Yi, M.Y. Kim, J.Y. Cho, Role of ginsenosides, the main active components
3 of *Panax ginseng*, in inflammatory responses and diseases, *J. Ginseng Res.* 41(4) (2017) 435-443.
4 <https://doi.org/10.1016/j.jgr.2016.08.004>.
- 5 [78] F.C. Wu, J.G. Jiang, Effects of diosgenin and its derivatives on atherosclerosis, *Food Funct.*
6 10(11) (2019) 7022-7036. <https://doi.org/10.1039/c9fo00749k>.
- 7 [79] A. Fatahian, S.M. Haftcheshmeh, S. Azhdari, H.K. Farshchi, B. Nikfar, A.A. Momtazi-Borojeni,
8 Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical
9 Studies. *Rev. Physiol. Biochem. Pharmacol.* 178 (2020) 83-110.
10 https://doi.org/10.1007/112_2020_42.
- 11 [80] A. Viljoen, N. Mncwangi, I. Vermaak, Anti-inflammatory iridoids of botanical origin, *Curr.*
12 *Med. Chem.* 19(14) (2012) 2104-2127. <https://doi.org/10.2174/092986712800229005>.
- 13 [81] S. Gao, Z. Liu, H. Li, P.J. Little, P. Liu, S. Xu, Cardiovascular actions and therapeutic potential
14 of tanshinone IIA, *Atherosclerosis* 220(1) (2012) 3-10.
15 <https://doi.org/10.1016/j.atherosclerosis.2011.06.041>.
- 16 [82] E. Sokoła-Wysoczańska, T. Wysoczański, J. Wagner, K. Czyż, R. Bodkowski, S. Lochyński, B.
17 Patkowska-Sokoła, 2018. Polyunsaturated Fatty Acids and Their Potential Therapeutic Role in
18 Cardiovascular System Disorders-A Review. *Nutrients.* 10(10), 1561.
19 <https://doi.org/10.3390/nu10101561>.
- 20 [83] Y. Kishimoto, H. Yoshida, K. Kondo, 2016. Potential Anti-Atherosclerotic Properties of
21 Astaxanthin. *Mar. Drugs.* 14(2), 35. <https://doi.org/10.3390/md14020035>.
- 22 [84] D.R. Fraser, Vitamin D toxicity related to its physiological and unphysiological supply, *Trends*
23 *Endocrinol. Metab.* 32(11) (2021) 929-940. <https://doi.org/10.1016/j.tem.2021.08.006>.
- 24 [85] A.M. Surdu, O. Pînzariu, D.M. Ciobanu, A.G. Negru, S.S. Căinap, C. Lazea, D. Iacob, G. Săraci,
25 D. Tirinescu, I.M. Borda, G. Cismaru, 2021. Vitamin D and Its Role in the Lipid Metabolism and the
26 Development of Atherosclerosis. *Biomedicines* 9(2), 172.
27 <https://doi.org/10.3390/biomedicines9020172>.
- 28 [86] Z. Xie, S.P. Baba, B.R. Sweeney, O.A. Barski, Detoxification of aldehydes by histidine-
29 containing dipeptides: from chemistry to clinical implications, *Chem. Biol. Interact.* 202(1-3) (2013)
30 288-297. <https://doi.org/10.1016/j.cbi.2012.12.017>.
- 31 [87] O.A. Barski, Z. Xie, S.P. Baba, S.D. Sithu, A. Agarwal, J. Cai, A. Bhatnagar, S. Srivastava,
32 Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice,
33 *Arterioscler. Thromb. Vasc. Biol.* 33(6) (2013) 1162-1170.
34 <https://doi.org/10.1161/ATVBAHA.112.300572>.
- 35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2 [88] I. Rashid, D.M. van Reyk, M.J. Davies, Carnosine and its constituents inhibit glycation of low-
3 density lipoproteins that promotes foam cell formation in vitro, *FEBS Lett.* 581(5) (2007) 1067-1070.
4 <https://doi.org/10.1016/j.febslet.2007.01.082>.
- 5 [89] S. Bhaskar, V. Shalini, A. Helen, Quercetin regulates oxidized LDL induced inflammatory
6 changes in human PBMCs by modulating the TLR-NF- κ B signaling pathway, *Immunobiology* 216(3)
7 (2011) 367-373. <https://doi.org/10.1016/j.imbio.2010.07.011>.
- 8 [90] X. Zhang, G. Wang, E.C. Gurley, H. Zhou, 2014. Flavonoid apigenin inhibits
9 lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophages.
10 *PLoS One* 9(9), e107072. <https://doi.org/10.1371/journal.pone.0107072>.
- 11 [91] X. Zhang, J. Cao, L. Jiang, L. Zhong, Suppressive effects of hydroxytyrosol on oxidative stress
12 and nuclear Factor-kappaB activation in THP-1 cells, *Biol. Pharm. Bull.* 32(4) (2009) 578-82.
13 <https://doi.org/10.1248/bpb.32.578>.
- 14 [92] E. Scoditti, A. Nestola, M. Massaro, N. Calabriso, C. Storelli, R. De Caterina, M.A. Carluccio,
15 Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human
16 monocytes via PKC α and PKC β 1 inhibition, *Atherosclerosis* 232(1) (2014) 17-24.
17 <https://doi.org/10.1016/j.atherosclerosis.2013.10.017>.
- 18 [93] M.C. Maiuri, D. De Stefano, P. Di Meglio, C. Irace, M. Savarese, R. Sacchi, M.P. Cinelli, R.
19 Carnuccio, Hydroxytyrosol, a phenolic compound from virgin olive oil, prevents macrophage
20 activation, *Naunyn Schmiedebergs Arch. Pharmacol.* 371(6) (2005) 457-465.
21 <https://doi.org/10.1007/s00210-005-1078-y>.
- 22 [94] S. Gargiulo, D. Rossin, G. Testa, P. Gamba, E. Staurenghi, F. Biasi, G. Poli, G. Leonarduzzi,
23 Up-regulation of COX-2 and mPGES-1 by 27-hydroxycholesterol and 4-hydroxynonenal: A crucial
24 role in atherosclerotic plaque instability, *Free Radic. Biol. Med.* 129 (2018) 354-363. doi:
25 <https://doi.org/10.1016/j.freeradbiomed.2018.09.046>.
- 26 [95] Y. Liu, X. Wang, J. Pang, H. Zhang, J. Luo, X. Qian, Q. Chen, W. Ling, Attenuation of
27 Atherosclerosis by Protocatechuic Acid via Inhibition of M1 and Promotion of M2 Macrophage
28 Polarization, *J. Agric. Food Chem.* 67(3) (2019) 807-818. <https://doi.org/10.1021/acs.jafc.8b05719>.
- 29 [96] S. Singh, B.B. Aggarwal, Activation of transcription factor NF-kappa B is suppressed by
30 curcumin (diferuloylmethane) [corrected], *J. Biol. Chem.* (1995) 270(42) 24995-5000.
31 <https://doi.org/10.1074/jbc.270.42.24995>.
- 32 [97] Y. Zhou, T. Zhang, X. Wang, X. Wei, Y. Chen, L. Guo, J. Zhang, C. Wang, Curcumin Modulates
33 Macrophage Polarization Through the Inhibition of the Toll-Like Receptor 4 Expression and its
34 Signaling Pathways, *Cell. Physiol. Biochem.* 36(2) (2015) 631-641.
35 <https://doi.org/10.1159/000430126>.
- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [98] F. Chen, N. Guo, G. Cao, J. Zhou, Z. Yuan, Molecular analysis of curcumin-induced polarization of murine RAW264.7 macrophages, *J. Cardiovasc. Pharmacol.* (2014) 63(6) 544-52. <https://doi.org/10.1097/FJC.000000000000079>.
- [99] A. Jacob, R. Wu, M. Zhou, P. Wang, 2007. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation. *PPAR Res.* 2007, 89369. <https://doi.org/10.1155/2007/89369>.
- [100] V.R. Narala, M.R. Smith, R.K. Adapala, R. Ranga, K. Panati, B.B. Moore, T. Leff, V.D. Reddy, A.K. Kondapi, R.C. Reddy, Curcumin is not a ligand for peroxisome proliferator-activated receptor- γ , *Gene Ther. Mol. Biol.* 13(1) (2009) 20-25.
- [101] M.R. Guimarães, F.R. Leite, L.C. Spolidorio, K.L. Kirkwood, C. Rossa Jr, Curcumin abrogates LPS-induced pro-inflammatory cytokines in RAW 264.7 macrophages. Evidence for novel mechanisms involving SOCS-1, -3 and p38 MAPK, *Arch. Oral Biol.* 58(10) (2013) 1309-1317. <https://doi.org/10.1016/j.archoralbio.2013.07.005>.
- [102] J. Hong, M. Bose, J. Ju, J.H. Ryu, X. Chen, S. Sang, M.J. Lee, C.S. Yang, Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase, *Carcinogenesis* 25(9) (2004) 1671-1679. <https://doi.org/10.1093/carcin/bgh165>.
- [103] B. Buttari, E. Profumo, L. Segoni, D. D'Arcangelo, S. Rossi, F. Facchiano, L. Saso, R. Businaro, L. Iuliano, R. Riganò, 2014. Resveratrol counteracts inflammation in human M1 and M2 macrophages upon challenge with 7-oxo-cholesterol: potential therapeutic implications in atherosclerosis. *Oxid. Med. Cell. Longev.* 2014, 257543. <https://doi.org/10.1155/2014/257543>.
- [104] C. Ma, Y. Wang, A. Shen, W. Cai, Resveratrol upregulates SOCS1 production by lipopolysaccharide-stimulated RAW264.7 macrophages by inhibiting miR-155, *Int. J. Mol. Med.* 39(1) (2017) 231-237. <https://doi.org/10.3892/ijmm.2016.2802>.
- [105] Y. Zong, L. Sun, B. Liu, Y.S. Deng, D. Zhan, Y.L. Chen, Y. He, J. Liu, Z.J. Zhang, J. Sun, D. Lu, 2012. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. *PLoS One.* 7(8), e44107. <https://doi.org/10.1371/journal.pone.0044107>.
- [106] H.Y. Chang, H.N. Lee, W. Kim, Y.J. Surh, Docosahexaenoic acid induces M2 macrophage polarization through peroxisome proliferator-activated receptor γ activation, *Life Sci.* 120 (2015) 39-47. <https://doi.org/10.1016/j.lfs.2014.10.014>.
- [107] K. Yamagata, C. Tsuruta, A. Ohtuski, M. Tagami, Docosahexaenoic acid decreases TNF- α -induced lectin-like oxidized low-density lipoprotein receptor-1 expression in THP-1 cells, *Prostaglandins Leukot. Essent. Fatty Acids* 90(4) (2014) 125-132. <https://doi.org/10.1016/j.plefa.2013.12.011>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [108] A. Takashima, D. Fukuda, K. Tanaka, Y. Higashikuni, Y. Hirata, S. Nishimoto, S. Yagi, H. Yamada, T. Soeki, T. Wakatsuki, Y. Taketani, M. Shimabukuro, M. Sata Combination of n-3 polyunsaturated fatty acids reduces atherogenesis in apolipoprotein E-deficient mice by inhibiting macrophage activation, *Atherosclerosis* 254 (2016) 142-150. <https://doi.org/10.1016/j.atherosclerosis.2016.10.002>.
- [109] X. Li, Y. Yu, C.D. Funk, Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4), *FASEB J.* 27(12) (2013) 4987-4997. <https://doi.org/10.1096/fj.13-235333>.
- [110] C. De Pascale, V. Graham, R.C. Fowkes, C.P.D. Wheeler-Jones, K.M. Botham, Suppression of nuclear factor-kappaB activity in macrophages by chylomicron remnants: modulation by the fatty acid composition of the particles, *FEBS J.* 276(19) (2009) 5689-5702. <https://doi.org/10.1111/j.1742-4658.2009.07260.x>.
- [111] T.L. Si, Q. Liu, Y.F. Ren, H. Li, X.Y. Xu, E.H. Li, S.Y. Pan, J.L. Zhang, K.X. Wang, Enhanced anti-inflammatory effects of DHA and quercetin in lipopolysaccharide-induced RAW264.7 macrophages by inhibiting NF- κ B and MAPK activation, *Mol. Med. Rep.* 14(1) (2016) 499-508. <https://doi.org/10.3892/mmr.2016.5259>.
- [112] N. Martinez-Micaelo, N. González-Abuín, X. Terra, C. Richart, A. Ardèvol, M. Pinent, M. Blay, Omega-3 docosahexaenoic acid and procyanidins inhibit cyclo-oxygenase activity and attenuate NF- κ B activation through a p105/p50 regulatory mechanism in macrophage inflammation, *Biochem. J.* 441(2) (2012) 653-663. <https://doi.org/10.1042/BJ20110967>.
- [113] Y. Yu, P.H. Correll, J.P. Vanden Heuvel, Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPAR gamma-dependent mechanism, *Biochim. Biophys. Acta* 1581(3) (2002) 89-99. [https://doi.org/10.1016/s1388-1981\(02\)00126-9](https://doi.org/10.1016/s1388-1981(02)00126-9).
- [114] E. Stachowska, J. Kijowski, V. Dziedziejko, A. Siennicka, D. Chlubek, Conjugated linoleic acid regulates phosphorylation of PPAR γ by modulation of ERK 1/2 and p38 signaling in human macrophages/fatty acid-laden macrophages, *J. Agric. Food Chem.* 59(21) (2011) 11846-11852. <https://doi.org/10.1021/jf2014233>.
- [115] Y. Lee, J.T. Thompson, A.R. de Lera, J.P. Vanden Heuvel, Isomer-specific effects of conjugated linoleic acid on gene expression in RAW 264.7, *J. Nutr. Biochem.* 20(11) (2009) 848-859, 859.e1-5. <https://doi.org/10.1016/j.jnutbio.2008.07.013>.
- [116] C. McCarthy, M.M. Duffy, D. Mooney, W.G. James, M.D. Griffin, D.J. Fitzgerald, O. Belton, IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis, *FASEB J.* 27(2) (2013) 499-510. <https://doi.org/10.1096/fj.12-215442>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [117] H.N. Lee, Y.J. Surh, Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis, *Biochem. Pharmacol.* 86(6) (2013) 759-769. <https://doi.org/10.1016/j.bcp.2013.07.002>.
- [118] A. Ryan, C. Godson, Lipoxins: regulators of resolution, *Curr. Opin. Pharmacol.* 10(2) (2010) 166-172. <https://doi.org/10.1016/j.coph.2010.02.005>.
- [119] B.E. Sansbury, M. Spite, Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology. *Circ. Res.* 119(1) (2016) 113-30. <https://doi:10.1161/CIRCRESAHA.116.307308>.
- [120] J. Mai, W. Liu, Y. Fang, S. Zhang, Q. Qiu, Y. Yang, X. Wang, T. Huang, H. Zhang, Y. Xie, M. Lin, Y. Chen, J. Wang, The atheroprotective role of lipoxin A₄ prevents oxLDL-induced apoptotic signaling in macrophages via JNK pathway, *Atherosclerosis* 278 (2018) 259-268. <https://doi.org/10.1016/j.atherosclerosis.2018.09.025>.
- [121] Z. Huang, S. Meng, L. Wang, Y. Wang, T. Chen, C. Wang, Suppression of oxLDL-induced MMP-9 and EMMPRIN expression by berberine via inhibition of NF-κB activation in human THP-1 macrophages, *Anat. Rec. (Hoboken)* 295(1) (2012) 78-86. <https://doi.org/10.1002/ar.21489>.
- [122] L. Lu, J. Huang, X. Xue, T. Wang, Z. Huang, J. Li, 2021. Berberine Regulated miR150-5p to Inhibit P2X7 Receptor, EMMPRIN and MMP-9 Expression in oxLDL Induced Macrophages. *Front. Pharmacol.* 12, 639558. <https://doi.org/10.3389/fphar.2021.639558>.
- [123] J. Li, H.T. Lei, L. Cao, Y.N. Mi, S. Li, Y.X. Cao, Crocin alleviates coronary atherosclerosis via inhibiting lipid synthesis and inducing M2 macrophage polarization, *Int. Immunopharmacol.* 55 (2018) 120-127. <https://doi.org/10.1016/j.intimp.2017.11.037>.
- [124] J. Marcotorchino, B. Romier, E. Gouranton, C. Riollet, B. Gleize, C. Malezet-Desmoulins, J.F. Landrier, Lycopene attenuates LPS-induced TNF-α secretion in macrophages and inflammatory markers in adipocytes exposed to macrophage-conditioned media, *Mol. Nutr. Food Res.* 56(5) (2012) 725-732. <https://doi.org/10.1002/mnfr.201100623>.
- [125] L. Speranza, M. Pesce, A. Patruno, S. Franceschelli, M.A. de Lutiis, A. Grilli, M. Felaco, Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target, *Mar. Drugs* 10(4) (2012) 890-899. <https://doi.org/10.3390/md10040890>.
- [126] E. Bas, M.C. Recio, S. Mánuez, R.M. Giner, J.M. Escandell, C. López-Ginés, J.L. Ríos, New insight into the inhibition of the inflammatory response to experimental delayed-type hypersensitivity reactions in mice by scropolioside A, *Eur. J. Pharmacol.* 555(2-3) (2007) 199-210. <https://doi.org/10.1016/j.ejphar.2006.10.012>.

- 1
2 [127] Y. Zhang, D.Y. Leung, B.N. Richers, Y. Liu, L.K. Remigio, D.W. Riches, E. Goleva, Vitamin
3 D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK
4 phosphatase-1, *J. Immunol.* 188(5) (2012) 2127-2135. <https://doi.org/10.4049/jimmunol.1102412>.
- 5 [128] F. Carbone, N. Satta, F. Burger, A. Roth, S. Lenglet, S. Pagano, P. Lescuyer, M. Bertolotto, G.
6 Spinella, B. Pane, D. Palombo, A. Pende, F. Dallegri, F. Mach, N. Vuilleumier, F. Montecucco,
7 Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory
8 M1 macrophages, *Vascul. Pharmacol.* 85 (2016) 57-65. <https://doi.org/10.1016/j.vph.2016.08.004>.
- 9 [129] S. Kumar, R. Nanduri, E. Bhagyaraj, R. Kalra, N. Ahuja, A.P. Chacko, D. Tiwari, K. Sethi, A.
10 Saini, V. Chandra, M. Jain, S. Gupta, D. Bhatt, P. Gupta, Vitamin D3-VDR-PTPN6 axis mediated
11 autophagy contributes to the inhibition of macrophage foam cell formation, *Autophagy* 17(9) (2021)
12 2273-2289. <https://doi.org/10.1080/15548627.2020.1822088>.
- 13 [130] D.Y. Lee, H. Li, H.J. Lim, H.J. Lee, R. Jeon, J.H. Ryu, Anti-inflammatory activity of sulfur-
14 containing compounds from garlic, *J. Med. Food.* 15(11) (2012) 992-999.
15 <https://doi.org/10.1089/jmf.2012.2275>.
- 16 [131] M. Guo, J. Xiao, X. Sheng, X. Zhang, Y. Tie, L. Wang, L. Zhao, X. Ji, 2018. Ginsenoside Rg3
17 Mitigates Atherosclerosis Progression in Diabetic apoE^{-/-} Mice by Skewing Macrophages to the M2
18 Phenotype. *Front. Pharmacol.* 9, 464. <https://doi.org/10.3389/fphar.2018.00464>.
- 19 [132] X. Zhang, M.H. Liu, L. Qiao, X.Y. Zhang, X.L. Liu, M. Dong, H.Y. Dai, M. Ni, X.R. Luan, J.
20 Guan, H.X. Lu, Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages
21 to the M2 phenotype, *J. Cell. Mol. Med.* 22(1) (2018) 409-416. <https://doi.org/10.1111/jcmm.13329>.
- 22 [133] A. Binesh, S.N. Devaraj, H. Devaraj, Inhibition of nuclear translocation of notch intracellular
23 domain (NICD) by diosgenin prevented atherosclerotic disease progression, *Biochimie* 148 (2018)
24 63-71. <https://doi.org/10.1016/j.biochi.2018.02.011>.
- 25 [134] D.H. Jung, H.J. Park, H.E. Byun, Y.M. Park, T.W. Kim, B.O. Kim, S.H. Um, S. Pyo, Diosgenin
26 inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, NF-
27 kappaB and AP-1 activation, *Int. Immunopharmacol.* 10(9) (2010) 1047-1054.
28 <https://doi.org/10.1016/j.intimp.2010.06.004>.
- 29 [135] B.C. Zhang, C.W. Zhang, C. Wang, D.F. Pan, T.D. Xu, D.Y. Li, Luteolin Attenuates Foam Cell
30 Formation and Apoptosis in Ox-LDL-Stimulated Macrophages by Enhancing Autophagy, *Cell.*
31 *Physiol. Biochem.* 39(5) (2016) 2065-2076. <https://doi.org/10.1159/000447902>.
- 32 [136] J. Wei, L. Huang, D. Li, J. He, Y. Li, F. He, W. Fang, G. Wei, 2021. Total Flavonoids of
33 *Engelhardia roxburghiana* Wall. Leaves Alleviated Foam Cells Formation through AKT/mTOR-
34 Mediated Autophagy in the Progression of Atherosclerosis. *Chem. Biodivers.* 18(9), e2100308.
35 <https://doi.org/10.1002/cbdv.202100308>.
- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [137] S. Jamuna, R. Ashokkumar, M.S. Sakeena Sadullah, S.N. Devaraj, Oligomeric proanthocyanidins and epigallocatechin gallate aggravate autophagy of foam cells through the activation of Class III PI3K/Beclin1-complex mediated cholesterol efflux, *Biofactors* 45(5) (2019) 763-773. <https://doi.org/10.1002/biof.1537>.
- [138] B. Liu, B. Zhang, R. Guo, S. Li, Y. Xu, Enhancement in efferocytosis of oxidized low-density lipoprotein-induced apoptotic RAW264.7 cells through Sirt1-mediated autophagy, *Int. J. Mol. Med.* (2014) 33(3) 523-533. <https://doi.org/10.3892/ijmm.2013.1609>.
- [139] W.J. Duan, Y.F. Li, F.L. Liu, J. Deng, Y.P. Wu, W.L. Yuan, B. Tsoi, J.L. Chen, Q. Wang, S.H. Cai, H. Kurihara, R.R. He, A SIRT3/AMPK/autophagy network orchestrates the protective effects of trans-resveratrol in stressed peritoneal macrophages and RAW 264.7 macrophages, *Free Radic. Biol. Med.* 95 (2016) 230-242. <https://doi.org/10.1016/j.freeradbiomed.2016.03.022>.
- [140] H. Cao, Q. Jia, L. Yan, C. Chen, S. Xing, D. Shen, 2019. Quercetin Suppresses the Progression of Atherosclerosis by Regulating MST1-Mediated Autophagy in ox-LDL-Induced RAW264.7 Macrophage Foam Cells. *Int. J. Mol. Sci.* 20(23), 6093. <https://doi.org/10.3390/ijms20236093>.
- [141] F. Kong, B. Ye, J. Cao, X. Cai, L. Lin, S. Huang, W. Huang, Z. Huang, 2016. Curcumin Represses NLRP3 Inflammasome Activation via TLR4/MyD88/NF-κB and P2X7R Signaling in PMA-Induced Macrophages. *Front. Pharmacol.* 7, 369. <https://doi.org/10.3389/fphar.2016.00369>.
- [142] P. Chalons, S. Amor, F. Courtaut, E. Cantos-Villar, T. Richard, C. Auger, P. Chabert, V. Schni-Kerth, V. Aires, D. Delmas, 2018. Study of Potential Anti-Inflammatory Effects of Red Wine Extract and Resveratrol through a Modulation of Interleukin-1-Beta in Macrophages. *Nutrients.* 10(12), 1856. <https://doi.org/10.3390/nu10121856>.
- [143] B.C. Zhang, Z. Li, W. Xu, C.H. Xiang, Y.F. Ma, Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells, *Am. J. Transl. Res.* 10(1) (2018) 265-273.
- [144] J.Y. Kou, Y. Li, Z.Y. Zhong, Y.Q. Jiang, X.S. Li, X.B. Han, Z.N. Liu, Y. Tian, L.M. Yang, 2018. Berberine-sonodynamic therapy induces autophagy and lipid unloading in macrophage. *Cell Death Dis.* 8(1), e2558. <https://doi.org/10.1038/cddis.2016.354>.
- [145] X. Fan, J. Wang, J. Hou, C. Lin, A. Bensoussan, D. Chang, J. Liu, B. Wang, 2015. Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway. *J. Transl. Med.* 13, 92. <https://doi.org/10.1186/s12967-015-0450-z>.
- [146] Y. Luo, S. Lu, Y. Gao, K. Yang, D. Wu, X. Xu, G. Sun, X. Sun, Araloside C attenuates atherosclerosis by modulating macrophage polarization via Sirt1-mediated autophagy, *Aging (Albany NY)* 12(2) (2020) 1704-1724. <https://doi.org/10.18632/aging.102708>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [147] L. Qiao, X. Zhang, M. Liu, X. Liu, M. Dong, J. Cheng, X. Zhang, C. Zhai, Y. Song, H. Lu, W. Chen, 2017. Ginsenoside Rb1 Enhances Atherosclerotic Plaque Stability by Improving Autophagy and Lipid Metabolism in Macrophage Foam Cells. *Front. Pharmacol.* 8, 727. <https://doi.org/10.3389/fphar.2017.00727>.
- [148] J. Kim, H. Ahn, B.C. Han, S.H. Lee, Y.W. Cho, C.H. Kim, E.J. Hong, B.S. An, E.B. Jeung, G.S. Lee, Korean red ginseng extracts inhibit NLRP3 and AIM2 inflammasome activation, *Immunol. Lett.* 158(1-2) (2014) 143-150. <https://doi.org/10.1016/j.imlet.2013.12.017>.
- [149] S. Leng, S. Iwanowycz, F. Saaoud, J. Wang, Y. Wang, I. Sergin, B. Razani, D. Fan, Ursolic acid enhances macrophage autophagy and attenuates atherogenesis, *J. Lipid Res.* 57(6) (2016) 1006-1016. <https://doi.org/10.1194/jlr.M065888>.
- [150] W. Chen, X. Li, S. Guo, N. Song, J. Wang, L. Jia, A. Zhu, Tanshinone IIA harmonizes the crosstalk of autophagy and polarization in macrophages via miR-375/KLF4 pathway to attenuate atherosclerosis, *Int. Immunopharmacol.* 70 (2019) 486-497. <https://doi.org/10.1016/j.intimp.2019.02.054>.
- [151] T. Zhu, L. Zhang, S. Ling, J. Duan, F. Qian, Y. Li, J.W. Xu, 2014. Scropolioside B inhibits IL-1 β and cytokines expression through NF- κ B and inflammasome NLRP3 pathways. *Mediators Inflamm.* 2014, 819053. <https://doi.org/10.1155/2014/819053>.
- [152] L. Shen, Y. Yang, T. Ou, C.C. Key, S.H. Tong, R.C. Sequeira, J.M. Nelson, Y. Nie, Z. Wang, E. Boudyguina, S.V. Shewale, X. Zhu, Dietary PUFAs attenuate NLRP3 inflammasome activation via enhancing macrophage autophagy, *J. Lipid Res.* 58(9) (2017) 1808-1821. <https://doi.org/10.1194/jlr.M075879>.
- [153] Y. Yan, W. Jiang, T. Spinetti, A. Tardivel, R. Castillo, C. Bourquin, G. Guarda, Z. Tian, J. Tschopp, R. Zhou, Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation, *Immunity* 38(6) (2013) 1154-1163. <https://doi.org/10.1016/j.immuni.2013.05.015>.
- [154] E. Bigagli, L. Cinci, S. Paccosi, A. Parenti, M. D'Ambrosio, C. Luceri, Nutritionally relevant concentrations of resveratrol and hydroxytyrosol mitigate oxidative burst of human granulocytes and monocytes and the production of pro-inflammatory mediators in LPS-stimulated RAW 264.7 macrophages, *Int. Immunopharmacol.* 43 (2017) 147-155. <https://doi.org/10.1016/j.intimp.2016.12.012>.
- [155] G. Pepe, E. Sommella, D. Cianciarulo, C. Ostacolo, M. Manfra, V. Di Sarno, S. Musella, M. Russo, A. Messori, B. Parrino, A. Bertamino, G. Autore, S. Marzocco, P. Campiglia, 2018. Polyphenolic Extract from Tarocco (*Citrus sinensis* L. Osbeck) Clone "Lempso" Exerts Anti-

1 Inflammatory and Antioxidant Effects via NF-kB and Nrf-2 Activation in Murine Macrophages.
2 Nutrients. 10(12), 1961. <https://doi.org/10.3390/nu10121961>.

3 [156] R. Vari, M. D'Archivio, C. Filesi, S. Carotenuto, B. Scazzocchio, C. Santangelo, C. Giovannini,
4 R. Masella, Protocatechuic acid induces antioxidant/detoxifying enzyme expression through JNK-
5 mediated Nrf2 activation in murine macrophages, J. Nutr. Biochem. 22(5) (2011) 409-417.
6 <https://doi.org/10.1016/j.jnutbio.2010.03.008>.

7 [157] S.G. Lee, C.R. Brownmiller, S.O. Lee, H.W. Kang, 2020. Anti-Inflammatory and Antioxidant
8 Effects of Anthocyanins of *Trifolium pratense* (Red Clover) in Lipopolysaccharide-Stimulated
9 RAW-267.4 Macrophages. Nutrients. 12(4), 1089. <https://doi.org/10.3390/nu12041089>.

10 [158] S.J. Chapple, R.C. Siow, G.E. Mann, Crosstalk between Nrf2 and the proteasome: therapeutic
11 potential of Nrf2 inducers in vascular disease and aging, Int. J. Biochem. Cell Biol. 44(8) (2012)
12 1315-1320. <https://doi.org/10.1016/j.biocel.2012.04.021>.

13 [159] M.K. Kwak, N. Wakabayashi, J.L. Greenlaw, M. Yamamoto, T.W. Kensler, Antioxidants
14 enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway, Mol. Cell.
15 Biol. 23(23) (2003) 8786-8794. <https://doi.org/10.1128/MCB.23.23.8786-8794.2003>.

16 [160] A.J. Greaney, N.K. Maier, S.H. Leppla, M. Moayeri, Sulforaphane inhibits multiple
17 inflammasomes through an Nrf2-independent mechanism, J. Leukoc. Biol. 99(1) (2016) 189-199.
18 <https://doi.org/10.1189/jlb.3A0415-155RR>.

19 [161] M. Ali, M. Bonay, V. Vanhee, S. Vinit, T.B. Deramautd, 2020. Comparative effectiveness of
20 4 natural and chemical activators of Nrf2 on inflammation, oxidative stress, macrophage polarization,
21 and bactericidal activity in an in vitro macrophage infection model. PLoS One. 15(6), e0234484.
22 <https://doi.org/10.1371/journal.pone.0234484>.

23 [162] R.T. Ruhee, S. Ma, K. Suzuki, 2019. Sulforaphane Protects Cells against Lipopolysaccharide-
24 Stimulated Inflammation in Murine Macrophages. Antioxidants (Basel). 8(12), 577.
25 <https://doi.org/10.3390/antiox8120577>.

26 [163] A.E. Wagner, C. Boesch-Saadatmandi, J. Dose, G. Schultheiss, G. Rimbach, Anti-
27 inflammatory potential of allyl-isothiocyanate--role of Nrf2, NF-(κ) B and microRNA-155, J. Cell.
28 Mol. Med. 16(4) (2012) 836-843. <https://doi.org/10.1111/j.1582-4934.2011.01367.x>.

29 [164] S.B. Vasamsetti, S. Karnewar, R. Gopaju, P.N. Gollavilli, S.R. Narra, J.M. Kumar, S.
30 Kotamraju, Resveratrol attenuates monocyte-to-macrophage differentiation and associated
31 inflammation via modulation of intracellular GSH homeostasis: Relevance in atherosclerosis, Free
32 Radic Biol. Med. 96 (2016) 392-405. <https://doi.org/10.1016/j.freeradbiomed.2016.05.003>.

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2 [165] X. Liu, J. Li, X. Peng, B. Lv, P. Wang, X. Zhao, B. Yu, Geraniin Inhibits LPS-Induced THP-1
3 Macrophages Switching to M1 Phenotype via SOCS1/NF- κ B Pathway, *Inflammation* 39(4) (2016)
4 1421-1433. <https://doi.org/10.1007/s10753-016-0374-7>.
- 5 [166] S. Qi, Z. Feng, Q. Li, Z. Qi, Y. Zhang, 2017. Myricitrin Modulates NADPH Oxidase-Dependent
6 ROS Production to Inhibit Endotoxin-Mediated Inflammation by Blocking the JAK/STAT1 and
7 NOX2/p47phox Pathways. *Oxid. Med. Cell. Longev.* 2017, 9738745.
8 <https://doi.org/10.1155/2017/9738745>.
- 9 [167] M. Shiner, B. Fuhrman, M. Aviram, Macrophage paraoxonase 2 (PON2) expression is up-
10 regulated by pomegranate juice phenolic anti-oxidants via PPAR gamma and AP-1 pathway
11 activation, *Atherosclerosis* 195(2) (2007) 313-321.
12 <https://doi.org/10.1016/j.atherosclerosis.2007.01.007>.
- 13 [168] Y. Manabe, Y. Takii, T. Sugawara, Siphonaxanthin, a carotenoid from green algae, suppresses
14 advanced glycation end product-induced inflammatory responses, *J. Nat. Med.* 74(1) (2020) 127-134.
15 <https://doi.org/10.1007/s11418-019-01354-z>.
- 16 [169] Y. Zhang, C. Wang, Y. Jin, Q. Yang, Q. Meng, Q. Liu, Y. Dai, L. Cai, Z. Liu, K. Liu, H. Sun,
17 2018. Activating the PGC-1 α /TERT Pathway by Catalpol Ameliorates Atherosclerosis via
18 Modulating ROS Production, DNA Damage, and Telomere Function: Implications on Mitochondria
19 and Telomere Link. *Oxid. Med. Cell. Longev.* 2018, 2876350. <https://doi.org/10.1155/2018/2876350>.
- 20 [170] Q. Chen, X. Qi, W. Zhang, Y. Zhang, Y. Bi, Q. Meng, H. Bian, Y. Li, 2021. Catalpol Inhibits
21 Macrophage Polarization and Prevents Postmenopausal Atherosclerosis Through Regulating
22 Estrogen Receptor Alpha. *Front. Pharmacol.* 12, 655081. <https://doi.org/10.3389/fphar.2021.655081>.
- 23 [171] L.K. Sarna, N. Wu, S.Y. Hwang, Y.L. Siow, K. O, Berberine inhibits NADPH oxidase mediated
24 superoxide anion production in macrophages, *Can. J. Physiol. Pharmacol.* 88(3) (2010) 369-378.
25 <https://doi.org/10.1139/Y09-136>.
- 26 [172] M. Vivancos, J.J. Moreno, beta-Sitosterol modulates antioxidant enzyme response in RAW
27 264.7 macrophages, *Free Radic. Biol. Med.* (2005) 39(1) 91-97.
28 <https://doi.org/10.1016/j.freeradbiomed.2005.02.025>.
- 29 [173] J. Jiang, Z.C. Mo, K. Yin, G.J. Zhao, Y.C. Lv, X.P. Ouyang, Z.S. Jiang, Y. Fu, C.K. Tang,
30 Epigallocatechin-3-gallate prevents TNF- α -induced NF- κ B activation thereby upregulating ABCA1
31 via the Nrf2/Keap1 pathway in macrophage foam cells, *Int. J. Mol. Med.* 29(5) (2012) 946-956.
32 <https://doi.org/10.3892/ijmm.2012.924>.
- 33 [174] J. Saenz, C. Santa-María, M.E. Reyes-Quiroz, I. Geniz, J. Jiménez, F. Sobrino, G. Alba,
34 Grapefruit Flavonoid Naringenin Regulates the Expression of LXR α in THP-1 Macrophages by
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Modulating AMP-Activated Protein Kinase, *Mol. Pharm.* 15(5) (2018) 1735-1745.
2 <https://doi.org/10.1021/acs.molpharmaceut.7b00797>.

3 [175] A. Iio, K. Ohguchi, M. Inuma, Y. Nozawa, M. Ito, Hesperetin upregulates ABCA1 expression
4 and promotes cholesterol efflux from THP-1 macrophages, *J. Nat. Prod.* (2012) 75(4) 563-566.
5 <https://doi.org/10.1021/np200696r>.

6 [176] L. Sun, E. Li, F. Wang, T. Wang, Z. Qin, S. Niu, C. Qiu, 2015. Quercetin increases macrophage
7 cholesterol efflux to inhibit foam cell formation through activating PPARgamma-ABCA1 pathway.
8 *Int. J. Clin. Exp. Pathol.* 8(9), 10854-60.

9 [177] T.T. Liu, Y. Zeng, K. Tang, X. Chen, W. Zhang, X.L. Xu, Dihydromyricetin ameliorates
10 atherosclerosis in LDL receptor deficient mice, *Atherosclerosis* 262 (2017) 39-50.
11 <https://doi.org/10.1016/j.atherosclerosis.2017.05.003>.

12 [178] X.Y. Li, L.X. Kong, J. Li, H.X. He, Y.D. Zhou, Kaempferol suppresses lipid accumulation in
13 macrophages through the downregulation of cluster of differentiation 36 and the upregulation of
14 scavenger receptor class B type I and ATP-binding cassette transporters A1 and G1, *Int. J. Mo.l Med.*
15 31(2) (2013) 331-338. <https://doi.org/10.3892/ijmm.2012.1204>.

16 [179] G. Ye, G. Chen, H. Gao, Y. Lin, X. Liao, H. Zhang, X. Liu, Y. Chi, Q. Huang, H. Zhu, Y. Fan,
17 S. Dong, Resveratrol inhibits lipid accumulation in the intestine of atherosclerotic mice and
18 macrophages, *J. Cell. Mol. Med.* 23(6) (2019) 4313-4325. <https://doi.org/10.1111/jcmm.14323>.

19 [180] S. Zhao, J. Li, L. Wang, X. Wu, Pomegranate peel polyphenols inhibit lipid accumulation and
20 enhance cholesterol efflux in raw264.7 macrophages, *Food Funct.* 7(7) (2016) 3201-3210.
21 <https://doi.org/10.1039/c6fo00347h>.

22 [181] C. Wu, H. Luan, X. Zhang, S. Wang, X. Zhang, X. Sun, P. Guo, 2014. Chlorogenic acid protects
23 against atherosclerosis in ApoE^{-/-} mice and promotes cholesterol efflux from RAW264.7
24 macrophages. *PLoS One*, 9(9), e95452. <https://doi.org/10.1371/journal.pone.0095452>.

25 [182] J.F. Zhao, L.C. Ching, Y.C. Huang, C.Y. Chen, A.N. Chiang, Y.R. Kou, S.K. Shyue, T.S. Lee,
26 Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage
27 foam cells and atherosclerosis, *Mol. Nutr. Food Res.* 56(5) (2012) 691-701.
28 <https://doi.org/10.1002/mnfr.201100735>.

29 [183] X.L. Lin, M.H. Liu, H.J. Hu, H.R. Feng, X.J. Fan, W.W. Zou, Y.Q. Pan, X.M. Hu, Z. Wang,
30 Curcumin enhanced cholesterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-
31 LXRA signaling in THP-1 macrophage-derived foam cells, *DNA Cell Biol.* (2015) 34(9) 561-572.
32 <https://doi.org/10.1089/dna.2015.2866>.

33 [184] F.Y. Chen, J. Zhou, N. Guo, W.G. Ma, X. Huang, H. Wang, Z.Y. Yuan, Curcumin retunes
34 cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

atherosclerosis, *Biochem. Biophys. Res. Commun.* 467(4) (2015) 872-878.
<https://doi.org/10.1016/j.bbrc.2015.10.051>.

[185] J.H. Chen, C.W. Tsai, C.P. Wang, H.H. Lin, Anti-atherosclerotic potential of gossypetin via inhibiting LDL oxidation and foam cell formation, *Toxicol. Appl. Pharmacol.* 272(2) (2013) 313-324. <https://doi.org/10.1016/j.taap.2013.06.027>.

[186] W. Dong, X. Wang, S. Bi, Z. Pan, S. Liu, H. Yu, H. Lu, X. Lin, X. Wang, T. Ma, W. Zhang, Inhibitory effects of resveratrol on foam cell formation are mediated through monocyte chemotactic protein-1 and lipid metabolism-related proteins, *Int. J. Mol. Med.* (2014) 33(5) 1161-1168. <https://doi.org/10.3892/ijmm.2014.1680>.

[187] Q. Jia, H. Cao, D. Shen, L. Yan, C. Chen, S. Xing, 2019. Fisetin, via CKIP-1/REGgamma, limits oxidized LDL-induced lipid accumulation and senescence in RAW264.7 macrophage-derived foam cells. *Eur J Pharmacol.* 865, 172748. <https://doi.org/10.1016/j.ejphar.2019.172748>.

[188] J.F. Varghese, R. Patel, M. Singh, U. Chand Singh Yadav, Fisetin prevents oxidized low-density lipoproteins induced macrophage foam cell formation, *J. Cardiovasc. Pharmacol.* 78(5) (2021) e729-e737. <https://doi.org/10.1097/FJC.0000000000001096>.

[189] R.G. Carroll, Z. Zaslona, S. Galván-Peña, E.L. Koppe, D.C. Sévin, S. Angiari, M. Triantafilou, K. Triantafilou, L.K. Modis, L.A. O'Neill, An unexpected link between fatty acid synthase and cholesterol synthesis in proinflammatory macrophage activation, *J. Biol. Chem.* 293(15) (2018) 5509-5521. <https://doi.org/10.1074/jbc.RA118.001921>.

[190] M. Rosenblat, N. Volkova, M. Aviram, Pomegranate phytosterol (beta-sitosterol) and polyphenolic antioxidant (punicalagin) addition to statin, significantly protected against macrophage foam cells formation, *Atherosclerosis* 226(1) (2013) 110-117. <https://doi.org/10.1016/j.atherosclerosis.2012.10.054>.

[191] N.S. Sabeva, C.M. McPhaul, X. Li, T.J. Cory, D.J. Feola, G.A. Graf, Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foamcells, *J. Nutr. Biochem.* 22(8) (2011) 777-783. <https://doi.org/10.1016/j.jnutbio.2010.07.002>.

[192] J.W. Moss, T.S. Davies, I. Garaiova, S.F. Plummer, D.R. Michael, D.P. Ramji, 2016. A Unique Combination of Nutritionally Active Ingredients Can Prevent Several Key Processes Associated with Atherosclerosis In Vitro. *PLoS One.* 11(3), e0151057. <https://doi.org/10.1371/journal.pone.0151057>.

[193] J. Ishiyama, R. Taguchi, Y. Akasaka, S. Shibata, M. Ito, M. Nagasawa, K. Murakami, Unsaturated FAs prevent palmitate-induced LOX-1 induction via inhibition of ER stress in macrophages, *J. Lipid Res.* 52(2) (2011) 299-307. <https://doi.org/10.1194/jlr.M007104>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [194] O. Rom, H. Jeries, T. Hayek, M. Aviram, Supplementation with linoleic acid-rich soybean oil stimulates macrophage foam cell formation via increased oxidative stress and diacylglycerol acyltransferase1-mediated triglyceride biosynthesis, *Biofactors* 43(1) (2017) 100-116. <https://doi.org/10.1002/biof.1319>.
- [195] Y. Wang, J.F. Oram, Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1, *J. Biol. Chem.* 277(7) (2002) 5692-5697. <https://doi.org/10.1074/jbc.M109977200>.
- [196] J.E. Kanter, C. Tang, J.F. Oram, K.E. Bornfeldt, Acyl-CoA synthetase 1 is required for oleate and linoleate mediated inhibition of cholesterol efflux through ATP-binding cassette transporter A1 in macrophages, *Biochim. Biophys. Acta* 1821(3) (2012) 358-364. <https://doi.org/10.1016/j.bbaliip.2011.10.008>.
- [197] C.S. Ku, Y. Park, S.L. Coleman, J. Lee, Unsaturated fatty acids repress expression of ATP binding cassette transporter A1 and G1 in RAW 264.7 macrophages, *J. Nutr. Biochem.* (2012) 23(10) 1271-1276. <https://doi.org/10.1016/j.jnutbio.2011.07.007>.
- [198] M. de Gaetano, K. Alghamdi, S. Marcone, O. Belton, 2015. Conjugated linoleic acid induces an atheroprotective macrophage MΦ2 phenotype and limits foam cell formation. *J. Inflamm. (Lond)*. 12, 15. <https://doi.org/10.1186/s12950-015-0060-9>.
- [199] C. McCarthy, N.T. Lieggi, D. Barry, D. Mooney, M. de Gaetano, W.G. James, S. McClelland, M.C. Barry, L. Escoubet-Lozach, A.C. Li, C.K. Glass, D.J. Fitzgerald, O. Belton, Macrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid, *EMBO Mol. Med.* 5(9) (2013) 1443-1457. <https://doi.org/10.1002/emmm.201302587>.
- [200] S. Weldon, S. Mitchell, D. Kelleher, M.J. Gibney, H.M. Roche, Conjugated linoleic acid and atherosclerosis: no effect on molecular markers of cholesterol homeostasis in THP-1 macrophages, *Atherosclerosis* 174(2) (2004) 261-273. <https://doi.org/10.1016/j.atherosclerosis.2004.02.007>.
- [201] J. Ecker, T. Langmann, C. Moehle, G. Schmitz, Isomer specific effects of Conjugated Linoleic Acid on macrophage ABCG1 transcription by a SREBP-1c dependent mechanism, *Biochem. Biophys. Res. Commun.* 352(3) (2007) 805-811. <https://doi.org/10.1016/j.bbrc.2006.11.087>.
- [202] P. Palozza, R. Simone, A. Catalano, N. Parrone, G. Monego, F.O. Ranelletti, Lycopene regulation of cholesterol synthesis and efflux in human macrophages, *J. Nutr. Biochem.* 22(10) (2011) 971-978. <https://doi.org/10.1016/j.jnutbio.2010.08.010>.
- [203] S. Bechor, N. Zolberg Relevy, A. Harari, T. Almog, Y. Kamari, A. Ben-Amotz, D. Harats, A. Shaish, 2016. 9-cis β -Carotene Increased Cholesterol Efflux to HDL in Macrophages. *Nutrients*. 8(7), 435. <https://doi.org/10.3390/nu8070435>.

- 1
2 [204] J. Liu, Y. Wei, Y. Lin, P. Zhang, Z. Zhang, H. Huang, H. Wu, T. Zou, 2021. Expression of the
3 circular RNAs in astaxanthin promotes cholesterol efflux from THP-1 cells based on RNA-seq. *Genes*
4 *Nutr.* 16(1), 13. <https://doi.org/10.1186/s12263-021-00693-5>.
- 5 [205] Y.C. Lv, J. Yang, F. Yao, W. Xie, Y.Y. Tang, X.P. Ouyang, P.P. He, Y.L. Tan, L. Li, M. Zhang,
6 D. Liu, F.S. Cayabyab, X.L. Zheng, C.K. Tang, Diosgenin inhibits atherosclerosis via suppressing
7 the MiR-19b-induced downregulation of ATP-binding cassette transporter A1, *Atherosclerosis*
8 240(1) (2015) 80-89. <https://doi.org/10.1016/j.atherosclerosis.2015.02.044>.
- 9 [206] X.L. Lin, H.J. Hu, Y.B. Liu, X.M. Hu, X.J. Fan, W.W. Zou, Y.Q. Pan, W.Q. Zhou, M.W. Peng,
10 C.H. Gu, Allicin induces the upregulation of ABCA1 expression via PPARgamma/LXRalpha
11 signaling in THP-1 macrophage-derived foam cells, *Int. J. Mol. Med.* 39(6) (2017) 1452-1460.
12 <https://doi.org/10.3892/ijmm.2017.2949>.
- 13 [207] K. Yin, Y. You, V. Swier, L. Tang, M.M. Radwan, A.N. Pandya, D.K. Agrawal, Vitamin D
14 Protects Against Atherosclerosis via Regulation of Cholesterol Efflux and Macrophage Polarization
15 in Hypercholesterolemic Swine, *Arterioscler. Thromb. Vasc. Biol.* (2015) 35(11) 2432-2442.
16 <https://doi.org/10.1161/ATVBAHA.115.306132>.
- 17 [208] Z. Huang, F. Dong, S. Li, M. Chu, H. Zhou, Z. Lu, W. Huang, Berberine-induced inhibition of
18 adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and
19 foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages, *Eur. J. Pharmacol.*
20 690(1-3) (2012) 164-169. <https://doi.org/10.1016/j.ejphar.2012.07.009>.
- 21 [209] X.J. Yang, F. Liu, N. Feng, X.S. Ding, Y. Chen, S.X. Zhu, L.C. Yang, X.F. Feng, Berberine
22 Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and
23 Activation of the Nrf2/HO-1 Pathway, *J. Cardiovasc. Pharmacol.* 75(1) (2020) 45-53.
24 <https://doi.org/10.1097/FJC.0000000000000769>
- 25 [210] L. Chi, L. Peng, N. Pan, X. Hu, Y. Zhang, The anti-atherogenic effects of berberine on foam
26 cell formation are mediated through the upregulation of sirtuin 1, *Int. J. Mol. Med.* 34(4) (2014) 1087-
27 1093. <https://doi.org/10.3892/ijmm.2014.1868>.
- 28 [211] F. Zimetti, M.P. Adorni, N. Ronda, R. Gatti, F. Bernini, E. Favari, The natural compound
29 berberine positively affects macrophage functions involved in atherogenesis, *Nutr. Metab.*
30 *Cardiovasc. Dis.* 25(2) (2015) 195-201. [10.1016/j.numecd.2014.08.004](https://doi.org/10.1016/j.numecd.2014.08.004).
- 31 [212] J.E. McLaren, D.R. Michael, I.A. Guschina, J.L. Harwood, DP. Ramji, Eicosapentaenoic acid
32 and docosahexaenoic acid regulate modified LDL uptake and macropinocytosis in human
33 macrophages, *Lipids* 46(11) (2011) 1053-1061. <https://doi.org/10.1007/s11745-011-3598-1>.
- 34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [213] Z. Liu, J. Wang, E. Huang, S. Gao, H. Li, J. Lu, K. Tian, P.J. Little, X. Shen, S. Xu, P. Liu, Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1, *J. Lipid Res.* 55(2) (2014) 201-213. <https://doi.org/10.1194/jlr.M040394>.
- [214] L. Dugo, M.G. Belluomo, C. Fanali, M. Russo, F. Cacciola, M. Maccarrone, A.M. Sardanelli, 2017. Effect of Cocoa Polyphenolic Extract on Macrophage Polarization from Proinflammatory M1 to Anti-Inflammatory M2 State. *Oxid. Med. Cell. Longev.* 2017, 6293740. <https://doi.org/10.1155/2017/6293740>.
- [215] G. Caruso, C.G. Fresta, A. Fidilio, F. O'Donnell, N. Musso, G. Lazzarino, M. Grasso, A.M. Amorini, F. Tascetta, C. Bucolo, F. Drago, B. Tavazzi, G. Lazzarino, S.M. Lunte, F. Caraci, 2019. Carnosine Decreases PMA-Induced Oxidative Stress and Inflammation in Murine Macrophages. *Antioxidants (Basel)*. 8(8), 281. <https://doi.org/10.3390/antiox8080281>.
- [216] C.G. Fresta, A. Fidilio, G. Lazzarino, N. Musso, M. Grasso, S. Merlo, A.M. Amorini, C. Bucolo, B. Tavazzi, G. Lazzarino, S.M. Lunte, F. Caraci, G. Caruso, 2020. Modulation of Pro-Oxidant and Pro-Inflammatory Activities of M1 Macrophages by the Natural Dipeptide Carnosine. *Int. J. Mol. Sci.* 21(3), 776. <https://doi.org/10.3390/ijms21030776>.
- [217] R. Bahramsoltani, F. Ebrahimi, M.H. Farzaei, A. Baratpournoghaddam, P. Ahmadi, P. Rostamiasrabadi, A.H. Rasouli Amirabadi, R. Rahimi, Dietary polyphenols for atherosclerosis: A comprehensive review and future perspectives, *Crit. Rev. Food Sci. Nutr.* 59(1) (2019) 114-132. <https://doi.org/10.1080/10408398.2017.1360244>.
- [218] R. Casas, R. Estruch, E. Sacanella, 2018. Influence of Bioactive Nutrients on the Atherosclerotic Process: A Review. *Nutrients*. 10(11), 1630. <https://doi.org/10.3390/nu10111630>.
- [219] M. Urpi-Sarda, R. Casas, E. Sacanella, D. Corella, C. Andrés-Lacueva, R. Llorach, G. Garrabou, F. Cardellach, A. Sala-Vila, E. Ros, M. Ruiz-Canela, M. Fitó, J. Salas-Salvadó, R. Estruch, 2021. The 3-Year Effect of the Mediterranean Diet Intervention on Inflammatory Biomarkers Related to Cardiovascular Disease. *Biomedicines*. 9(8), 862. <https://doi.org/10.3390/biomedicines9080862>.
- [220] A. Medina-Remón, R. Casas, A. Tresserra-Rimbau, E. Ros, M.A. Martínez-González, M. Fitó, D. Corella, J. Salas-Salvadó, R.M. Lamuela-Raventos, R. Estruch; PREDIMED Study Investigators, Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers related to atherosclerosis: a substudy of the PREDIMED trial, *Br. J. Clin. Pharmacol.* 83(1) (2017) 114-128. <https://doi.org/10.1111/bcp.12986>.
- [221] M.A. Martínez-González, J. Salas-Salvadó, R. Estruch, D. Corella, M. Fitó, E. Ros; PREDIMED INVESTIGATORS, Benefits of the Mediterranean Diet: Insights From the PREDIMED Study, *Prog. Cardiovasc. Dis.* 58(1) (2015) 50-60. <https://doi.org/10.1016/j.pcad.2015.04.003>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [222] R. Casas, E. Sacanella, M. Urpí-Sardà, G. Chiva-Blanch, E. Ros, M.A. Martínez-González, M.I. Covas, R.M. Lamuela-Raventos, J. Salas-Salvadó, M. Fiol, F. Arós, R. Estruch, 2014. The effects of the mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial. *PLoS One*. 9(6), e100084. doi: <https://doi.org/10.1371/journal.pone.0100084>.
- [223] M. Urpi-Sarda, R. Casas, G. Chiva-Blanch, E.S. Romero-Mamani, P. Valderas-Martínez, S. Arranz, C. Andres-Lacueva, R. Llorach, A. Medina-Remón, R.M. Lamuela-Raventos, R. Estruch, Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomarkers related to atherosclerosis, *Pharmacol. Res.* 65(6) (2012) 577-583. <https://doi.org/10.1016/j.phrs.2012.03.006>.
- [224] V. Konstantinidou, M.I. Covas, R. Sola, M. Fitó, Up-to date knowledge on the in vivo transcriptomic effect of the Mediterranean diet in humans, *Mol. Nutr. Food Res.* 57(5) (2013) 772-783. <https://doi.org/10.1002/mnfr.201200613>.
- [225] N. Khan, O. Khymenets, M. Urpí-Sardà, S. Tulipani, M. Garcia-Aloy, M. Monagas, X. Mora-Cubillos, R. Llorach, C. Andres-Lacueva, Cocoa polyphenols and inflammatory markers of cardiovascular disease, *Nutrients* 6(2) (2014) 844-880. <https://doi.org/10.3390/nu6020844>.
- [226] M. Monagas, N. Khan, C. Andres-Lacueva, R. Casas, M. Urpí-Sardà, R. Llorach, R.M. Lamuela-Raventós, R. Estruch, Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease, *Am. J. Clin. Nutr.* 90(5) (2009) 1144-1150. <https://doi.org/10.3945/ajcn.2009.27716>.
- [227] N. Khan, H. Mukhtar, Tea and health: studies in humans, *Curr. Pharm. Des.* 19(34) (2013) 6141-6147. <https://doi.org/10.2174/1381612811319340008>.
- [228] M. Massaro, E. Scoditti, M.A. Carluccio, R. De Caterina, 2010. Nutraceuticals and prevention of atherosclerosis: focus on omega-3 polyunsaturated fatty acids and Mediterranean diet polyphenols. *Cardiovasc. Ther.* 28(4), e13-9. <https://doi.org/10.1111/j.1755-5922.2010.00211.x>.
- [229] P. Ditano-Vázquez, J.D. Torres-Peña, F. Galeano-Valle, A.I. Pérez-Caballero, P. Demelo-Rodríguez, J. Lopez-Miranda, N. Katsiki, J. Delgado-Lista, L.A. Alvarez-Sala-Walther, 2019. The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. *Nutrients*. 11(11), 2833. <https://doi.org/10.3390/nu11112833>.
- [230] J. Tomé-Carneiro, M. González, M. Larrosa, M.J. Yáñez-Gascón, F.J. García-Almagro, J.A. Ruiz-Ros, F.A. Tomás-Barberán, M.T. García-Conesa, J.C. Espín, Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease, *Cardiovasc. Drugs Ther.* 27(1) (2013) 37-48. <https://doi.org/10.1007/s10557-012-6427-8>.

[231] J. Tomé-Carneiro, M. Larrosa, M.J. Yáñez-Gascón, A. Dávalos, J. Gil-Zamorano, M. González, F.J. García-Almagro, J.A. Ruiz Ros, F.A. Tomás-Barberán, J.C. Espín, M.T. García-Conesa, One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease, *Pharmacol. Res.* 72 (2013) 69-82. <https://doi.org/10.1016/j.phrs.2013.03.011>.

[232] A. Camargo, J. Delgado-Lista, A. Garcia-Rios, C. Cruz-Teno, E.M. Yubero-Serrano, P. Perez-Martinez, F.M. Gutierrez-Mariscal, P. Lora-Aguilar, F. Rodriguez-Cantalejo, F. Fuentes-Jimenez, F.J. Tinahones, M.M. Malagon, F. Perez-Jimenez, J. Lopez-Miranda, Expression of proinflammatory, proatherogenic genes is reduced by the Mediterranean diet in elderly people, *Br. J. Nutr.* 108(3) (2012) 500-508. <https://doi: 10.1017/S0007114511005812>.

[233] G.M. Quintana-Navarro, J.F. Alcalá-Díaz, J. Lopez-Moreno, I. Perez-Corral, A. Leon-Acuña, J.D. Torres-Peña, O.A. Rangel-Zuñiga, A.P. Arenas de Larriva, A. Corina, A. Camargo, E.M. Yubero-Serrano, F. Rodriguez-Cantalejo, A. Garcia-Rios, R.M. Luque, J.M. Ordovas, P. Perez-Martinez, J. Lopez-Miranda, J. Delgado-Lista, Long-term dietary adherence and changes in dietary intake in coronary patients after intervention with a Mediterranean diet or a low-fat diet: the CORDIOPREV randomized trial, *Eur. J. Nutr.* 59(5) (2020) 2099-2110. <https://doi.org/10.1007/s00394-019-02059-5>.

[234] J. Jimenez-Torres, J.F. Alcalá-Díaz, J.D. Torres-Peña, F.M. Gutierrez-Mariscal, A. Leon-Acuña, P. Gómez-Luna, C. Fernández-Gandara, G.M. Quintana-Navarro, J.C. Fernandez-Garcia, P. Perez-Martinez, J.M. Ordovas, J. Delgado-Lista, E.M. Yubero-Serrano, J. Lopez-Miranda, Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial, *Stroke* 52(11) (2021) 3440-3449. <https://doi.org/10.1161/STROKEAHA.120.033214>.

[235] Y. Hu, F.B. Hu, J.E. Manson, 2019. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. *J. Am. Heart Assoc.* 8(19), e013543. <https://doi.org/10.1161/JAHA.119.013543>.

[236] A.S. Abdelhamid, T.J. Brown, J.S. Brainard, P. Biswas, G.C. Thorpe, H.J. Moore, K.H. Deane, C.D. Summerbell, H.V. Worthington, F. Song, L. Hooper, 2020. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst. Rev.* 3(2), CD003177. <https://doi.org/10.1002/14651858.CD003177.pub5>.

1 [237] C. Skarke, N. Alamuddin, J.A. Lawson, X. Li, J.F. Ferguson, M.P. Reilly, G.A. FitzGerald,
2 Bioactive products formed in humans from fish oils, *J. Lipid Res.* 56(9) (2015) 1808-1820.
3 <https://doi.org/10.1194/jlr.M060392>.

4 [238] J. So, D. Wu, A.H. Lichtenstein, A.K. Tai, N.R. Matthan, K.R. Maddipati, S. Lamon-Fava,
5 EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic
6 inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-
7 blind, crossover study, *Atherosclerosis* 316 (2021) 90-98.
8 <https://doi.org/10.1016/j.atherosclerosis.2020.11.018>.

9 [239] M.S. Schaller, M. Chen, R.A. Colas, T.A. Sorrentino, A.A. Lazar, S.M. Grenon, J. Dalli, M.S.
10 Conte, 2020. Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte
11 Phenotype in Healthy Patients and Those With Peripheral Artery Disease. *J. Am. Heart Assoc.* 9(15),
12 e016113. <https://doi.org/10.1161/JAHA.120.016113>.

13 [240] T. Niki, T. Wakatsuki, K. Yamaguchi, Y. Taketani, H. Oeduka, K. Kusunose, T. Ise, T. Iwase,
14 H. Yamada, T. Soeki, M. Sata, Effects of the Addition of Eicosapentaenoic Acid to Strong Statin
15 Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated
16 Backscatter Intravascular Ultrasound, *Circ. J.* 80(2) (2016) 450-460. <https://doi.org/10.1253/circj.CJ-15-0813>.

17 [241] A.L. Cawood, R. Ding, F.L. Napper, R.H. Young, J.A. Williams, M.J. Ward, O. Gudmundsen,
18 R. Vige, S.P. Payne, S. Ye, C.P. Shearman, P.J. Gallagher, R.F. Grimble, P.C. Calder,
19 Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into
20 advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque
21 inflammation and increased stability, *Atherosclerosis* 212(1) (2010) 252-259.
22 <https://doi.org/10.1016/j.atherosclerosis.2010.05.022>.

23 [242] F. Thies, J.M. Garry, P. Yaqoob, K. Rerkasem, J. Williams, C.P. Shearman, P.J. Gallagher,
24 P.C. Calder, R.F. Grimble, Association of n-3 polyunsaturated fatty acids with stability of
25 atherosclerotic plaques: a randomised controlled trial, *Lancet* 361(9356) (2003) 477-485.
26 [https://doi.org/10.1016/S0140-6736\(03\)12468-3](https://doi.org/10.1016/S0140-6736(03)12468-3).

27 [243] Y. Yao, H.M. Goh, J.E. Kim, The Roles of Carotenoid Consumption and Bioavailability in
28 Cardiovascular Health, *Antioxidants (Basel)* 10(12) (2021) 1978. [https://doi:](https://doi.org/10.3390/antiox10121978)
29 [10.3390/antiox10121978](https://doi.org/10.3390/antiox10121978).

30 [244] J. Huang, S.J. Weinstein, K. Yu, S. Männistö, D. Albanes, Serum Beta Carotene and Overall
31 and Cause-Specific Mortality, *Circ. Res.* 123(12) (2018) 1339-1349.
32 <https://doi.org/10.1161/CIRCRESAHA.118.313409>.

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [245] G. Bjelakovic, D. Nikolova, L.L. Gluud, R.G. Simonetti, C. Gluud, 2012. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst. Rev.* 2012(3), CD007176. <https://doi.org/10.1002/14651858.CD007176.pub2>.
- [246] V.A. Moyer, Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. preventive services task force recommendation statement, *Ann. Intern. Med.* 160(8) (2014) 558-564. <https://doi.org/10.7326/M14-0198>.
- [247] H.M. Cheng, G. Koutsidis, J.K. Lodge, A. Ashor, M. Siervo, J. Lara, Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis, *Atherosclerosis* 257 (2017) 100-108. <https://doi.org/10.1016/j.atherosclerosis.2017.01.009>.
- [248] Z.Y. Zou, X.R. Xu, X.M. Lin, H.B. Zhang, X. Xiao, L. Ouyang, Y.M. Huang, X. Wang, Y.Q. Liu, Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial, *Br. J. Nutr.* 111(3) (2014) 474-480. <https://doi.org/10.1017/S0007114513002730>.
- [249] M. Colmán-Martínez, M. Martínez-Huélamo, P. Valderas-Martínez, S. Arranz-Martínez, E. Almanza-Aguilera, D. Corella, R. Estruch, R.M. Lamuela-Raventós, 2017. trans-Lycopene from tomato juice attenuates inflammatory biomarkers in human plasma samples: An intervention trial. *Mol. Nutr. Food Res.* 61(11). <https://doi.org/10.1002/mnfr.201600993>.
- [250] F. Thies, L.F. Masson, A. Rudd, N. Vaughan, C. Tsang, J. Brittenden, W.G. Simpson, S. Duthie, G.W. Horgan, G. Duthie, Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial, *Am. J. Clin. Nutr.* 95(5) (2012) 1013-1022. <https://doi.org/10.3945/ajcn.111.026286>.
- [251] P.R. Gajendragadkar, A. Hubsch, K.M. Mäki-Petäjä, M. Serg, I.B. Wilkinson, J. Cheriyan, 2014. Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. *PLoS One.* 9(6), e99070. <https://doi.org/10.1371/journal.pone.0099070>.
- [252] S. Devaraj, I. Jialal, J. Rockwood, D. Zak, Effect of orange juice and beverage with phytosterols on cytokines and PAI-1 activity, *Clin. Nutr.* 30(5) (2011) 668-671. <https://doi.org/10.1016/j.clnu.2011.03.009>.
- [253] V.Z. Rocha, R.T. Ras, A.C. Gagliardi, L.C. Mangili, E.A. Trautwein, R.D. Santos, Effects of phytosterols on markers of inflammation: A systematic review and meta-analysis, *Atherosclerosis* 248 (2016) 76-83. <https://doi.org/10.1016/j.atherosclerosis.2016.01.035>
- [254] Z. Luo, Y. Liu, Z. Zhao, X. Yan, D. Wang, Q. Liu, 2020. Effects of Astragalus injection and Salvia Miltiorrhiza injection on serum inflammatory markers in patients with stable coronary heart

disease: a randomized controlled trial protocol. *Trials*. 21(1), 267. <https://doi.org/10.1186/s13063-020-4109-6>.

[255] K. Gul, A.K. Singh, R. Jabeen, *Nutraceuticals and Functional Foods: The Foods for the Future World*, *Crit. Rev. Food Sci. Nutr.* (2016) 56(16) 2617-2627. <https://doi.org/10.1080/10408398.2014.903384>.

[256] A.M. Ruiz-León, M. Lapuente, R. Estruch, R. Casas, 2019. *Clinical Advances in Immunonutrition and Atherosclerosis: A Review*. *Front. Immunol.* 10, 837. <https://doi.org/10.3389/fimmu.2019.00837>.

[257] A.F.G. Cicero, F. Fogacci, A. Colletti, *Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach*, *Food Funct.* 8(6) (2017) 2076-2088. <https://doi.org/10.1039/c7fo00178a>.

[258] B. Scolaro, H. Soo Jin Kim, I.A. de Castro, *Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention*, *Crit. Rev. Food Sci. Nutr.* 58(6) (2018) 958-971. <https://doi.org/10.1080/10408398.2016.1235546>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Fig. 1. Different macrophage subtypes found in atherosclerotic lesion. Stimuli present in atherosclerotic lesions direct macrophage polarization towards different phenotypes characterized by specific expression and function profiles.

Fig. 2. Nutraceutical modulation of the most relevant macrophage signaling pathways and the relative beneficial effects against atheroma progression.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- Pro- or anti-inflammatory macrophage polarization drives atheroma development.
- Oxidative stress and lipid dyshomeostasis promote pro-inflammatory polarization.
- Nutraceuticals affect macrophage inflammatory, oxidative and metabolic pathways.
- Nutraceutical use may favor antiinflammatory atherosclerotic macrophage polarization.





Figure 1

[Click here to access/download;Figure;Fig.1.pdf](#)



MOLECULAR SPECIES	AFFECTED SIGNALING	EFFECTS
<ul style="list-style-type: none"> • Polyphenols • Resveratrol • Curcumin • Hydroxytyrosol • Unsaturated fatty acids (UFAs) • ω-3 Polyunsaturated fatty acids (PUFAs) • ω-6 Polyunsaturated fatty acids (PUFAs) • Docosahexaenoic acid (DHA) • Carotenoids • Organosulfur compounds • Vitamin D • Iridoids • Berberine • Saponins • Diosgenin • Ginsenosides, Apigenin, β-Sitosterol 	<ul style="list-style-type: none"> → NF-κB, MAPKs, TLRs, STATs, PPARγ, PI3K/Akt, inflammasome, autophagy → SOCS, CREB → SOCS, PLA₂ → PKC, IRF-R → NF-κB, MAPKs, TLRs, STATs, PPARγ → SPMs, inflammasome → SPMs → PI3K/Akt, GPRs → NF-Kb → NF-κB, MAPKs → MAPKs, TLRs → NF-κB, inflammasome, autophagy → NF-κB, MAPKs, miR150-5p, autophagy → NF-κB, MAPKs, STATs, PPARγ, autophagy → AP-1, CK2, NOTCH → Inflammasome, autophagy 	<p style="text-align: center;">ATTENUATION OR RESOLUTION OF INFLAMMATION</p>
<ul style="list-style-type: none"> • Polyphenols, Organosulfur compounds • Resveratrol • Geraniin • Hydroxytyrosol • Punicalagin, Gallic acid • Myricitrin • Protocatechuic acid • Docosahexaenoic acid (DHA) • Siphonaxanthin • β-Sitosterol • Catalpol 	<ul style="list-style-type: none"> → Nrf2 → AMPK, miR-146a, Nrf2 → NF-κB, SOCS → miR-146a, Nrf2 → PPARγ, AP-1 → JAK/STAT → MAPKs → PI3K/Akt → NF-κB → PI3K/Akt, estrogen receptors → PGC/TERT, estrogen receptors 	<p style="text-align: center;">REDUCTION OF OXIDATIVE STRESS</p>
<ul style="list-style-type: none"> • Polyphenols • Fisetin • Epigallocatechin gallate (EGCG) • Conjugated linoleic acid (CLA) • Vitamin D • Berberine • Carnosine, Tanshinone II, Berberine • Lycopene, Allicin 	<ul style="list-style-type: none"> → LXRs, AMPK, PPARs, SIRT6 → SREBPs, CKIP-1, inflammasome, proteasome → NF-κB, Nrf2 → LXRs, SREBPs, PPARs → LXRs → PPARs, SIRT6 → Nrf2 → LXRs, PPARs 	<p style="text-align: center;">REDIRECTION OF CELLULAR METABOLISM</p>

Table 1. Principal nutraceutical compounds and their food sources.

Compounds	Food sources
- Polyphenols:	
Resveratrol	Grape and red wine
Curcumin	Turmeric (curcuma)
Epigallocatechin gallate (EGCG)	Green tea, hibiscus
Punicalagin, Gallic acid	Pomegranate juice
Protocatechuic acid	Black olives, mushrooms, chicory
Phenolic acids	Coffee
Hydroxytyrosol	Olive oil
Others	Fruits (citrus), vegetables, cocoa, spices
- Carotenoids:	
Carotenes	Green leafy vegetables, crucifers, orange and yellow fruits and vegetables, egg yolk
Xanthophylls	Green algae, salmon, trout, fish eggs, crustaceans
- Organosulfur compounds:	
Allicin, Ajoene	Garlic
Sulforaphane, Allyl-isothiocyanate	Crucifers, mustard
- Saponins:	
Ginsenosides, Ursolic acid	Ginseng
Diosgenin	Fenugreek seeds, soy beans
- Iridoids	Plants
- Monounsaturated fatty acids (MUFAs)	Vegetable oils, nuts
- Polyunsaturated fatty acids (PUFAs):	
ω -3 PUFAs, ω -6 PUFAs	Salmon, herring, cod, bluefish
ω -6 Linoleic acid	Milk, dairy products, meat of ruminants
- Vitamin D	Eggs, fish, meat, milk
- Carnosine	Mammal and poultry meat
- Berberine	Goldenseal, Oregon grape, barberry, tree turmeric
- Phytosterols	Vegetable oils, fruits, nuts, cereals
- Tanshinone II	Root of Danshen (<i>Salvia miltiorrhiza</i>)

Macrophage polarization by potential nutraceutical compounds: a strategic approach to counteract inflammation in atherosclerosis.

Barbara Sottero*, Gabriella Testa*, Paola Gamba, Erica Staurenghi, Serena Giannelli, Gabriella Leonarduzzi[§]

Department of Clinical and Biological Sciences, School of Medicine, University of Turin, Orbassano, Torino

*These authors contributed equally to this work.

§ Corresponding author: Department of Clinical and Biological Sciences, School of Medicine, University of Turin, San Luigi Hospital, 10043 Orbassano, Torino, Italy.

E-mail address: gabriella.leonarduzzi@unito.it (G. Leonarduzzi)

ABSTRACT: Chronic inflammation represents a main event in the onset and progression of atherosclerosis and is closely associated with oxidative stress in a sort of vicious circle that amplifies and sustains all stages of the disease. Key players of atherosclerosis are monocytes/macrophages. According to their pro- or anti-inflammatory phenotype and biological function, lesional macrophages can release various mediators and enzymes, which in turn contribute to plaque progression and destabilization or, alternatively, lead to its resolution. Among the factors connected to atherosclerotic disease, lipid species carried by low density lipoproteins and pro-oxidant stimuli strongly promote inflammatory events in the vasculature, also by modulating the macrophage phenotyping. Therapies specifically aimed to balance macrophage inflammatory state are increasingly considered as powerful tools to counteract plaque formation and destabilization. In this connection, several molecules of natural origin have been recognized to be active mediators of diverse metabolic and signaling pathways regulating lipid homeostasis, redox state, and inflammation; they are, thus, considered as promising candidates to modulate macrophage responsiveness to pro-atherogenic stimuli. The current knowledge of the capability of nutraceuticals to target macrophage polarization and to counteract atherosclerotic lesion progression, based mainly on *in vitro* investigation, is summarized in the present review.

KEYWORDS: atherosclerosis, inflammation, oxidative stress, macrophage polarization, nutraceuticals, lipid homeostasis

Abbreviations

ABC: ATP-binding cassette transporter

AMPK: adenosine 5'-monophosphate-activated protein kinase

AP-1: activator protein-1

ASC: apoptosis-associated speck-like protein containing a CARD

ATF: AMP-dependent transcription factor-1

Atg: autophagy-related gene

CLA: conjugated linoleic acid

CK2: casein kinase 2

COX: cyclooxygenase

CREB: cAMP-responsive element-binding

CRP: C-reactive protein

CVD: cardiovascular disease

DHA: docosahexanoic acid

EGCG: epigallocatechin gallate

EPA: eicosapentenoic acid

ER: endoplasmic reticulum

ERK: extracellular signal-regulated kinase

FA: fatty acid

FOX: Forkhead box protein

GPR: G protein-coupled receptor

GSH: glutathione

Hb: hemoglobin

HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A

HIF1 α : hypoxia inducible factor 1 α

HO-1: heme oxygenase-1

IFN: interferon

IL: interleukin

iNOS: inducible nitric oxide synthase
IRF: interferon regulatory factor
JAK: Janus kinase
JNK: c-Jun N-terminal kinase
KLF: Kruppel-like factor
LA: linoleic acid
LDL: low density lipoprotein
LOX-1: lectin-like low-density lipoprotein receptor-1
LPS: lipopolysaccharides
LXR: liver X receptor
MAPK: mitogen-activated protein kinase
MCP1: monocyte chemotactic protein 1
miR: microRNA
MKP-1: MAPK phosphatase-1 NOX
MMP: metalloprotease
mTOR: mammalian target of rapamycin
MUFA: monounsaturated fatty acid
MyD88: myeloid differentiation 88
NF- κ B: nuclear factor- κ B
NLRP3: nucleotide-binding domain (NOD)-like receptor protein 3
NO: nitric oxide
NOX: NADPH oxidase
Nrf2: nuclear factor E2-related factor 2
oxLDL: oxidized LDL
PAMP: pathogen-associated molecular pattern
PBMC: peripheral blood monocyte
PGC: PPAR γ -coactivator
PG: prostaglandin
PI3K: phosphoinositide 3-kinase
PMA: phorbol myristate acetate
PPAR: peroxisome proliferator-activated receptor
PPP: pentose phosphate pathway
PRR: pattern recognition receptor
PUFA: polyunsaturated fatty acid

ROS: reactive oxygen species
Rv: resolvin
RXR: retinoid X receptor
SIRT: sirtuin
SOCS: suppressor of the cytokine signaling
SOD: superoxide dismutase
SPM: specialized pro-resolving mediator
SREBP: sterol regulatory element binding protein
STAT: signal transducer and activator of transcription
TCA: tricarboxylic acid
TERT: telomerase reverse transcriptase
TGF β : transforming growth factor β
Th: T-helper lymphocyte
TLR: Toll-like receptor
TNF α : tumor necrosis factor α
UFA: unsaturated fatty acid
Vit D: vitamin D

Introduction

Atherosclerosis is a chronic inflammatory disorder affecting large and medium-sized arteries and is characterized by the subendothelial accumulation of lipid species carried by low density lipoproteins (LDLs) together with fibrotic tissue and cell debris. The formation of these deposits is the consequence of endothelial cell dysfunction that triggers a cascade of inflammatory reactions characterized by the continuous and uncontrollable transmigration of circulating immune cells into the vessel wall, giving rise to the atherosclerotic plaque. Key players of atherosclerosis are monocytes/macrophages that are provided with several tasks such as lipid and cellular debris clearance, orchestration of inflammatory response, and tissue repairing. As disease progresses, plaque macrophages engulf more and more lipids, transforming themselves into foam cells able to secrete inflammatory molecules and proteolytic factors, and to release reactive oxygen species (ROS). If the insult to the vasculature persists, the inflammatory response becomes chronic and plaque macrophages start displaying perturbed capability to migrate and phagocytize. As a consequence the

number of apoptotic/necrotic cells in the lesion core increases, leading to advanced plaque vulnerability and, eventually, rupture. On the contrary, when noxious materials, including lipids and necrotic debris, are efficiently removed, the inflammatory response can be reversed under the modulation of protective factors and lesion regression occurs. Resident macrophages can, thus, strongly participate to the resolution process by acquiring anti-inflammatory features and functions [1,2].

Lipid accumulation represents a preeminent event in the atheroma development. Hypercholesterolemia associated to high levels of the cholesterol-carrier LDLs is in fact a well-recognized risk factor for atherosclerosis. In particular, oxidative modifications of these lipoproteins favor their uptake by macrophages via specific scavenger receptors (e.g., SR-A, CD-36) and confer pro-inflammatory properties on these particles, contributing significantly to the lesion lipid-rich necrotic core expansion [3].

Macrophages are the most abundant immune cell type in atherosclerotic lesions whose expansion they significantly contribute during all stages of the disease. In fact, they play prominent roles in oxidized LDL (oxLDL) uptake and cholesterol accumulation, lesion matrix remodeling, cytokine release, and clearance of dead cell debris [1,2].

Most recent advances regarding the macrophage dynamics in atherosclerosis point out the complexity of lesional macrophage phenotype: it has been recognized that rather than a few distinct populations, a broad spectrum of cell subsets could be present depending on the environmental signals, including lipid and cholesterol loading, and that the balance among all these cell populations directs plaque evolution [4]. According to this view, a growing consideration is being given to therapeutic strategies specifically aimed at targeting the atherosclerotic macrophage phenotype, thus promoting disease regression [5,6]. In this context, various molecules of natural origin may represent an important opportunity. Thanks to their multiple activities as antioxidants, lipid-lowering agents, and cell signaling modulators, they can likely be effective in counteracting lesion development and, in particular, in regulating the macrophage inflammatory response [7,8].

The purpose of the present review is to provide the major current insights on the applicability of natural compounds in the prevention and treatment of atherosclerosis, taking advantage of their capability to affect macrophage polarization. In particular, we focus on basic research evidence that elucidates the molecular mechanisms in support of beneficial effects of micronutrients as nutraceuticals, principally focusing on macrophage cell models.

1. Macrophage polarization: a general overview

Macrophages are highly versatile cells able to adopt different functional programs in response to the surrounding microenvironmental stimuli, a process known as macrophage polarization. Classically, they are classified into two main cell phenotypes according to their state of activation: in the presence of harmful stimuli they acquire the so-called M1 phenotype, which is able to promote inflammation; conversely, they assume the alternative inflammation suppressing and reparative phenotype M2 when the inflammatory response is no longer needed [9].

Although initially well accepted, more extensive *in vitro* and *ex vivo* studies have shown that this bipolar M1/M2 classification does not accurately represent the macrophage diversity. In fact, M1 and M2 are only the extremes of a broader spectrum of cell subpopulations, overlapping with each other in terms of metabolic adaptation, gene expression, and function associated with a variety of inflammatory, anti-inflammatory, and remodeling gene program. Noteworthy, these phenotypes are transient and reversible consistently with milieu changes [9]. For instance, M2 macrophages have been further classified into M2a, M2b, M2c, and M2d subgroups, according to the different stimuli that activate them and to their protein production. Among them, M2a subgroup contributes to tissue repair, M2b stands out for the production of both pro- and anti-inflammatory cytokines that regulate immune cell functions, M2c exerts the strongest anti-inflammatory activity and is responsible for phagocytosis and apoptotic cell clearance, and finally M2d has angiogenic properties [10].

1.1. Cell signaling involved in macrophage polarization

The inflammatory orientation of macrophages is under strict control by a variety of transcription factors and coregulatory molecules.

Cytokines released by T-helper 1 (Th1) lymphocytes, such as interferon γ (IFN γ), interleukin-1 β (IL-1 β), and tumor necrosis factor α (TNF α), but also pathogen-associated molecular patterns (PAMPs) detected by pattern recognition receptors (PRRs), lipopolysaccharides (LPS) and lipoproteins activate the M1 phenotype, or classically-activated macrophages, via involvement of the signal transducer and activator of transcription (STAT) family member STAT1/2 [9,11,12]. Among the inflammatory factors pointed to promote M1 differentiation rather than M2 is also included C-reactive protein (CRP) [13]. Conversely, alternatively-activated M2 macrophages are activated by the Th2-derived cytokines IL-4 and IL-13, or by other anti-inflammatory stimuli through STAT3 or STAT6 modulation [9,12]. Nuclear transcription factors involved in lipid homeostasis, namely peroxisome proliferator-activated receptor (PPAR)- γ and liver X receptors (LXRs), are also identified as mediators in M2 anti-inflammatory phenotyping [14]. More in detail, M2a macrophages express high levels of mannose receptors and respond to IL-4 and IL-13, M2b macrophages are activated by

immune complexes and Toll-like receptor (TLR) ligands or IL-1 receptor agonists, M2c macrophages by IL-10 and glucocorticoids [15], and M2d macrophages by TLR-signals through the adenosine receptor [16].

In response to their activation, M1 macrophages release ROS, nitric oxide (NO) via inducible nitric oxide synthase (iNOS), as well as pro-inflammatory cytokines such as TNF α , IL-1 β , IL-12, and IL-23, while all types of M2 macrophages produce anti-inflammatory cytokines and growth factors, such as IL-10, IL-4 and transforming growth factor β (TGF β), and are angiogenic and pro-fibrotic [10,12,17].

1.2. Metabolic requirements associated to macrophage polarization

Macrophages with M1 and M2 phenotypes significantly differ also for the metabolic requirements necessary to sustain their specific activity: while M1 macrophages depend almost on glucose uptake, glycolysis, and pentose phosphate pathway (PPP), bioenergetic supply in M2 macrophages is ensured mainly by oxidative phosphorylation and fatty acid (FA) oxidation [18,19]. On the other hand, metabolic shifts switched on by growth factors and nutrient availability can themselves be the up-stream signals that control macrophage polarization. Overall, polarizing and metabolic cues finely communicate with each other to coordinate the induction of different phenotype activities and the metabolic processes needed to sustain them [17].

Metabolic signaling pathways activated by polarizing signals include Akt, mammalian target of rapamycin (mTOR), and adenosine 5'-monophosphate-activated protein kinase (AMPK) [18]. In fact, activation of the TANK-binding kinase/inhibitor of nuclear factor- κ B kinase/Akt pathway or of the mTOR/Akt pathway drives to different glucose utilization in LPS- and IL-4-activated macrophages [20,21]. The transcription factor hypoxia-inducible factor 1 α (HIF1 α) mediates the M1 reprogramming by LPS and hypoxia through up-regulation of genes involved in glycolysis [22], whose metabolites in turn stabilize HIF1 α protein itself [23]. Induction of HIF1 α by mTOR also can be responsible for shifts towards glycolytic reactions [24]. Conversely, the oxidative metabolism typical for the anti-inflammatory phenotype is prompted by STAT6 and PPAR γ -coactivator (PGC)-1 β in response to IL-4 [25], and by AMPK in response to IL-10 [26]. The tricarboxylic acid (TCA) cycle and oxidative phosphorylation are enhanced by IL-4 macrophage activation by up-regulation of genes linked to these routes too, as for example the sedoheptulose kinase carbohydrate kinase-like protein (CARKL), which restricts the glucose flux through the PPP [27]. As a consequence, also mitochondrial metabolism adjustment is associated to macrophage polarization [28]. By perturbing the electron transport chain in mitochondria, both NO and ROS affect energetic supply and metabolic

profile of macrophages, accounting for the suppression of the oxidative phosphorylation and for the switching to glycolytic commitments [18,29,30]. In particular, NO regulates the amount of the catalytic Complex I subunits in murine macrophages and, besides that, the balance of succinate and citrate, the key metabolites of TCA cycle [31]. In addition, ROS overproduction is promoted in mitochondria of inflammatory macrophages by excessive glucose utilization and leads to dimerization of the glycolytic enzyme pyruvate kinase M2 (PKM2), further sustaining glycolysis and the PPP pathway [32]. Activation of NOTCH represents another mechanism to reprogram mitochondrial metabolism in favor of glycolysis and glucose flux to the TCA cycle, thus contributing to mitochondrial ROS generation and ROS-dependent induction of nuclear and mitochondrial M1 genes [33].

2. Macrophage polarization in the atherosclerotic plaque

Macrophage heterogeneity has been recognized in the context of atherosclerosis. Different macrophage populations can originate in response to systemic factors circulating in the blood and to local plaque-specific stimuli; the prevalence of some cell subsets on others can drive plaque evolution and atherosclerosis outcome [34,10]. It has been observed that plaques from symptomatic patients suffering from acute ischemic attack have indeed a greater concentration of M1 macrophages, while M2 macrophages prevail in plaques from asymptomatic patients [35]. At least in mice models, M2 cells are more numerous in early lesions but they shift toward a M1 phenotype as lesion progresses [36]. Moreover, pro-inflammatory macrophages are preferentially located on the rupture-prone shoulders of the plaque, while there are no significant differences between cell subsets in the fibrous caps [37].

In addition to the typical M1 and M2 classes, other macrophage subsets have been specifically recognized in the atheroma (Fig. 1), whose proportion and distribution might reflect plaque vulnerability [5,17].

Oxidative stress is undoubtedly one of the main promoter of atherosclerotic macrophage polarization towards more inflammatory phenotypes: overproduction of oxidant species by macrophages is not only a hallmark of their inflammatory adaptation, but it is also responsible for LDL modification in more pro-atherogenic particles that can in turn trigger and sustain the inflammatory response by the cells. Indeed, in mouse models of atherosclerosis, oxidized phospholipids present in oxLDLs have been established to induce a subtype of macrophages with a Mox phenotype. Compared to M1 and M2, Mox macrophages display reduced phagocytic and chemotactic properties but express antioxidative and detoxifying genes, mainly regulated by the

nuclear factor E2-related factor 2 (Nrf2), which are fundamental for intracellular redox balance maintenance [38].

A non-foam cell type of macrophages, termed as hemoglobin (Hb)-stimulated macrophage, or M(Hb), was identified at hemorrhagic sites of human atherosclerotic lesions. Besides an enhanced cholesterol efflux, they are characterized by a decrease in ROS production and by the expression of anti-inflammatory factors such as IL-10 [39]. Heme also polarizes macrophages towards an atheroprotective hemorrhage-mitigating phenotype, the Mhem subtype, which, by expressing heme oxygenase-1 (HO-1), contributes to cholesterol efflux, Hb clearance via erythrocyte phagocytosis, and oxidative stress reduction [40]. Finally, a very recent publication reported the macrophage polarization towards a pro-atherogenic phenotype after cell exposure to ferrylHb, an oxidized form of Hb commonly present in hemorrhagic atheromas as a consequence of damaged erythrocyte accumulation. FerrylHb internalization by macrophages seems to lead to HO-1 up-regulation and iron overloading within lysosomes. The event induces a transcriptome profile, distinct from that of native Hb and overlapping with gene expression found in human complicated lesions; this gene profile is associated with macrophage activation, inflammation, iron metabolism, apoptosis, and lipid transport, and appears to be driven by activation of the phosphoinositide 3-kinase (PI3K)/HIF1 α pathway [41].

A further macrophage state, completely distinct from all the other known phenotypes, namely M4, was described to be induced by the platelet chemokine CXCL4 and to lack phagocytosis capacity but to possess pro-atherogenic properties, including the secretion of metalloprotease (MMP)-7 and MMP-12 [42]. This subtype is predominantly present in the tunica adventitia and intima of coronary arteries of patients with severe coronary artery disease [43].

2.1. Cell signaling and metabolic requirements driving atherosclerotic macrophage polarization

Intra-plaque macrophages, in particular macrophage-derived foam cells, express several PRRs, including TLRs and scavenger receptors (e.g. CD36), and the intracellular PRR inflammasomes [44]. As M1-promoters, PRRs are implicated in the onset and progression of lesions: upon their activation by binding to a multitude of ligands, they trigger diverse signaling cascades in macrophages, resulting in the expression of pro-inflammatory proteins. Ligands of PRRs are PAMPs present in atherosclerotic plaques such as bacterial nucleic acids, peptidoglycans, and exogenous heat shock proteins (HSPs). Beside them, damage-associated molecular patterns (DAMPs), which include cholesterol crystals, oxLDLs, necrotic cell debris, and extracellular matrix components accumulating in growing lesions, also interact with PRRs [11,12]. In response to them, myeloid differentiation 88 (MyD88)-dependent and/or TIR-domain-containing adaptor protein inducing IFN β (TRIF)-

dependent pathways are triggered leading to TLR activation and final induction of transcription factors such as interferon regulatory factors (IRFs), nuclear factor- κ B (NF- κ B), c-Jun, Forkhead Box (FOX) O3a, and p53 [11,12]. For example, TLR4 is stimulated by saturated FAs and by minimally modified LDLs via either MyD88-dependent or MyD88-independent/ROS-dependent mechanisms, while oxLDLs stimulate TLR4/6 after binding to the scavenger receptor CD36 [11]; macrophage activation by lysosomal damaging cholesterol crystals requires the involvement of the intracellular nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome [45]; other factors able to induce NLRP3 are ROS, oxLDLs, mitochondrial dysfunction, and endoplasmic reticulum (ER) stress [46-48]. Upon NLRP3 activation, both apoptosis and pyroptosis, a caspase-dependent form of cell death characterized by plasma membrane pore formation and intracellular content release [49], occur contributing to the necrotic core formation [50].

Furthermore, the on-off switch of inflammasome can depend on autophagy, a process aimed at eliminating intracellular macromolecules and aged/damaged organelles, and essential to maintain cellular energy balance and nutritional status, including lipid availability. In particular, lipophagy, namely the autophagic clearance of intracellular lipid materials, regulates cholesterol efflux from macrophages by modulating the lysosomal acid lipase, which is responsible for the hydrolysis of cholesteryl esters stored in the lipid droplets [51]. Autophagy is relevant in determining the macrophage inflammatory state; indeed, its loss promotes systemic inflammation by polarizing macrophages towards M1 cells at the expense of M2 cells [52], thus it is reasonable that it acts in the same way in the plaque. In support of this, in ApoE-null mice macrophages autophagy was seen to become dysfunctional with plaque progression, triggering inflammasome hyper-activation and IL-1 β overproduction [53]. *In vitro* and *in vivo* studies pointed to the metabolic anti-inflammatory PI3K/Akt/mTOR pathway being critical for autophagy execution by atherosclerotic macrophages and, ultimately, for determining their differentiation [54,55]. Certain sirtuins (SIRTs), a class of deacetylases involved in various physiological processes, including cell metabolism and cellular response to stress, have also been reported to promote autophagy. This occurs through deacetylation of autophagy-related nuclear and cytosolic factors, such as FOXO1, FOXO3, and autophagy-related genes (Atgs), through involvement in rapamycin complex 1 (mTORC1)- and AMPK-dependent signals, counteracting foam cell formation [56].

In addition, dysregulation of lipophagy accounts for inefficient removal of apoptotic cells by efferocytosis, contributing to accumulation of toxic cell debris in the lesion core [57]. One of the main regulators of the efferocytic machinery, which appears to be compromised in the lipid engulfed macrophages, is Mer tyrosine kinase (MerTK). Activation of this kinase depends on NADPH oxidase (NOX)-derived ROS and TLR4, and is promoted by oxidized polyunsaturated fatty acids (PUFAs)

[58,59]. Of note, efferocytosis presumably addresses macrophages to an anti-inflammatory phenotype since its inhibition promotes IL-1 β , IL-6, and TNF α expression, but decreases IL-10 and TGF β levels [60]. In addition, LXR signaling has been shown to be critical for a functional efferocytic process [61]. A close relationship exists also between efferocytosis and the lipid mediators lipoxins, resolvins (Rvs), protectins, and maresins; all these molecules favor a correct efferocytosis execution contributing to pro-resolving macrophage skewing and quelling of inflammation [62]. In this connection, biosynthesis of these lipid mediators appears higher in M2 compared to M1 macrophages, where biosynthesis of pro-inflammatory autocooids prevails, demonstrating that different macrophage subtypes are also characterized by a specific profile of endogenous lipid mediators [63].

Besides PRRs, other signal cascades have been suggested to drive macrophage polarization. For example, NOTCH pathway promotes the activation of M1 macrophages in atherosclerotic plaques [64], whereas its inhibition raises the secretion of IL-10 by M2-like population [65]. Members of the transcription factor Kruppel-like factor (KLF) family can also underlie macrophage differentiation: KLF4 promotes M2 polarization by inhibiting NF- κ B signaling, and likely cooperates with STAT6 and PPAR γ , constituting an alternative axis for the anti-inflammatory transition [66]. Conversely, exposure to oxLDLs switches M2 macrophages to a pro-inflammatory M1 profile by preventing the expression of KLF2 [67].

As regards the macrophage classes specifically present in the atherosclerotic plaque, Mox differentiation by oxidized phospholipids depends on Nrf2 activation [38], M(Hb) differentiation depends on haptoglobin-Hb complex formation [39], while Mhem differentiation occurs through induction of activating cyclic AMP-dependent transcription factor-1 (ATF-1), which subsequently induces both HO-1 and LXR β [40].

Moreover, polarization of atherosclerotic macrophages can be affected by dysfunctional metabolism. Limited oxygen supply in the lesion leads to HIF1 α -dependent suppression of FA oxidation and favors, instead, glucose metabolism and lipid accumulation, likely contributing to the inflammatory activation of macrophages [68-70]. Furthermore, ROS overproduction through the mitochondrial oxidative metabolism of foam cells causes mitochondrial damage and blockage of oxidative phosphorylation, and consequently directs to M1 polarization [71].

3. Modulation of atherosclerotic macrophage polarization by nutraceuticals

Classical pharmacological approaches for the prevention and treatment of atherosclerosis aim to correct disorders in the lipid profile, mainly in cholesterol metabolism; however, new strategies, able

to counteract the inflammatory boost that drives plaque progression, are gaining increasing consideration by the clinical community.

Given the importance of dietary habits for health, constituents of foods can offer a reliable support. It is well recognized that the consumption of fruits, vegetables, spices, nuts, fish, and olive oil is able to decrease atherosclerosis incidence, not only by regulating lipid levels but likely also by regulating other processes that contribute to atheroma development [8]. Indeed, the majority of these foods have a high content of bioactive compounds with proven antioxidant, cell signaling, and metabolic activity, which are thus strong candidates for the inhibition of the pro-inflammatory activation of immune cells and consequently for plaque stabilization and even regression [8]. Noteworthy, some advantages derive for the long-term use of natural origin molecules compared to synthetic drugs due to their more relative safety, fewer side effects, and greater efficacy. The list of potentially anti-atherogenic micronutrients includes polyphenols, carotenoids, terpenoids, unsaturated fatty acids (UFAs), and vitamins (Table 1).

Polyphenols are undoubtedly the most important and abundant phytochemicals in the human diet. They are classified in different subclasses, among which are flavonoids, phenolic acids, phenolic alcohols, stilbenes, and lignans; they are chemically characterized by the presence of one or more benzene rings joined to hydroxyl groups, which confers them with antioxidant capacity [72]. Among them are curcumin, isolated from the rhizomes of turmeric and present in the spice curcuma, resveratrol, the main polyphenol in wine, and the olive oil derivatives oleuropein, tyrosol and hydroxytyrosol, all of which have been extensively investigated in the contest of vascular pathology [8].

Other antioxidants of plant origin are carotenoids, a class of lipophilic pigments that comprises carotenes and xanthophylls, according to the presence or absence of oxygen groups, respectively. Lycopene, abundant in tomato, and β -carotene, present in green leafy vegetables, and in orange and yellow fruits and vegetables, are the most widespread carotenes in nature, whereas lutein, from crucifers and egg yolk, is the most common xanthophyll; all of them have been considered for their positive health outcomes. Noteworthy, carotenoids cannot be synthesized by most animals where they are substrates of the enzymatic cleavage that gives rise to vitamin A. The latter, in its active form (i.e. retinoic acid), is the ligand of the transcriptional factors retinoid X receptors (RXRs), fundamental for immune system differentiation and function, as well as for energy metabolism [73].

Olive oil and other vegetable oils provide monounsaturated fatty acids (MUFAs), also recognized to be beneficial for cardiovascular health [74].

Certain organosulfur compounds, such as allicin from garlic and sulforaphane from cruciferous vegetables and mustard, appear beneficial against cardiovascular diseases (CVD) by improving lipid metabolism and modulating crucial redox sensitive pathways [8,75].

Phytosterols are steroid compounds found in vegetable sources such as oils, nuts, fruits, and cereals. The family includes β -sitosterol, stigmasterol, campesterol, and brassicasterol. Thanks to their structure similarity to cholesterol, they have been considered to correct aberrations in cholesterol homeostasis [76].

Ginseng is another world-wide used herbal medicine potentially effective in the treatment of cardiovascular and, more generally, of metabolic diseases. Its anti-inflammatory activity relies principally on members of the saponin family, ginsenosides [77]. Another saponin of interest is diosgenin from fenugreek seeds and soy beans [78].

Berberine, an alkaloid extracted from the root, rhizome, and stem bark of many medicinally important plants, such as *Hydrastis canadensis* (goldenseal), *Coptis chinensis Franch* (Coptis orgoldenthread), *Berberis aquifolium* (Oregon grape), *Berberis vulgaris* (barberry), and *Berberis aristata* (tree turmeric), has been found to regulate lipid metabolism and homeostasis [79].

More recently, research attention focused on iridoids, which are secondary metabolites of alkaloid biosynthesis occurring in several plants and some animals. These monoterpenes are provided with anti-inflammatory and antioxidant properties [80].

Another promising natural compound is the diterpene tanshinone IIA, the main fat-soluble monomer component of the root of Danshen (*Salvia miltiorrhiza*), extensively used in traditional folk medicine for the treatment of cerebrovascular disease and CVD [81]

Although fruits and vegetables are preferentially recommended for healthy diets, foodstuffs of animal origin can be sources of bioactive molecules as well. Indeed, not only nuts and vegetable oils but also fish, fish oil, and animal fats are supplies of UFAs, which might be taken into account as potential valuable micronutrients. It is worth to be underlined, however, that ω -6 PUFAs also possess pro-inflammatory features, thus their consumption should be carefully considered [8,82]. Dietary intake of ω -3 and ω -6 PUFAs, many of which cannot be synthesized *in vivo* and therefore are called essential FAs, is determinant for the endogenous production of eicosanoid molecules involved in the inflammatory response. The major examples are the ω -3 eicosapentenoic acid (EPA) and its metabolite docosahexanoic acid (DHA). Besides the intake from fish such as salmon, herring, cod, and bluefish, minimal amount of EPA can also be provided by conversion in the body of the other essential ω -3 PUFA α -linolenic acid [82].

The carotenoid astaxanthin too is commonly found in seafood such as salmon, trout, fish eggs, and crustaceans, to which it confers the typical pink or red color [83].

In addition, eggs, fish, meat, and milk fat are sources of the lipophilic cholesterol-based vitamin D (vit D). Of note, although vit D is commonly considered an essential micronutrient, its content in foods is very low; thus, additional provision by means of supplements might be necessary to reach the effective dose. Vit D, initially identified as a crucial hormone in the metabolism of bone calcium, is now gaining growing consideration for its role in other physiopathological processes, including lipid metabolism, oxidative stress, immune and inflammatory responses. For this reason, it has been suggested as a coadjuvant in atherosclerosis treatment, but its real benefit is still questionable, since pro-atherogenic consequences have also been reported for oral vit D intake over time, at least in animal models [84,85].

The nervous system and skeletal muscles of mammals and poultry also store carnosine, a natural histidine-containing dipeptide known as a metal chelator as well as scavenger of ROS and reactive aldehydes [86]. Thanks to these properties, carnosine is recognized to be beneficial against atherogenesis, in particular against foam cell formation [87,88].

3.1. Nutraceuticals as modulators of inflammation: direct effects on inflammatory pathways

Almost all the transcription factors and up/down-stream effectors of the signaling pathways, accounted for macrophage pro- or anti-inflammatory polarization, appeared sensitive to the intervention of micronutrients.

In human peripheral blood mononuclear cells, quercetin lessened the oxLDL-induced TLR2 and TLR4 mRNA levels and modulated the TLR/NF- κ B signaling pathway, thereby inhibiting cell inflammatory response [89]. In both murine and human macrophages, the flavonoid apigenin counterbalanced the LPS-induced increase of crucial pro-inflammatory cytokines, partly through mRNA destabilization, thus favoring IL-10 expression. Apigenin was also found to block NF- κ B and extracellular signal-regulated kinase (ERK)1/2 activation, as well as to interfere with inflammasome assembly [90]. Hydroxytyrosol, a main polyphenol of olive oil, attenuated the expression of pro-inflammatory molecules, including various cytokines and MMPs, in different macrophage models, principally interfering with NF- κ B and protein kinase C (PKC) α and PKC β 1 signaling [91,92], but also with STAT1 α and IRF-2, through ROS generation [93]. Epigallocatechin gallate (EGCG), the most abundant flavonoid in green tea, markedly attenuated the cyclooxygenase-2 (COX-2)/membrane-bound prostaglandin (PG) E synthases-1 (PGES-1)/PGE₂ pathway in U937 cells activated by oxidized lipids; also in this case, the flavonoid reduced secretion of inflammatory cytokines and MMP-9, which are responsible for plaque instability [94]. Alternative M2 polarization was promoted by a bacterial metabolite of antocyanins, namely protocatechuic acid, which is present

in black olives, mushrooms, and chicory; in J774 macrophages the protocatechuic acid was able to abolish the PI3K/Akt/NF- κ B cascade in favor of the STAT6/PPAR γ pathway [95]. Deep consideration has been paid to curcumin as an agent employable to polarize macrophage inflammatory state. Originally recognized as an NF- κ B suppressor in myeloid cells [96], this polyphenol has been further demonstrated to abolish NF- κ B/mitogen-activated protein kinase (MAPK) activation and to contrast M1 polarization of LPS/IFN γ -primed THP1 differentiated cells by inhibiting TLR4 expression [97]. It appears to switch M0 non-activated and RAW264.7 M1 activated macrophages to M2 phenotype too, via activation of the inhibitor of NF- κ B α (IkB α) and PPAR γ , respectively [98]. Nevertheless, whether curcumin can act as a natural agonist of PPAR γ [99] or not [100], regulating it indirectly by other mechanisms, is still debated. In addition, in RAW264.7 macrophages curcumin appeared to inhibit LPS-induced IL-6, TNF α , and COX-2 expression, as well as p38 MAPK activity, and to restore, instead, the expression and synthesis of two members of the suppressor of the cytokine signaling (SOCS) family, namely SOCS-1 and SOCS-3 [101]. Of note, curcumin ability to affect arachidonic acid metabolism in the same cell model has already been reported: it inhibited the formation of PGE₂ by blocking cytosolic phospholipase A2 (cPLA2) phosphorylation, decreasing COX-2 expression, and inhibiting the catalytic activities of 5-lipoxygenase [102]. Resveratrol was able to prevent the NF- κ B-dependent macrophage switching to M1 phenotype limiting the production of inflammatory cytokines and MMPs [103]. In murine macrophages, resveratrol was able down-regulated LPS-induced TNF α and IL-6 production by limiting p38 MAPK phosphorylation and, through inhibition of the small noncoding microRNA (miR) immune response regulator miR-155, by promoting the expression of SOCS-1, a STAT inhibitor [104]. Previously, in the same cells resveratrol has demonstrated to reverse LPS effects in terms of inflammatory species' generation, by negatively regulating the cAMP-responsive element-binding protein (CREB) and MAPK pathways, and by activating the PI3K/Akt signaling [105].

Incubation with the ω -3 PUFA DHA was proven to elicit, in the murine macrophage-like lineage RAW264.7, the activation of PPAR γ and, consequently, M2 macrophage polarization and efferocytosis of apoptotic cells [106]. Moreover, DHA diminished the responsiveness of human monocytic THP1 cells to TNF α in terms of ROS production and foam cell formation, in a PI3K-dependent manner [107]. To further support the pleiotropic activity of PUFAs as signaling modulators, LPS-stimulated RAW264.7 macrophages exhibited a lower expression of inflammatory cytokines after supplementation with high doses of DHA alone or DHA plus EPA. In this case, suppression of LPS-induced TLR4 expression in the lipid rafts of cell membrane has been suggested to underlie, at least in part, ω -3 PUFAs action, which resulted in the decrease and stabilization of aorta plaques of Western-diet fed ApoE-deficient mice [108]. Anti-inflammatory activity of DHA

might also rely on its interaction with the free fatty acid receptor 4 (FFA4). Acting as an FFA4 agonist, DHA limited COX-2 expression and thereby prostanoid synthesis by LPS-stimulated RAW264.7 cells, independently of COX-1 regulation. Presumably, activation by DHA would promote FFA4 coupling to β -arrestin 2; as a consequence, it would suppress TLR4-dependent Akt/c-Jun N-terminal kinase (JNK) phosphorylation and, finally, p65 nuclear translocation and binding to NF- κ B response elements in the COX-2 promoter [109]. An *in vitro* model consisting of human THP-1-derived macrophages treated with chylomicron remnants was used to elucidate the properties of diverse dietary fats. The chylomicron remnants were enriched in saturated FA, MUFAs, ω -6 PUFAs, or ω -3 PUFAs, respectively derived from palm, olive, corn or fish oil. All FAs suppressed NF- κ B transcriptional activity, with fish oil FAs causing the strongest inhibition followed by corn oil, palm oil, and then olive oil FAs. With a similar trend, they also enhanced cholesterol removal by the cells, suggesting that NF- κ B inhibition might play a role in this modulation [110].

Interestingly, DHA and the flavonoid quercetin used in combination potentiated the anti-inflammatory effects of the single compounds, as observed in LPS-stimulated RAW264.7 cells. Indeed, they synergistically inhibited the expression and activity of NF- κ B/MAPK signaling mediators [111]. In human macrophages, DHA, the flavonoid procyanidins B1, B2 and C1, and the combination of DHA with any of the procyanidins, at concentrations typical of the Mediterranean diet, all attenuated NF- κ B signaling. These compounds inhibited I κ B α phosphorylation, induced the cytoplasmic retention of NF- κ B complex through p105 (NF- κ B1) overexpression, and inhibited p65 nuclear translocation and DNA binding [112].

Naturally occurring isomers of ω -6 linoleic acid (LA), identified in milk, dairy products, and meat of ruminants, and named conjugated LA (CLA), were originally recognized as ligands for PPAR γ and thus able to exert anti-inflammatory effects on murine macrophages [113]; but more recent data indicated a PPAR γ suppressive regulation by these compounds, at least in human macrophages, due to diminished ERK1/2 and p38 phosphorylation [114]. In this connection, it was demonstrated that in RAW 264.7 cells CLA isomers regulate LPS-induced inflammatory cytokine gene expression in an isomer-specific manner that likely implies a selective modulation of the PPAR/RXR heterodimer. Among the tested CLA isomers, 9-trans,11-trans-CLA was the most effective, while 9-cis,11-trans-CLA did not significantly affect immune cell activation [115]. Subsequently, CLA was reported to prime mouse bone marrow-derived macrophages to an M2 phenotype secreting IL-10, likely as a consequence of IL-10 receptor overexpression and STAT3 phosphorylation [116].

Furthermore, ω -3 PUFAs give rise to specialized pro-resolving mediators (SPMs), such as E-series resolvins (Rvs) from EPA and D-series Rvs protectins and maresins from DHA; SPMs provide

an additional contribution to M2 phenotyping and to inflammation resolution [63]. Noteworthy, thanks to SPM production, ω -3 PUFAs might direct macrophage activity towards plaque resolution independently from induction of cytokines. For example, RvD1 protects murine macrophages from apoptosis through anti-apoptotic protein up-regulation and also by attenuating oxidative stress through PKA-mediated inactivation of NOX [117].

As regards the ω -6 PUFA arachidonic acid, its role is multifaceted: although its modification by 5-lipoxygenase gives rise to the pro-inflammatory autocooids leukotrienes and PGs, a shift to the 12-lipoxygenase or 15-lipoxygenase enzymatic pathways promotes the synthesis of the SPM lipoxins [118,119]. Among them, lipoxin A₄ inhibited foam cell formation, inflammation, and apoptosis occurrence induced by oxLDL in macrophages [120].

Down-regulation of MMPs and of the extracellular matrix MMP inducer (EMMPRIN), subsequent to NF- κ B inhibition, was observed in oxLDL-stimulated macrophages after incubation with the alkaloid berberine [121]. This modulation might depend on miR150-5p increase that leads to the purinergic receptor P2X7 repression and consequently to AMPK α and MAPK inactivation, as newly brought to light in human and murine oxLDL-induced macrophages [122].

In a rat model, crocin, the carotenoid responsible for saffron yellow color, favored the M2 macrophage polarization and balanced the levels of inflammatory cytokines by limiting NF- κ B p65 expression and nuclear translocation [123]. Similarly, lycopene and astaxanthin were proven to diminish, in activated M1 macrophages, the secretion of inflammatory mediators such as TNF α or ILs by inhibiting NF- κ B [124,125]. In particular, astaxanthin could be effective in preserving Src homology phosphatase 2 (SPH2), a negative regulator of NF- κ B activity [125].

NF- κ B binding activity has been reported to be inhibited also by the iridoid scopolioside A that reduced PGE₂ and COX-2 production in LPS-stimulated murine RAW264.7 macrophages [126].

Anti-inflammatory properties have been ascribed to the steroidal compound vit D. In LPS-activated macrophages, vit D biologically active form, namely 1,25-dihydroxyvitamin D (1,25(OH)₂D₃), up-regulated MAPK phosphatase-1 (MKP-1) turning off the p38 signaling responsible for cytokine production [127]. To further confirm the anti-inflammatory effect of vit D, *in vitro* incubation with 1,25(OH)₂D₃ decreased TLR4 expression on cell membranes of differentiated M1 macrophages and increased vit D receptor, the latter likely representing a negative feedback loop mechanism to contain the pro-inflammatory M1 response [128]. Of note, vit D receptor has been recently implied in the restoration of functional autophagy and consequently of lipid removal in both mice and human macrophages. The interaction between vit D and its receptor would indeed trigger a protein tyrosine phosphatase non-receptor type (6PTPN6)/SHP-1 dependent signaling underlying autophagy activation [129].

Ajoene isomers and their oxidized sulfonyl derivatives from garlic showed efficacy in attenuating LPS-induced inflammatory response of macrophages in terms of COX-2, PGE₂, and cytokine production. Inhibition of NF- κ B transcriptional activity and decreased phosphorylation of p38 and ERK MAPKs accounted for these effects [130].

Among saponins, ginsenoside 20(S)-Rg3 could promote M1 to M2 polarization within atherosclerotic plaques of diabetic mice, a switch which likely results from PPAR γ activation [131]; the enhancement of STAT6 phosphorylation could account for the improvement of M2 polarization of RAW264.7 macrophages by ginsenoside Rb1 [132]. In addition, the deactivation of the NOTCH signaling pathway, in particular the prevention of NOTCH intracellular domain nuclear translocation, could account for the suppression of oxLDL-loaded THP1 differentiation by diosgenin, another saponin [133]. Moreover, the last compound was previously reported to reduce the production of ROS and pro-inflammatory mediators by LPS/IFN γ -stimulated macrophages blocking the signaling of NF- κ B and activator protein-1 (AP-1), and of their down-stream mediators casein kinase 2 (CK2) and JNK [134].

3.2. Nutraceutical effects on inflammasome and autophagy

Several polyphenols were demonstrated to be effective in hindering autophagy impairment, among which luteolin [135], a flavonoid extract [136], proanthocyanidins, and EGCG [137]. Resveratrol has been recognized as a SIRT1 activator able to sustain macrophagic functional autophagy and ultimately apoptotic cell efferocytosis [138]. Another investigation reported that, in murine macrophages submitted to mitochondrial oxidative stress, autophagy was promoted by resveratrol through a SIRT3/AMPK positive feedback loop [139]. In oxLDL-induced RAW264.7 foam cells, the flavonoid quercetin restored autophagic process, thus reducing lipid accumulation and cell senescence, by abrogation of mammalian Ste20-like kinase 1 (MST1) expression [140]. Similarly, both EGCG and a mixture of oligomeric proanthocyanidins favored lipid disposal in oxLDL-induced foam cells by coordinated activation of autophagy and lysosomal acid lipase, and induction of the cholesterol transporters ATP-binding cassette transporter (ABC) A1 and ABCG1. In this case, autophagosome formation was triggered by activation of the Class PI3K/Beclin1 complex followed by assembly of the Atg12-Atg5-Atg16L and Atg8/LC3 complexes; interestingly, the same results were observed also by treatment with β -sitosterol [137]. Anti-atherogenic and anti-inflammatory properties of curcumin might rely on its capacity to reduce NLRP3 inflammasome expression, caspase-1 cleavage, and IL-1 β secretion, as observed in phorbol myristate acetate (PMA)-induced human macrophages. All these actions seem to depend not only on the down-regulation of

TLR4/MyD88/NF- κ B signal cascade but also on the deactivation of the purinergic 2X7 receptor (P2X7R), another up-stream factor for NLRP3 assembly induction [141]. To further support that polyphenols are effective in interfering with NLRP3 inflammasome signal switch on, there is the evidence that a red wine extract or, to a lesser extent, resveratrol alone negatively affected LPS-priming of murine macrophages necessary for NLRP3 synthesis and IL-1 β secretion; in addition, the wine extract preserved from activation of NLRP3 by complexation with the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC), whose expression was lessened by wine polyphenols [142]. Similarly, luteolin inhibited the expression of NLRP3, ASC, caspase-1, IL-18, and IL-1 β in LPS-stimulated RAW264.7 cells, thus promoting their polarization toward an M2 macrophage type, as confirmed by the induction of the M2 markers arginase-1 and IL-10. In addition, the polyphenol was also confirmed to limit ROS production [143].

Berberine might be considered for autophagy promotion too. In fact, this alkaloid was proven to reduce the inflammatory response of both human and murine oxLDL-loaded macrophages by stimulation of autophagy through intervention on Akt/mTOR or AMPK/mTOR signaling pathways [144,145].

Furthermore, the saponin araloside promoted M2 polarization of murine macrophages exposed to oxLDL reducing foam cell formation; also in this case, autophagy induction, mediated by SIRT1 up-regulation, was recognized as the driving force [146]. Another saponin, namely ginsenoside Rb1, improved autophagy in macrophage foam cells via AMPK phosphorylation that subsequently led to higher microtubule-associated protein light chain 3 (LC3)II and Atg5 levels [147]. Ginsenosides might also rescue cells from inflammasome activation, and likely from pro-inflammatory IL-1 β maturation and secretion, as demonstrated in mouse and human macrophages, in which both NLRP3 and AIM2 inflammasomes were inhibited by a red ginseng extract [148]. Moreover, ginseng is rich in ursolic acid, a triterpene that could additionally contribute to macrophage autophagy by increasing the expression of Atg5, Atg16L1, and LC3, thereby suppressing IL-1 β secretion and promoting cholesterol efflux [149].

Another natural compound acting on autophagy is tanshinone IIA. It resulted to activate KLF4 and to enhance autophagy and M2 polarization of oxLDL-induced macrophages by inhibiting miR-375 [150].

Scopolioside B, an iridoid, decreased expression and synthesis of NLRP3, pro-IL-1 β , and IL-1 β in LPS-induced THP1 cells [151].

As regards PUFAs, macrophages, isolated from mice fed on a diet supplemented with both fish or botanical ω -3 and ω -6 PUFAs, exhibited NLRP3 inflammasome suppression, and reduced IL-1 β secretion as a consequence of improved autophagy and mitochondrial function. Of note, botanical

ω -3 and ω -6 PUFAs action seemed independent of mitochondrial ROS production [152]. Administration of EPA, DHA, and other ω -3 PUFAs to bone-marrow derived macrophages prevented LPS-induced NLRP3 and NLRPb1 inflammasome activation and IL- β 1 secretion. At least for NLRP3, ω -3 PUFAs might signal through activation of FFA4 and GPR40 [153].

3.3. Nutraceuticals as modulators of cell redox equilibrium

Micronutrients might be helpful in alleviating disease exacerbation caused by imbalances in the redox equilibrium. According to their chemical structure, many of these substances work as classical antioxidants provided with ROS scavenging, chain-reaction quenching, and metal-chelating activities. Besides that or alternatively, they have been proven to affect the principal signal cascades that rule redox equilibrium inside and outside cells [8,72,75].

Polyphenols seem to act primarily through involvement of the transcription factor Nrf2, critical for the cells to carry out the antioxidant response against oxidative damage. For example, both hydroxytyrosol and resveratrol quenched the oxidative and inflammatory burst triggered by LPS in macrophages, reducing PGE₂ production likely through the negative regulation of the immune response regulator miR-146a and the promotion of Nrf2 nuclear translocation [154]. A polyphenolic extract from Tarocco citrus reduced iNOS and COX-2 expression and ROS/NO release by murine macrophages under inflammatory condition. Inhibition of NF- κ B and activation of Nrf2 would account for the extract anti-inflammatory and antioxidant activities, respectively [155]. Protocatechuic acid potentiated the glutathione (GSH) antioxidant system of J774A.1 cells by inducing JNK-mediated Nrf2 phosphorylation [156]. Conversely, an extract of the flavonoids anthocyanins appeared to suppress Nrf2 expression and consequently ROS production and expression of inflammatory cytokines, iNOS, and COX-2 that were induced in RAW264.7 macrophages by LPS [157].

Other micronutrients, besides polyphenols, could improve redox balance in macrophages primarily by Nrf2 modulation. For example, the isothiocyanate sulforaphane from broccoli is a well-established inducer of Nrf2 and, in response to primary oxidative stress, it favors the expression of endogenous phase II and antioxidant enzymes, including GSH related enzymes [158]. Interestingly, Keap1/Nrf2 induction by sulforaphane was proven to promote, at least in non-macrophagic cells, the expression of most of the 20S proteasome subunits involved in the degradation of oxidized proteins, thus representing a strategy to prevent long-term oxidative damage and possibly ER stress [158,159]. As regards macrophages, in RAW264.7 cells sulforaphane inhibited the NLRP1b, NLRP3, NAIP/NLRC4, and AIM2 inflammasomes through an Nrf2-independent pathway. The down-stream

results were the deactivation of caspase-1, together with the repression of IL-1 β processing and secretion, and of macrophage pyroptosis [160]. Likely through Nrf2 activation and NF- κ B inhibition, sulforaphane elicited the M1 to M2 phenotypic change in PMA-differentiated THP1-derived macrophages, assessed in terms of expression levels of M1 (IL-1 β , IL-6, TNF- α , IL-23, CCR7) and M2 (IL-10, PPAR γ , MRC1, CCL22) marker genes [161]. Nrf2-mediated anti-inflammatory activity of sulforaphane, including down-regulation of iNOS, was reported also in RAW264.7 cells challenged with LPS [162]. Considering all these evidences, it would be of interest to investigate the possible involvement of Nrf2 and proteasome in the sulforaphane antioxidant activity also in the context of atherosclerosis.

Another isothiocyanate, namely allyl-isothiocyanate from brassica species, counteracted inflammation in LPS-stimulated RAW264.7 macrophages through Nrf2/HO-1 activation. In this case, although not verified, the immune response regulator miR-155 was pointed to as the mediator of the signaling triggered by allyl-isothiocyanate [163].

In addition to Nrf2, other redox sensitive pathways can undergo modulation by natural compounds. Resveratrol counterbalanced PMA-induced intracellular GSH depletion and consequently pro-inflammatory differentiation of THP1 cells via AMPK α activation [164]. Geraniin interrupted, through a SOCS-1/NF- κ B-dependent mechanism, the M1 inflammatory response due to ROS and iNOS-derived NO in THP1 cells stimulated with LPS [165]. Myricitrin has been suggested to attenuate the inflammatory activation of murine macrophages by inhibiting the assembly of NOX components. Indeed, the decrease of intracellular ROS resulting by myricitrin administration could account for the abolition of both Janus kinases (JAKs) and STAT1 phosphorylation, induced by LPS, and consequently for the suppression of DNA-binding activity of STAT1 [166]. The antioxidant properties of punicalagin and gallic acid, two polyphenols typical of pomegranate juice, could rely on the stimulation of macrophage paraoxonase-2 expression which, in turn, could depend on the activation of PPAR γ and AP-1 [167].

Siphonaxanthin, a xanthophyll present in green algae, but not other carotenoids such as lutein and fucoxanthin, attenuated ER stress and the subsequent NF- κ B activation, pro-inflammatory cytokine expression, and NO generation induced by the pro-atherogenic advanced glycation end products in RAW264.7 macrophages. In particular, high doses of siphonaxanthin increased the expression of some antioxidant genes that contribute to ER stress mitigation [168].

In oxLDL-treated macrophages, DNA damage, telomere shortening, cell senescence, and apoptosis due to ROS overproduction have been reversed by the iridoid catalpol, acting on the PGC-1 α /telomerase reverse transcriptase (TERT) pathway [169]. Alternatively, this iridoid might attenuate M1 polarization, inflammatory response, and oxidative stress elicited by IFN γ in J774.A1

macrophages through induction of estrogen receptor α . The effect could depend on iNOS suppression and on promotion of endothelial NOS instead [170].

Berberine has been shown to reduce macrophage superoxide anion concentration by inhibiting the expression of its source NOX subunit gp91phox, and by recovering superoxide dismutase (SOD) activity [171]. Moreover, β -sitosterol, a molecule which does not show significant ROS scavenger activity, might protect against oxidative stress because of manganese SOD and GSH peroxidase activation in PMA-stimulated RAW264.7 macrophages, likely through mediation of estrogen receptors and PI3K [172].

3.4. Nutraceuticals as modulators of cell metabolism: effects on lipid homeostasis and other metabolic routes

A large number of polyphenols has been reported to reduce foam cell development. EGCG restored ABCA1-mediated reverse cholesterol transport by inhibition in macrophages of the NF- κ B activity induced by TNF α . The entire process appeared to depend on the Nrf2-Kelch-like ECH-associated protein 1 (Keap1) signaling, which controls NF- κ B function [173]. Transformation of human macrophages into foam cells was also prevented by the citrus flavonoids naringenin and hesperitin by up-regulation of LXR α and its target genes ABCA1 and ABCG1 in an AMPK or PPAR γ dependent manner, respectively [174,175]. Other polyphenols effective against lipid-laden cell development are quercetin [176], dihydromyricetin [177], kaempferol [178], resveratrol [179], pomegranate ellagic acid and punicalagin, [180], coffee phenolic acids [181], and curcumin [182]; they act by improving LXR α , PPAR γ , and/or ABC-transporters, and eventually by regulating scavenger receptor expression. More in detail, in THP-1 cells LXR α /ABCA1 up-regulation by curcumin might derive from AMPK-SIRT1 signaling activation [183]. On the other hand, it was evidenced that curcumin treatment of M1 subtype RAW264.7 cells led to PPAR γ overexpression and, in turn, to ABCA1 and CD36 induction. These effects, together with improved intracellular cholesterol esterification, have been deemed as mechanisms efficient to favor noxious lipid handling by atherosclerotic macrophages and to attenuate their inflammatory response [184]. In contrast with the aforementioned data, the flavonoid gossypetin isolated from the flowers of Hibiscus species limited foam cell formation by PPAR γ blockage, promoting the PPAR α /LXR α /ABCA1 signal with down-regulation of the CD36-dependent oxLDL uptake by J774.A1 murine macrophages [185]. Similarly, resveratrol was reported to down-regulate PPAR γ , but also PPAR α , without affecting PPAR β / δ , thus reducing the conversion of THP1 PMA-differentiated cells into foam cells, pointing to AMPK and SIRT1 overexpression as the causative mechanism [186]. A novel mechanism has

been recently discovered to explain the protective action of the flavonoid fisetin against lipid accumulation in oxLDL-exposed macrophages. It comprises the induction of CK2-interacting protein-1 (CKIP-1), a protection factor for the cardiovascular system, and of REG γ (11S regulatory particles, 28 kDa proteasome activator, proteasome activator subunit 3), a member of the 11S proteasome activators already recognized as a therapeutic target for lipid metabolism disorders; indeed, REG γ limits organic cation transporter-1 (Oct-1) transcriptional activity, with the subsequent down-regulation of lectin-like LDL receptor-1 (LOX-1), a scavenger receptor responsible for oxLDL uptake [187]. Very recently, fisetin was demonstrated to regulate lipid homeostasis of oxLDL-induced U937 macrophages also by reducing the sterol regulatory element binding protein 1 (SREBP-1)-dependent expression of the liposynthesis genes 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and FA synthase. The process was shown to depend on the antioxidant properties of the flavonoid that, by quenching ROS production, abolished up-stream NLRP3 activation by oxLDLs [188]. In this connection, FA synthase has been recently suggested to be essential for the TLR-mediated macrophage pro-inflammatory activation and its activity was associated to the promotion of cholesterol biosynthesis [189]. The addition of the pomegranate polyphenols punicalagin and/or β -sitosterol to simvastatin raised the drug efficacy against foam cell formation. Punicalagin and/or β -sitosterol appeared to inhibit cholesterol biosynthesis in J774.A1 macrophages and, in combination with simvastatin, significantly reduced ROS production [190].

Phytosterols are well-known to reduce plasma LDL levels by competitive exclusion of cholesterol from micellar space in the intestinal lumen and modulation of enterocyte cholesterol trafficking. In addition, they might have a direct effect on cholesterol homeostasis in macrophage-derived foam cells; stigmasterol, but not campesterol and sitosterol, positively regulated the expression of ABCA1 and ABCG1. Surprisingly, while stigmasterol attenuated the inflammatory response and campesterol was almost inert, sitosterol exacerbated it [191].

A nutritional mixture of flavanol rich cocoa extract and ω -3 PUFA-rich fish oil, with or without phytosterols, increased ApoA-I mediated cholesterol outflow, possibly reversing foam cell formation, and delayed M1 polarization of a monocyte derived THP-1 macrophage model of atherosclerosis [192]. Nevertheless, the potentiality of UFAs to offset against aberrant lipid homeostasis in atherosclerotic macrophages is controversial. Attenuating the ER stress, both the monounsaturated FA oleic acid and the ω -6 PUFA LA were proven to suppress LOX-1 expression, which was induced by palmitic acid in macrophage-like cells [193]. Apparently, this evidence conflicts with a more recent investigation reporting that LA and its natural source soy oil are pro-atherogenic since, by exacerbation of oxidative stress and modulation of the redox-sensitive p38 MAPK, they favor triglyceride biosynthesis and accumulation in J774.A1 cells [194]. In agreement

to that, the UFAs palmitoleate, oleate, linoleate, and arachidonate had been previously implicated in atherogenesis since their supply impaired cholesterol release by macrophages by enhancing ABCA1 degradation [195]. In particular, the action of oleate and linoleate appears to be mediated by their acyl-CoA derivatives and could depend on acyl-CoA synthetase 1 up-regulation [196]. In addition, palmitic, oleic, linoleic, linolenic, or eicosapentaenoic acids significantly reduced both ABCA1 and ABCG1 macrophage content by altering, at a transcriptional level, the LXR/histone deacetylase signaling and possibly, in a LXR-independent manner, by inhibiting post-transcriptional pathways [197]. In human macrophage-derived foam cells also CLA seemed to reduce intracellular cholesterol content by up-regulation of ABCA1 through both PPAR γ - and LXR α -dependent pathways. This occurred although the expression of CD36 was increased by CLA [198]. This is consistent with inhibition by CLA of PGC-1 α -mediated macrophage transition to foam cells [199], but contrasts with cholesterol accumulation observed in CD36-overexpressing human macrophages exposed to CLA [200]. It is possible that different CLA isomers have distinct features; in fact, trans-9,trans-11-CLA, but not cis-9,trans-11 and trans-10,cis-12-CLA, activated the cholesterol transporter ABCG1 in murine macrophages by a SREBP1c-dependent mechanism [201].

Among carotenoids, lycopene might be helpful against foam cell formation by affecting cholesterol metabolism of human macrophages. The signal machinery triggered by this compound consisted in an initial inhibition of the cholesterol synthesis key enzyme HMG-CoA reductase followed by small GTPase RhoA inactivation, subsequent increase in PPAR γ and LXR activities, and final enhancement of ABCA1 expression [202]. Cholesterol efflux from murine macrophages to high density lipoproteins (HDLs) was accelerated by all-trans-retinoic acid and by its precursor 9-cis- β -carotene. Both compounds increased ApoE protein level but only 9-cis- β -carotene was effective in the induction of ABCA1, ABCG1, and ApoE genes [203]. A novel mechanism was recently suggested to underlie ABCA1, ABCG1, and scavenger receptor class B type I (SR-BI) overexpression, as well as cholesterol outflow promoted by astaxanthin in oxLDL-overloaded macrophages. This mechanism identified noncoding circular RNAs as key players of the process induced by the carotenoid [204].

In PMA-differentiated THP-1 monocytes, the steroidal saponin diosgenin was proven to induce ABCA1 protein and ABCA1-mediated cholesterol outflow without affecting LXR but suppressing miR-19b, a post-transcriptional regulator of ABCA1 [205].

PPAR α and LXR α are likely the target of the anti-atherogenic action of the garlic derived allicin too, resulting in improved cholesterol exchange by ABCA1 overexpressing macrophages [206].

Cholesterol efflux associated to M2 polarization was favored by $1,25(\text{OH})_2\text{D}_3$ in THP-1-derived foam cells. In this case, LXR-dependent ABCA1 and ABCG1 overexpression was the consequence of the induction of CYP27A1, the enzyme responsible for the synthesis of the LXR agonist 27-hydroxycholesterol [207].

Macrophage differentiation into foam cells has been prevented by berberine too, but through other mechanisms: in oxLDL-stimulated THP1 cells this alkaloid down-regulated the expression of CD36 and LOX-1, and increased the expression of adipocyte enhancer-binding protein 1 (AEBP1), a key regulator of genes associated with intracellular cholesterol homeostasis, including PPAR γ , LXR α , and ABC-transporters [208]. In addition, cholesterol-lowering effects of berberine were exerted by activation of Nrf2/HO-1, which accounted for ABC-transporter overexpression, and by inhibition of AP-1, which suppressed scavenger receptor expression [209]. Berberine has also been demonstrated to act by up-regulating AMPK and SIRT1 and by down-regulating PPAR γ [210]. Berberine as well as ω -3 the PUFAs DHA and EPA were proven to reduce modified LDL uptake by human macrophages, in a scavenger receptor-independent manner, likely as the result of diminished macropinocytosis [211,212].

A preventive effect of tanshinone II on foam cell formation was observed in human monocyte-derived THP-1 cells challenged with oxLDL. This compound markedly down-regulated SR-A and up-regulated ABCA1 and ABCG1 expression. This was the consequence of ERK activation, Nrf2 phosphorylation and nuclear translocation, and final HO-1 overexpression [213].

All these observations point to metabolism and cell homeostasis of lipids, in particular of cholesterol, as the main processes that can be affected by bioactive micronutrients, but other metabolic cycles can be affected as well. A flavonoid-rich cocoa extract has prompted M2 polarization of active THP-1 derived macrophages which was shown by the reduction of inflammatory cytokine secretion and the increase of IL-10 and IL-12 release. The conversion from M1 to M2 phenotype was accompanied with enhanced oxygen consumption and ATP production through the mitochondrial oxidative phosphorylation, suggesting that flavonoids could act principally as antioxidants that favor the switch towards the oxidative metabolism [214].

Rescue of mitochondrial functions and of the anti-inflammatory metabolism and phenotype might be promoted in M1 macrophages also by carnosine. Indeed, this molecule was recently proven to restore ATP/ADP and NAD(P)⁺/NAD(P)H balance in activated RAW264.7 macrophages, the last effect being indicative of a strong inhibition of the main reactions responsible for cell ROS production. Furthermore, carnosine antioxidant efficacy appeared to be strengthened by its ability to improve the antioxidant defense through up-regulation of Nrf2, HO-1, and ROS scavenger enzymes,

and simultaneously to decrease NOX-2 and COX-2 expression, reactive nitrogen species formation, and lipid peroxidation [215,216].

4. Nutraceutical approaches to the treatment of atherosclerosis: outcomes from human studies

The evidence, at a molecular level, of the antiatherogenic potential of many natural derivatives has prompted to evaluate their efficacy also in humans. Literature in this field, from small observational or interventional studies to larger epidemiological or clinical trials, has been continuously growing [8, 74,217,218]. In some cases, as exemplified by some relevant studies hereinafter reported, the micronutrient impact on vascular events was assessed together with inflammatory and oxidative state indices; this provides some information about the correlation between nutraceutical intake and the mechanisms that mainly contribute to atherosclerosis progression. Of note, although the last parameters are usually measured in the circulation and not specifically in the lesions or in the atherosclerotic macrophages, it is conceivable that the systemic condition could reflect what occurs in the plaque cells, among which macrophages.

Polyphenols, UFAs, and carotenoids are the bioactive compounds probably most widespread in nature and abundant in food, thus they are the most investigated for nutritional and pharmacological applications. The PREDIMED trial is undoubtedly one of the most extensive study carried out to analyze the contribute of the Mediterranean nutritional pattern (i.e. increased intake of vegetables, fruits, legumes, fish or seafood, moderate red wine consumption, and reduced intake of red meat), characterized by a high content of polyphenols and PUFAs, on the primary prevention of CVD. Almost 7500 high-risk participants were submitted to two Mediterranean diet regimens supplemented with either virgin olive oil or nuts, or to a control low-fat diet. Intervention with both the enriched diets brought to short-term and long-term decreases in the circulation of inflammatory cytokines, and to an increase of plaque stability markers, together with an improvement of the classical cardiovascular risk factors, including the lipid profile. Of note, the total polyphenol intake, measured as urinary polyphenol excretion, inversely correlated with the levels of inflammatory markers, suggesting a dose-dependent anti-inflammatory efficacy of polyphenols. In spite of that, no significant changes were observed for the expression of genes involved in the atherosclerosis-related inflammation [219-223].

A meta-analysis of human nutrigenomic studies highlighted the capacity of acute or sustained interventions with a Mediterranean dietary regimen to down-regulate, in peripheral blood monocytes (PBMCs), the expression of inflammatory and pro-oxidant mediators involved in atherosclerosis. Olive oil appeared the main responsible for gene modulation, thanks to its high content of MUFAs,

carotenoids and, in particular, of polyphenols; in fact, some genes, such as TNF α and monocyte chemotactic protein 1 (MCP1), have been affected by olive oil and its polyphenols, within and out of the context of the Mediterranean diet [224].

Other dietary sources of polyphenols have been considered for preventive purposes too. Several epidemiological studies have demonstrated the positive association between cocoa and its products and lower CVD risk and mortality, pointing to a pivotal role played by cocoa flavanols. Indeed, systemic levels of inflammatory markers such as ILs and C-reactive protein (CRP) appeared reduced, mainly in studies considering healthy subjects, after short- and medium-term consumption of cocoa derivatives. Nevertheless, a neutral effect on CRP, ILs, and on other inflammatory proteins (TNF α , MCP1) has also been reported, either in healthy subjects and in individuals at cardiovascular risk [225]. Furthermore, cocoa powder supplementation to high-cardiovascular risk volunteers significantly lowered monocyte CD36 expression [226]. As regards polyphenolic compounds present in green and black tea, both case-control studies and meta-analysis data are in support of an inverse association between tea consumption and the risk of coronary artery disease and its fatal outcomes [227].

Resveratrol and its sources grape and wine were taken into consideration for secondary cardiovascular prevention [228,229]. One-year daily consumption of a grape-extract of the phytochemical was able to modulate, in PBMCs of stable coronary artery disease patients, the expression of inflammation-related transcription factors, including KLF2, NF- κ B, AP-1, c-Jun, ATF-2, and CREB-binding protein. In the cells the expression of IL-1 β and TNF- α was also significantly reduced, but no significant changes of inflammatory markers were observed in the serum, except the reduction of IL-6 levels. Of note, lower expression of the inflammatory cytokines in PBMCs was concomitant with increased levels of miR-21, miR-181b, miR-663, and miR-30c2, and with lower levels of miR-155 and miR-34a, all involved in monocyte and macrophage inflammatory pathways such as TLR and NF- κ B signaling. However, the authors could not detect circulating resveratrol or other grape-derived metabolites, thus the direct relation between resveratrol and the effects observed might be only speculative [230,231].

An anti-inflammatory activity was also ascribed to UFAs, which characterize some dietary patterns, such as the Mediterranean and the Greenland ones, proven to be health promoting [228, 229]. In elderly healthy people, consumption of a Mediterranean diet enriched in MUFAs limited the postprandial inflammatory response in mononuclear cells compared to a saturated FA-rich diet, reducing the expression of TNF α , IL-6 and MCP1, and of MMP-9, thus suggesting a plaque stabilizing efficacy. Of note, MUFA-diet appeared able to act directly on the up-stream NF- κ B signaling, by lowering p65 subunit expression [232]. Very recently, outcomes from the ongoing

CORDIOPREV randomized trial further suggest the anti-atherogenic potential of a Mediterranean diet at high virgin olive oil content. It emerged that, compared to a low-fat diet, 5 and 7 years adherence to an olive oil-rich pattern reduced the arterial intima-media thickness of subjects with coronary heart disease at baseline. One might presume that MUFAs present in olive oil largely contribute to vascular protection, although no data about the actual intake of bioactive species, in terms of compound concentration in the plasma and/or urine of participants, were provided to confirm that [233,234].

As precursors of the pro-resolving mediators SPMs, ω -3 PUFA have been explored for atherosclerosis treatment as well, but to date observations from clinical trials did not give conclusive results [235]. On one hand, ω -3 PUFAs, including EPA and DHA, did not significantly reduce cardiovascular events in humans [236]. In this connection, ω -3 PUFAs did not seem to affect SPM levels in urine and plasma of healthy volunteers after fish oil dietary consumption [237]. Conversely, in patients with chronic inflammation, high doses of purified EPA and DHA affected plasma levels of intermediates of SPM biosynthesis and attenuated the expression of pro-inflammatory cytokines in LPS-stimulated PBMCs isolated from study's participants [238].

Moreover, EPA, DHA, docosapentaenoic acid (DPA), and monohydroxylated SPM precursors down-regulated M1 and up-regulated M2 genes of LPS-stimulated monocyte-derived macrophages that were isolated from patients with peripheral artery disease after a short-term intake of marine oil enriched with these FAs and SPM precursors. The phenotypic changes strongly correlated with the plasma SPMs/PGs ratio [239].

More generally, ω -3 PUFAs were demonstrated to promote plaque stabilization: the lipid core of coronary plaques of patients under statin therapy was significantly reduced by EPA co-administration, while fibrous cap formation was favored. It decreased also plasma MCP1 [240]. The OCEAN trial, which enrolled patients awaiting carotid endarterectomy, reported that interventions with ω -3 PUFA ethyl ester capsules decreased plaque foam cell number and mRNA levels of MMP-7, MMP-9, MMP-12, and IL-6, in association with a higher plaque EPA content [241]. These observations are consistent with an earlier study showing that ω -3 PUFAs-enriched fish oil supplementation to patients with advanced lesions were readily incorporated in the carotid plaque, and were able to limit macrophage infiltration and to enhance atheroma stability. By contrast, the same results were not observed for increased consumption of ω -6 PUFAs [242]. Overall, the latest results are consistent with the outcomes of meta-analysis of clinical trials, including the DART, the GISSI-Prevenzione, and the Jelis trials, from which it emerged that marine ω -3 PUFA supplementation lowered the risk for the major vascular diseases [235].

Among carotenoids, most attention was given to β -carotene and lycopene, while other carotenoids were less investigated. In consideration of data variability, employment of β -carotene for the reduction of vascular morbidity is still debated and should be considered carefully [243]. On one hand, a prospective quantification of β -carotene in the serum of more than 29.000 men, enrolled for the ATBC study, provided evidence for an inverse correlation between β -carotene levels and the occurrence of CVD, heart disease, and stroke during the 31-years follow-up period [244]. On the other hand, according to the Cochrane Database review, β -carotene and vitamin A could increase all-cause mortality [245], and in agreement with that β -carotene was not recommended for prevention of CVD by the US Preventive Task Force [246].

As regards lycopene, interventional studies indicated that its consumption by means of tomato-based foods might be vasoprotective and reduce cardiovascular risk [247]. In addition, in subjects with subclinical atherosclerosis, 1-year treatment with lycopene, alone or in combination with luteolin, induced a decrease in the intima-media thickness that was inversely associated to plasma levels of both carotenoids [248]. These effects might be ascribed to lycopene antioxidant and anti-inflammatory properties; indeed, in individuals at high cardiovascular risk, a daily tomato-juice intake led to a plasmatic trans-lycopene increase that correlated with lessening of plasma IL-8 [249]. However, other studies did not sustain lycopene anti-atherogenic activity. In fact, a relatively high daily consumption of tomato-based products or lycopene supplements were ineffective at reducing vascular disease-related inflammatory markers in moderately overweight, healthy, middle-aged individuals, in spite of the lycopene increase in plasma [250], or at lowering CRP serum levels both in healthy volunteers and in CVD patients [251].

A saffron extract and its main carotenoid, crocin, have also been evaluated for the treatment of CVD patients; crocin, in particular, was able to promote SIRT1 and AMPK expression in the PMBCs of patients and to decrease NF- κ B. These effects were accompanied to the reduction of MCP1 and oxLDL levels in the serum [251].

As regards other less common natural bioactive compounds, literature is still limited and certainly less exhaustive, also in consideration of the few number of participants included in the studies presently available [8, 218]. Phytosterols have been considered mainly as cholesterol-lowering agents [218], while their application as atherosclerosis-related anti-inflammatory substances was less investigated. It has been reported that orange juice and orange juice fortified with phytosterols lessened IL levels in healthy human volunteers [252]; however, this evidence does not seem furtherly corroborated since a following meta-analysis of trials on humans did not report anti-inflammatory efficacy for phytosterol-enriched foods, at least in terms of CRP content [253]. Also for vit D evidence about benefits of its supplementation for atherosclerosis treatment is still scarce,

although its deficiency is increasingly referred to as a risk factor for vascular diseases, [85]. Of note, a trial is presently going on to explore the anti-inflammatory effects of the injection of a Danshen extract containing tanshinone II in patients with stable coronary artery disease [254].

Conclusions and future perspectives.

Atherosclerosis is a multifaceted pathological process in which macrophages play a pivotal role. Their orientation towards a more or less inflammatory phenotype can affect plaque evolution towards vulnerable lesions, which ultimately leads to fatal adverse outcomes such as ischemic stroke and myocardial infarction, or, conversely, towards atherosclerotic process resolution. In this connection, inflammatory state, redox balance, and metabolic regulation represent a unique complex network that in a coordinated manner drives macrophage polarization and is, in turn, orchestrated by macrophages themselves according to their phenotype. By operating on this network, several substances of natural origin, including extra-nutritional constituents in foods or micronutrients, have shown efficacy to direct macrophage polarization; for this reason, these compounds have been considered as adjuvants in the prevention and treatment of atherosclerosis

The body of evidence available shows that nutraceutical bioactivity mainly relies upon their capability to operate on the diverse signaling cascades that regulate macrophage functions (Fig. 2). Of note, the most widespread compounds in dietary sources, such as polyphenols, UFAs, and carotenoids, act on several pathways (e.g. NF- κ B, MAPKs, TLRs, Nrf2, and PPARs), involved in multiple fundamental macrophage metabolic cycles and immune responses. In some cases, molecules less common in natural sources or present at very low concentrations seem to target more selectively biochemical factors with more specific roles. Examples of that include the modulation of estrogen receptors by β -sitosterol [172], of inflammasomes by saponins [148], of noncoding RNA by berberine, tanshinone II, and diosgenin [122,150,205], or of TERT by the iridoid catalpol [169].

Considering that, the integration of specific compounds through concentrated forms, including non-food matrices like pills, extracts, or powders [255], might represent a promising tool for therapeutic approaches aimed to direct the inflammatory network in atherosclerotic macrophages. In particular, this could be the case of substances such as saponins, iridoids, and berberin, that not only show more peculiar bioactivities but whose uptake through foodstuffs is limited. Noteworthy, administration of molecules targeting machineries with a selective activity might limit perturbations of signaling pathways with a broad impact on important processes shared by vascular and extra-vascular cells, thus avoiding potentially harmful interferences. Other advantages of nutritional

supplements are their less sensitivity to those alterations brought about food storage and cooking that can change molecule biochemical reactivity, and eventually a major bioavailability due to the absence of complex foodstuff matrices.

Nevertheless, definitive and unanimous data about the atherosclerosis-related properties of certain nutraceuticals are still few, as well as information about their bioavailability or potential toxicity due to their overconsumption. This is likely the result of the great variability of the experimental models utilized for their investigation, especially as regards dose and duration of treatments. In particular, as regards studies on humans, the molecule anti-atherogenic efficacy is usually verified by means of clinical parameters, such as the intima-media thickness or the frequency and seriousness of cerebro- and cardiovascular events, while inflammatory and oxidative markers are less frequently observed. Moreover, only few investigations have evaluated the actual uptake of the administered substances, for example by measuring plasma, urine or other tissue levels of the presumed bioactive principle and of its metabolites. In the absence of these data, it is difficult to infer a conclusive correlation between a defined nutraceutical and the observed outcomes in humans. For this reason, further *in vitro* and *in vivo* studies on animals and humans, including extensive clinical trials, are necessary to confirm the effectiveness of natural compounds to induce anti-atherogenic polarization in macrophages and to establish the most suitable guide lines for their administration [256,257].

Consequently, the application of micronutrients for atherosclerosis treatment in fully replacement of current pharmacological therapies is not reliable yet. In spite of that, a balanced diet which comprises a variety of nutraceutical-containing foods, such as the Mediterranean diet, likely provides bioactive molecules in amounts adequate to counterbalance atheroma formation. Of note, the copresence in the same foodstuff or meal of more micronutrients could ensure even more efficacy, as highlighted by investigations reporting a synergistic action of them in mixtures [111,112,192]. Functional foods enriched with beneficial species could be also considered [255], in particular to enhance provision of essential micronutrients or when the everyday diet is not sufficient for their supplementation.

In conclusion, diets rich in bioactive species, fortified foods, and micronutrient supplements can be employed for early prevention and possibly to improve patient response to drugs [258], as emerged from the study of Rosenblat and collaborators about the combined effect of pomegranate micronutrients and simvastatin [179]. Of note, this could allow lower drug doses reducing their side-effects. For these reasons, nutraceuticals may represent a valid coadjuvant against atherosclerosis evolution and their consumption should become fundamental in daily nutrition.

Acknowledgments

The work was supported by the University of Turin (Italy) (grant ID: LEOG_RILO_20_01).

Conflict of interest

Authors declare not to have conflicts of interest.

References

- [1] O. Soehnlein, P. Libby, Targeting inflammation in atherosclerosis—from experimental insights to the clinic, *Nat. Rev. Drug Discov.* 20(8) (2021) 589-610. <https://doi.org/10.1038/s41573-021-00198-1>.
- [2] K.J. Moore, S. Koplev, E.A. Fisher, I. Tabas, J.L.M. Björkegren, A.C. Doran, J.C. Kovacic, Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2), *J. Am. Coll. Cardiol.* 72(18) (2018) 2181-2197. <https://doi.org/10.1016/j.jacc.2018.08.2147>.
- [3] S. Adamson, N. Leitinger, Phenotypic modulation of macrophages in response to plaque lipids, *Curr. Opin. Lipidol.* 22(5) (2011) 335-342. <https://doi.org/10.1097/MOL.0b013e32834a97e4>.
- [4] M.S. Gibson, N. Domingues, O.V. Vieira, 2018. Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis. *Front. Physiol.* 9, 654. <https://doi.org/10.3389/fphys.2018.00654>.
- [5] E.A.L. Biessen, K. Wouters, Macrophage complexity in human atherosclerosis: opportunities for treatment? *Curr. Opin. Lipidol.* 28(5) (2017) 419-426. <https://doi.org/10.1097/MOL.0000000000000447>.
- [6] A. Solanki, L.K. Bhatt, T.P. Johnston, Evolving targets for the treatment of atherosclerosis, *Pharmacol. Ther.* 187 (2018) 1-12. <https://doi.org/10.1016/j.pharmthera.2018.02.002>.
- [7] T.V. Kirichenko, V.N. Sukhorukov, A.M. Markin, N.G. Nikiforov, P.Y. Liu, I.A. Sobenin, V.V. Tarasov, A.N. Orekhov, G. Aliev, 2020. Medicinal Plants as a Potential and Successful Treatment Option in the Context of Atherosclerosis. *Front. Pharmacol.* 11, 403. <https://doi.org/10.3389/fphar.2020.00403>.
- [8] J.W. Moss, D.P. Ramji, Nutraceutical therapies for atherosclerosis, *Nat. Rev. Cardiol.* 13(9) (2016) 513-532. <https://doi.org/10.1038/nrcardio.2016.103>.

- [9] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation, *Nat. Rev. Immunol.* 2008 Dec;8(12):958-69. <https://doi.org/10.1038/nri2448>.
- [10] Y.V. Bobryshev, E.A. Ivanova, D.A. Chistiakov, N.G. Nikiforov, A.N. Orekhov, 2016. *Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis.* *Biomed. Res. Int.* 2016, 9582430. <https://doi.org/10.1155/2016/9582430>.
- [11] A.N. Seneviratne, B. Sivagurunathan, C. Monaco, Toll-like receptors and macrophage activation in atherosclerosis, *Clin. Chim. Acta* 413(1-2) (2012) 3-14. <https://doi.org/10.1016/j.cca.2011.08.021>.
- [12] M.P. Wolf, P. Hunziker, Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments, *J. Cardiovasc. Transl. Res.* 13(5) (2020) 744-757. <https://doi.org/10.1007/s12265-020-09961-y>.
- [13] S. Devaraj, I. Jialal, C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype, *Arterioscler. Thromb. Vasc. Biol.* 31(6) (2011) 1397-1402. <https://doi.org/10.1161/ATVBAHA.111.225508>.
- [14] A. Szanto, T. Roszer, Nuclear receptors in macrophages: a link between metabolism and inflammation, *FEBS Lett.* 582(1) (2008) 106-116. <https://doi.org/10.1016/j.febslet.2007.11.020>.
- [15] H. Jinnouchi, L. Guo, A. Sakamoto, S. Torii, Y. Sato, A. Cornelissen, S. Kuntz, K.H. Paek, R. Fernandez, D. Fuller, N. Gadhoke, D. Surve, M. Romero, F.D. Kolodgie, R. Virmani, A.V. Finn, Diversity of macrophage phenotypes and responses in atherosclerosis, *Cell. Mol. Life Sci.* 77(10) (2020) 1919-1932. <https://doi.org/10.1007/s00018-019-03371-3>.
- [16] C.J. Ferrante, S.J. Leibovich, Regulation of Macrophage Polarization and Wound Healing, *Adv. Wound Care (New Rochelle)* 1(1) (2012) 10-16. <https://doi.org/10.1089/wound.2011.0307>.
- [17] I. Tabas, K.E. Bornfeldt, Macrophage Phenotype and Function in Different Stages of Atherosclerosis, *Circ. Res.* 118(4) (2016) 653-667. <https://doi.org/10.1161/CIRCRESAHA.115.306256>.
- [18] G.F.P. Bories, N. Leitinger, Macrophage metabolism in atherosclerosis, *FEBS Lett.* 591(19) (2017) 3042-3060. <https://doi.org/10.1002/1873-3468.12786>.
- [19] G.J. Koelwyn, E.M. Corr, E. Erbay, K.J. Moore, Regulation of macrophage immunometabolism in atherosclerosis, *Nat. Immunol.* 19(6) (2018) 526-537. <https://doi.org/10.1038/s41590-018-0113-3>.
- [20] A.J. Covarrubias, H. I. Aksoylar, T. Horng, Control of macrophage metabolism and activation by mTOR and Akt signaling, *Semin. Immunol.* 27(4) (2015) 286-296. <https://doi.org/10.1016/j.smim.2015.08.001>.
- [21] A. Arranz, C. Doxaki, E. Vergadi, Y. Martinez de la Torre, K. Vaporidi, E.D. Lagoudaki, E. Ieronymaki, A. Androulidaki, M. Venihaki, A.N. Margioris, E.N. Stathopoulos, P.N. Tsihliis, C.

Tsatsanis, Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization, *Proc. Natl. Acad. Sci. USA* 109(24) (2012) 9517-9522. <https://doi.org/10.1073/pnas.1119038109>.

[22] T. Cramer, Y. Yamanishi, B.E. Clausen, I. Förster, R. Pawlinski, N. Mackman, V.H. Haase, R. Jaenisch, M. Corr, V. Nizet, G.S. Firestein, H.P. Gerber, N. Ferrara, R.S. Johnson, HIF-1 α is essential for myeloid cell-mediated inflammation, *Cell* 112(5) (2003) 645-657. [https://doi.org/10.1016/s0092-8674\(03\)00154-5](https://doi.org/10.1016/s0092-8674(03)00154-5).

[23] G.M. Tannahill, A.M. Curtis, J. Adamik, E.M. Palsson-McDermott, A.F. McGettrick, G. Goel, C. Frezza, N.J. Bernard, B. Kelly, N.H. Foley, L. Zheng, A. Gardet, Z. Tong, S.S. Jany, S.C. Corr, M. Haneklaus, B.E. Caffrey, K. Pierce, S. Walmsley, F.C. Beasley, E. Cummins, V. Nizet, M. Whyte, C.T. Taylor, H. Lin, S.L. Masters, E. Gottlieb, V.P. Kelly, C. Clish, P.E. Auron, R.J. Xavier, L.A.J. O'Neill, Succinate is an inflammatory signal that induces IL-1 β through HIF-1 α , *Nature* 496 (7444) (2013) 238-242. <https://doi.org/10.1038/nature11986>.

[24] S.C. Cheng, J. Quintin, R.A. Cramer, K.M. Shephardson, S. Saeed, V. Kumar, E.J. Giamarellos-Bourboulis, J.H. Martens, N.A. Rao, A. Aghajani-refah, G.R. Manjari, Y. Li, D.C. Ifrim, R.J. Arts, B.M. van der Veer, P.M. Deen, C. Logie, L.A. O'Neill, P. Willems, F.L. van de Veerdonk, J.W. van der Meer, A. Ng, L.A. Joosten, C. Wijmenga, H.G. Stunnenberg, R.J. Xavier, M.G. Netea, 2014. mTOR- and HIF-1 α -mediated aerobic glycolysis as metabolic basis for trained immunity. *Science* 345(6204), 1250684. <https://doi.org/10.1126/science.1250684>.

[25] D. Vats, L. Mukundan, J.I. Odegaard, L. Zhang, K.L. Smith, C.R. Morel, R.A. Wagner, D.R. Greaves, P.J. Murray, A. Chawla, Oxidative metabolism and PGC-1 β attenuate macrophage-mediated inflammation, *Cell Metab.* 4(1) (2006) 13-24. <https://doi.org/10.1016/j.cmet.2006.05.011>.

[26] D. Sag, D. Carling, R.D. Stout, J. Suttles, Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype, *J. Immunol.* 181(12) (2008) 8633-8641. <https://doi.org/10.4049/jimmunol.181.12.8633>.

[27] A. Haschemi, P. Kosma, L. Gille, C.R. Evans, C.F. Burant, P. Starkl, B. Knapp, R. Haas, J.A. Schmid, C. Jandl, S. Amir, G. Lubec, J. Park, H. Esterbauer, M. Bilban, L. Brizuela, J.A. Pospisilik, L.E. Otterbein, O. Wagner, The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism, *Cell Metab.* 15(6) (2012) 813-826. <https://doi.org/10.1016/j.cmet.2012.04.023>.

[28] E.L. Mills, L.A. O'Neill, Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal, *Eur. J. Immunol.* 46(1) (2016) 13-21. <https://doi.org/10.1002/eji.201445427>.

[29] J. Van den Bossche, J. Baardman, N.A. Otto, S. van der Velden, A.E. Neele, S.M. van den Berg, R. Luque-Martin, H.J. Chen, M.C. Boshuizen, M. Ahmed, M.A. Hoeksema, A.F. de Vos, M.P. de

Winther, Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages, *Cell Rep.* 17(3) (2016) 684-696. <https://doi.org/10.1016/j.celrep.2016.09.008>.

[30] W.A. Baseler, L.C. Davies, L. Quigley, L.A. Ridnour, J.M. Weiss, S.P. Hussain, D.A. Wink, D.W. McVicar, Autocrine IL-10 functions as a rheostat for M1 macrophage glycolytic commitment by tuning nitric oxide production, *Redox Biol.* 10 (2016) 12-23. <https://doi.org/10.1016/j.redox.2016.09.005>.

[31] J.D. Bailey, M. Diotallevi, T. Nicol, E. McNeill, A. Shaw, S. Chuaiphichai, A. Hale, A. Starr, M. Nandi, E. Stylianou, H. McShane, S. Davis, R. Fischer, B.M. Kessler, J. McCullagh, K.M. Channon, M.J. Crabtree, Nitric Oxide Modulates Metabolic Remodeling in Inflammatory Macrophages through TCA Cycle Regulation and Itaconate Accumulation, *Cell Rep.* 28(1) (2019) 218-230. <https://doi.org/10.1016/j.celrep.2019.06.018>.

[32] T. Shirai, R.R. Nazarewicz, B.B. Wallis, R.E. Yanes, R. Watanabe, M. Hilhorst, L. Tian, D.G. Harrison, J.C. Giacomini, T.L. Assimes, J.J. Goronzy, C.M. Weyand, The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease, *J. Exp. Med.* 213(3) (2016) 337-354. <https://doi.org/10.1084/jem.20150900>.

[33] J. Xu, F. Chi, T. Guo, V. Punj, W.N. Lee, S.W. French, H. Tsukamoto, NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation, *J. Clin. Invest.* 125 (2015) 1579-1590. <https://doi.org/10.1172/JCI76468>.

[34] G. Chinetti-Gbaguidi, S. Colin, B. Staels, Macrophage subsets in atherosclerosis, *Nat. Rev. Cardiol.* 12(1) (2015) 10-17. <https://doi.org/10.1038/nrcardio.2014.173>.

[35] K.Y. Cho, H. Miyoshi, S. Kuroda, H. Yasuda, K. Kamiyama, J. Nakagawara, M. Takigami, T. Kondo, T. Atsumi, The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery, *J. Stroke Cerebrovasc. Dis.* 22(7) (2013) 910-918. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.11.020>.

[36] J. Khallou-Laschet, A. Varthaman, G. Fornasa, C. Compain, A.T. Gaston, M. Clement, M. Dussiot, O. Levillain, S. Graff-Dubois, A. Nicoletti, G. Caligiuri, 2010. Macrophage plasticity in experimental atherosclerosis, *PLoS One* 5(1), e8852. <https://doi.org/10.1371/journal.pone.0008852>.

[37] J.L. Stöger, M.J. Gijbels, S. van der Velden, M. Manca, C.M. van der Loos, E.A. Biessen, M.J. Daemen, E. Lutgens, M.P. de Winther, Distribution of macrophage polarization markers in human atherosclerosis, *Atherosclerosis* 225(2) (2012) 461-468. <https://doi.org/10.1016/j.atherosclerosis.2012.09.013>.

[38] A. Kadl, A.K. Meher, P.R. Sharma, M.Y. Lee, A.C. Doran, S.R. Johnstone, M.R. Elliott, F. Gruber, J. Han, W. Chen, T. Kensler, K.S. Ravichandran, B.E. Isakson, B.R. Wamhoff, N. Leitinger, Identification of a novel macrophage phenotype that develops in response to atherogenic

phospholipids via Nrf2, *Circ. Res.* 107(6) (2010) 737-746.
<https://doi.org/10.1161/CIRCRESAHA.109.215715>.

[39] A.V. Finn, M. Nakano, R. Polavarapu, V. Karmali, O. Saeed, X. Zhao, S. Yazdani, F. Otsuka, T. Davis, A. Habib, J. Narula, F.D. Kolodgie, R. Virmani, Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques, *J. Am. Coll. Cardiol.* 59(2) (2012) 166-177. <https://doi.org/10.1016/j.jacc.2011.10.852>.

[40] J.J. Boyle, M. Johns, T. Kampfer, A.T. Nguyen, L. Game, D.J. Schaer, J.C. Mason, D.O. Haskard, Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection, *Circ. Res.* 110(1) (2012) 20-33. <https://doi.org/10.1161/CIRCRESAHA.111.247577>.

[41] L. Potor, Z. Hendrik, A. Patsalos, É. Katona, G. Méhes, S. Póliska, É. Csősz, G. Kalló, I. Komáromi, Z. Combi, N. Posta, K.É. Sikura, D. Pethő, M. Oros, G. Vereb, C. Tóth, P. Gergely, L. Nagy, G. Balla, J. Balla, Oxidation of Hemoglobin Drives a Proatherogenic Polarization of Macrophages in Human Atherosclerosis, *Antioxid. Redox Signal.* 35(12) (2021) 917-950. <https://doi.org/10.1089/ars.2020.8234>.

[42] C.A. Gleissner, Macrophage Phenotype Modulation by CXCL4 in Atherosclerosis, 2012. *Front. Physiol.* 3, 1. <https://doi.org/10.3389/fphys.2012.00001>.

[43] C. Erbel, A. Wolf, F. Lasitschka, F. Linden, G. Domschke, M. Akhavanpoor, A.O. Doesch, H.A. Katus, C.A. Gleissner, Prevalence of M4 macrophages within human coronary atherosclerotic plaques is associated with features of plaque instability, *Int. J. Cardiol.* 186 (2015) 219-225. <https://doi.org/10.1016/j.ijcard.2015.03.151>.

[44] M. Kloc, A. Uosef, J.Z. Kubiak, R.M. Ghobrial, 2020. Role of Macrophages and RhoA Pathway in Atherosclerosis, *Int. J. Mol. Sci.* 22(1), 216. <https://doi.org/10.3390/ijms22010216>.

[45] K. Rajamäki, J. Lappalainen, K. Oörni, E. Välimäki, S. Matikainen, P.T. Kovanen, K.K. Eklund, 2010. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. *PLoS One* 5(7), e11765. <https://doi.org/10.1371/journal.pone.0011765>.

[46] Z. Hoseini, F. Sepahvand, B. Rashidi, A. Sahebkar, A. Masoudifar, H. Mirzaei, NLRP3 inflammasome: Its regulation and involvement in atherosclerosis, *J. Cell. Physiol.* 233(3) (2018) 2116-2132. <https://doi.org/10.1002/jcp.25930>.

[47] F.J. Sheedy, A. Grebe, K.J. Rayner, P. Kalantari, B. Ramkhelawon, S.B. Carpenter, C.E. Becker, H.N. Ediriweera, A.E. Mullick, D.T. Golenbock, L.M. Stuart, E. Latz, K.A. Fitzgerald, K.J. Moore, CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble

- ligands into particulate ligands in sterile inflammation, *Nat. Immunol.* 14(8) (2013) 812-820. <https://doi.org/10.1038/ni.2639>.
- [48] X. Chen, X. Guo, Q. Ge, Y. Zhao, H. Mu, J. Zhang ER, 2019. Stress Activates the NLRP3 Inflammasome: A Novel Mechanism of Atherosclerosis. *Oxid. Med. Cell. Longev.* 2019, 3462530. <https://doi.org/10.1155/2019/3462530>.
- [49] J. Shi, Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, Y. Zhuang, T. Cai, F. Wang, F. Shao, Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death, *Nature* 526(7575) (2015) 660-665. <https://doi.org/10.1038/nature15514>.
- [50] R. Emanuel, I. Sergin, S. Bhattacharya, J. Turner, S. Epelman, C. Settembre, A. Diwan, A. Ballabio, B. Razani, Induction of lysosomal biogenesis in atherosclerotic macrophages can rescue lipid-induced lysosomal dysfunction and downstream sequelae, *Arterioscler. Thromb. Vasc. Biol.* 34(9) (2014) 1942-1952. <https://doi.org/10.1161/ATVBAHA.114.303342>.
- [51] R. Singh, A.M. Cuervo, 2012. Lipophagy: connecting autophagy and lipid metabolism. *Int. J. Cell Biol.* 2012, 282041. <https://doi.org/10.1155/2012/282041>.
- [52] K. Liu, E. Zhao, G. Ilyas, G. Lalazar, Y. Lin, M. Haseeb, K.E. Tanaka, M.J. Czaja, Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization, *Autophagy* 11(2) (2015) 271-284. <https://doi.org/10.1080/15548627.2015.1009787>.
- [53] B. Razani, C. Feng, T. Coleman, R. Emanuel, H. Wen, S. Hwang, J.P. Ting, H.W. Virgin, M.B. Kastan, C.F. Semenkovich, Autophagy links inflammasomes to atherosclerotic progression, *Cell Metab.* 15(4) (2012) 534-544. <https://doi.org/10.1016/j.cmet.2012.02.011>.
- [54] C. Zhai, J. Cheng, H. Mujahid, H. Wang, J. Kong, Y. Yin, J. Li, Y. Zhang, X. Ji, W. Chen, 2014. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque. *PLoS One* 9(3), e90563. <https://doi.org/10.1371/journal.pone.0090563>.
- [55] F. Tian, B.L. Yu, J.R. Hu, mTOR mediates the cross-talk of macrophage polarization and autophagy in atherosclerosis, *Int. J. Cardiol.* 177(1) (2014) 144-145. <https://doi.org/10.1016/j.ijcard.2014.09.035>.
- [56] M. Kitada, Y. Ogura, D. Koya, The protective role of Sirt1 in vascular tissue: its relationship to vascular aging and atherosclerosis, *Aging (Albany NY)* 8(10) (2016) 2290-2307. <https://doi.org/10.18632/aging.101068>.
- [57] X. Liao, J.C. Sluimer, Y. Wang, M. Subramanian, K. Brown, J.S. Pattison, J. Robbins, J. Martinez, I. Tabas, Macrophage autophagy plays a protective role in advanced atherosclerosis, *Cell Metab.* 15 (2012) 545-553. <https://doi.org/10.1016/j.cmet.2012.01.022>.

- [58] E. Thorp, T. Vaisar, M. Subramanian, L. Mautner, C. Blobel, I. Tabas, Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase C δ , and p38 mitogen-activated protein kinase (MAPK), *J. Biol. Chem.* 286(38) (2011) 33335-33344. <https://doi.org/10.1074/jbc.M111.263020>.
- [59] U. Garbin, E. Baggio, C. Stranieri, A. Pasini, S. Manfro, C. Mozzini, P. Vallerio, G. Lipari, F. Merigo, G. Guidi, L. Cominacini, A. Fratta Pasini, Expansion of necrotic core and shedding of MerTK receptor in human carotid plaques: a role for oxidized polyunsaturated fatty acids? *Cardiovasc. Res.* 97(1) (2013) 125-133. <https://doi.org/10.1093/cvr/cvs301>.
- [60] H. Tao, P.G. Yancey, V.R. Babaev, J.L. Blakemore, Y. Zhang, L. Ding, S. Fazio, M.F. Linton, Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis, *J. Lipid Res.* 56(8) (2015) 1449-1460. <https://doi.org/10.1194/jlr.M056689>.
- [61] N. A-Gonzalez, S.J. Bensinger, C. Hong, S. Beceiro, M.N. Bradley, N. Zelcer, J. Deniz, C. Ramirez, M. Díaz, G. Gallardo, C.R. de Galarreta, J. Salazar, F. Lopez, P. Edwards, J. Parks, M. Andujar, P. Tontonoz, A. Castrillo, Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR, *Immunity* 31(2) (2009) 245-258. doi: <https://doi.org/10.1016/j.immuni.2009.06.018>.
- [62] C. Kasikara, A.C. Doran, B. Cai, I. Tabas, The role of non-resolving inflammation in atherosclerosis, *J. Clin. Invest.* 128(7) (2018) 2713-2723. <https://doi.org/10.1172/JCI97950>.
- [63] J. Dalli, C. Serhan, 2016. Macrophage Proresolving Mediators-the When and Where. *Microbiol. Spectr.* 4(3), 10.1128/microbiolspec.MCHD-0001-2014. <https://doi.org/10.1128/microbiolspec.MCHD-0001-2014>.
- [64] E. Fung, S.M. Tang, J.P. Canner, K. Morishige, J.F. Arboleda-Velasquez, A.A. Cardoso, N. Carlesso, J.C. Aster, M. Aikawa, Delta-like 4 induces notch signaling in macrophages: implications for inflammation, *Circulation* 115(23) (2007) 2948-2956. <https://doi.org/10.1161/CIRCULATIONAHA.106.675462>.
- [65] D.K. Singla, J. Wang, R. Singla, Primary human monocytes differentiate into M2 macrophages and involve Notch-1 pathway, *Can. J. Physiol. Pharmacol.* 95(3) (2017) 288-294. <https://doi.org/10.1139/cjpp-2016-0319>.
- [66] C. Yang, X. Xiao, L. Huang, F. Zhou, L.H. Chen, Y.Y. Zhao, S.L. Qu, C. Zhang, Role of Kruppel-like factor 4 in atherosclerosis, *Clin. Chim. Acta* 512 (2021) 135-141. <https://doi.org/10.1016/j.cca.2020.11.002>.
- [67] L.J. van Tits, R. Stienstra, P.L. van Lent, M.G. Netea, L.A. Joosten, A.F. Stalenhoef, Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role

for Krüppel-like factor 2, *Atherosclerosis* 214(2) (2011) 345-349. <https://doi.org/10.1016/j.atherosclerosis.2010.11.018>.

[68] E.J. Folco, Y. Sheikine, V.Z. Rocha, T. Christen, E. Shvartz, G.K. Sukhova, M.F. Di Carli, P. Libby, Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography, *J. Am. Coll. Cardiol.* 58(6) (2011) 603-614. <https://doi.org/10.1016/j.jacc.2011.03.044>.

[69] M. Terasaki, M. Hiromura, Y. Mori, K. Kohashi, M. Nagashima, H. Kushima, T. Watanabe, T. Hirano, 2015. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice. *PLoS One* 10(11), e0143396. <https://doi.org/10.1371/journal.pone.0143396>.

[70] A. Tawakol, P. Singh, M. Mojena, M. Pimentel-Santillana, H. Emami, M. MacNabb, J.H. Rudd, J. Narula, J.A. Enriquez, P.G. Través, M. Fernández-Velasco, R. Bartrons, P. Martín-Sanz, Z.A. Fayad, A. Tejedor, L. Boscá, HIF-1 α and PFKFB3 Mediate a Tight Relationship Between Proinflammatory Activation and Anerobic Metabolism in Atherosclerotic Macrophages, *Arterioscler. Thromb. Vasc. Biol.* 35(6) (2015) 1463-1471. <https://doi.org/10.1161/ATVBAHA.115.305551>.

[71] Y. Chen, M. Yang, W. Huang, W. Chen, Y. Zhao, M.L. Schulte, P. Volberding, Z. Gerbec, M.T. Zimmermann, A. Zeighami, W. Demos, J. Zhang, D.A. Knaack, B.C. Smith, W. Cui, S. Malarkannan, K. Sodhi, J.I. Shapiro, Z. Xie, D. Sahoo, R.L. Silverstein, Mitochondrial Metabolic Reprogramming by CD36 Signaling Drives Macrophage Inflammatory Responses, *Circ. Res.* 125(12) (2019) 1087-1102. <https://doi.org/10.1161/CIRCRESAHA.119.315833>.

[72] A.B. Santhakumar, M. Battino, J.M. Alvarez-Suarez, Dietary polyphenols: Structures, bioavailability and protective effects against atherosclerosis, *Food Chem. Toxicol.* 113 (2018) 49-65. <https://doi.org/10.1016/j.fct.2018.01.022>.

[73] A.P. Miller, J. Coronel, J. Amengual, 2020. The role of β -carotene and vitamin A in atherogenesis: Evidences from preclinical and clinical studies. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids.* 1865(11), 158635. <https://doi.org/10.1016/j.bbalip.2020.158635>.

[74] I. Balta, L. Stef, I. Pet, T. Iancu, D. Stef, N. Corcionivoschi, Essential Fatty Acids as Biomedicines in Cardiac Health, *Biomedicines.* 9(10) (2021) 1466. <https://doi.org/10.3390/biomedicines9101466>. PMID: 34680583; PMCID: PMC8533423.

[75] Y. Bai, X. Wang, S. Zhao, C. Ma, J. Cui, Y. Zheng, 2015. Sulforaphane protects against cardiovascular disease via Nrf2 activation. *Oxid. Med. Cell. Longev.* 2015, 407580.

[76] Y. Chen, Y. She, R. Kaur, N. Guo, X. Zhang, R. Zhang, X. Gou, Is Plant Sterols a Good Strategy to Lower Cholesterol? *J. Oleo Sci.* 68(9) (2019) 811-816. <https://doi.org/10.5650/jos.ess19116>.

- [77] J.H. Kim, Y.S. Yi, M.Y. Kim, J.Y. Cho, Role of ginsenosides, the main active components of *Panax ginseng*, in inflammatory responses and diseases, *J. Ginseng Res.* 41(4) (2017) 435-443. <https://doi.org/10.1016/j.jgr.2016.08.004>.
- [78] F.C. Wu, J.G. Jiang, Effects of diosgenin and its derivatives on atherosclerosis, *Food Funct.* 10(11) (2019) 7022-7036. <https://doi.org/10.1039/c9fo00749k>.
- [79] A. Fatahian, S.M. Haftcheshmeh, S. Azhdari, H.K. Farshchi, B. Nikfar, A.A. Momtazi-Borojeni, Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical Studies. *Rev. Physiol. Biochem. Pharmacol.* 178 (2020) 83-110. https://doi.org/10.1007/112_2020_42.
- [80] A. Viljoen, N. Mncwangi, I. Vermaak, Anti-inflammatory iridoids of botanical origin, *Curr. Med. Chem.* 19(14) (2012) 2104-2127. <https://doi.org/10.2174/092986712800229005>.
- [81] S. Gao, Z. Liu, H. Li, P.J. Little, P. Liu, S. Xu, Cardiovascular actions and therapeutic potential of tanshinone IIA, *Atherosclerosis* 220(1) (2012) 3-10. <https://doi.org/10.1016/j.atherosclerosis.2011.06.041>.
- [82] E. Sokoła-Wysoczańska, T. Wysoczański, J. Wagner, K. Czyż, R. Bodkowski, S. Lochyński, B. Patkowska-Sokoła, 2018. Polyunsaturated Fatty Acids and Their Potential Therapeutic Role in Cardiovascular System Disorders-A Review. *Nutrients.* 10(10), 1561. <https://doi.org/10.3390/nu10101561>.
- [83] Y. Kishimoto, H. Yoshida, K. Kondo, 2016. Potential Anti-Atherosclerotic Properties of Astaxanthin. *Mar. Drugs.* 14(2), 35. <https://doi.org/10.3390/md14020035>.
- [84] D.R. Fraser, Vitamin D toxicity related to its physiological and unphysiological supply, *Trends Endocrinol. Metab.* 32(11) (2021) 929-940. <https://doi.org/10.1016/j.tem.2021.08.006>.
- [85] A.M. Surdu, O. Pînzariu, D.M. Ciobanu, A.G. Negru, S.S. Căinap, C. Lazea, D. Iacob, G. Săraci, D. Tirinescu, I.M. Borda, G. Cismaru, 2021. Vitamin D and Its Role in the Lipid Metabolism and the Development of Atherosclerosis. *Biomedicines* 9(2), 172. <https://doi.org/10.3390/biomedicines9020172>.
- [86] Z. Xie, S.P. Baba, B.R. Sweeney, O.A. Barski, Detoxification of aldehydes by histidine-containing dipeptides: from chemistry to clinical implications, *Chem. Biol. Interact.* 202(1-3) (2013) 288-297. <https://doi.org/10.1016/j.cbi.2012.12.017>.
- [87] O.A. Barski, Z. Xie, S.P. Baba, S.D. Sithu, A. Agarwal, J. Cai, A. Bhatnagar, S. Srivastava, Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice, *Arterioscler. Thromb. Vasc. Biol.* 33(6) (2013) 1162-1170. <https://doi.org/10.1161/ATVBAHA.112.300572>.

- [88] I. Rashid, D.M. van Reyk, M.J. Davies, Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro, *FEBS Lett.* 581(5) (2007) 1067-1070. <https://doi.org/10.1016/j.febslet.2007.01.082>.
- [89] S. Bhaskar, V. Shalini, A. Helen, Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF- κ B signaling pathway, *Immunobiology* 216(3) (2011) 367-373. <https://doi.org/10.1016/j.imbio.2010.07.011>.
- [90] X. Zhang, G. Wang, E.C. Gurley, H. Zhou, 2014. Flavonoid apigenin inhibits lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophages. *PLoS One* 9(9), e107072. <https://doi.org/10.1371/journal.pone.0107072>.
- [91] X. Zhang, J. Cao, L. Jiang, L. Zhong, Suppressive effects of hydroxytyrosol on oxidative stress and nuclear Factor-kappaB activation in THP-1 cells, *Biol. Pharm. Bull.* 32(4) (2009) 578-82. <https://doi.org/10.1248/bpb.32.578>.
- [92] E. Scoditti, A. Nestola, M. Massaro, N. Calabriso, C. Storelli, R. De Caterina, M.A. Carluccio, Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKC α and PKC β 1 inhibition, *Atherosclerosis* 232(1) (2014) 17-24. <https://doi.org/10.1016/j.atherosclerosis.2013.10.017>.
- [93] M.C. Maiuri, D. De Stefano, P. Di Meglio, C. Irace, M. Savarese, R. Sacchi, M.P. Cinelli, R. Carnuccio, Hydroxytyrosol, a phenolic compound from virgin olive oil, prevents macrophage activation, *Naunyn Schmiedebergs Arch. Pharmacol.* 371(6) (2005) 457-465. <https://doi.org/10.1007/s00210-005-1078-y>.
- [94] S. Gargiulo, D. Rossin, G. Testa, P. Gamba, E. Staurenghi, F. Biasi, G. Poli, G. Leonarduzzi, Up-regulation of COX-2 and mPGES-1 by 27-hydroxycholesterol and 4-hydroxynonenal: A crucial role in atherosclerotic plaque instability, *Free Radic. Biol. Med.* 129 (2018) 354-363. doi: <https://doi.org/10.1016/j.freeradbiomed.2018.09.046>.
- [95] Y. Liu, X. Wang, J. Pang, H. Zhang, J. Luo, X. Qian, Q. Chen, W. Ling, Attenuation of Atherosclerosis by Protocatechuic Acid via Inhibition of M1 and Promotion of M2 Macrophage Polarization, *J. Agric. Food Chem.* 67(3) (2019) 807-818. <https://doi.org/10.1021/acs.jafc.8b05719>.
- [96] S. Singh, B.B. Aggarwal, Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected], *J. Biol. Chem.* (1995) 270(42) 24995-5000. <https://doi.org/10.1074/jbc.270.42.24995>.
- [97] Y. Zhou, T. Zhang, X. Wang, X. Wei, Y. Chen, L. Guo, J. Zhang, C. Wang, Curcumin Modulates Macrophage Polarization Through the Inhibition of the Toll-Like Receptor 4 Expression and its Signaling Pathways, *Cell. Physiol. Biochem.* 36(2) (2015) 631-641. <https://doi.org/10.1159/000430126>.

- [98] F. Chen, N. Guo, G. Cao, J. Zhou, Z. Yuan, Molecular analysis of curcumin-induced polarization of murine RAW264.7 macrophages, *J. Cardiovasc. Pharmacol.* (2014) 63(6) 544-52. <https://doi.org/10.1097/FJC.000000000000079>.
- [99] A. Jacob, R. Wu, M. Zhou, P. Wang, 2007. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation. *PPAR Res.* 2007, 89369. <https://doi.org/10.1155/2007/89369>.
- [100] V.R. Narala, M.R. Smith, R.K. Adapala, R. Ranga, K. Panati, B.B. Moore, T. Leff, V.D. Reddy, A.K. Kondapi, R.C. Reddy, Curcumin is not a ligand for peroxisome proliferator-activated receptor- γ , *Gene Ther. Mol. Biol.* 13(1) (2009) 20-25.
- [101] M.R. Guimarães, F.R. Leite, L.C. Spolidorio, K.L. Kirkwood, C. Rossa Jr, Curcumin abrogates LPS-induced pro-inflammatory cytokines in RAW 264.7 macrophages. Evidence for novel mechanisms involving SOCS-1, -3 and p38 MAPK, *Arch. Oral Biol.* 58(10) (2013) 1309-1317. <https://doi.org/10.1016/j.archoralbio.2013.07.005>.
- [102] J. Hong, M. Bose, J. Ju, J.H. Ryu, X. Chen, S. Sang, M.J. Lee, C.S. Yang, Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase, *Carcinogenesis* 25(9) (2004) 1671-1679. <https://doi.org/10.1093/carcin/bgh165>.
- [103] B. Buttari, E. Profumo, L. Segoni, D. D'Arcangelo, S. Rossi, F. Facchiano, L. Saso, R. Businaro, L. Iuliano, R. Riganò, 2014. Resveratrol counteracts inflammation in human M1 and M2 macrophages upon challenge with 7-oxo-cholesterol: potential therapeutic implications in atherosclerosis. *Oxid. Med. Cell. Longev.* 2014, 257543. <https://doi.org/10.1155/2014/257543>.
- [104] C. Ma, Y. Wang, A. Shen, W. Cai, Resveratrol upregulates SOCS1 production by lipopolysaccharide-stimulated RAW264.7 macrophages by inhibiting miR-155, *Int. J. Mol. Med.* 39(1) (2017) 231-237. <https://doi.org/10.3892/ijmm.2016.2802>.
- [105] Y. Zong, L. Sun, B. Liu, Y.S. Deng, D. Zhan, Y.L. Chen, Y. He, J. Liu, Z.J. Zhang, J. Sun, D. Lu, 2012. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. *PLoS One.* 7(8), e44107. <https://doi.org/10.1371/journal.pone.0044107>.
- [106] H.Y. Chang, H.N. Lee, W. Kim, Y.J. Surh, Docosahexaenoic acid induces M2 macrophage polarization through peroxisome proliferator-activated receptor γ activation, *Life Sci.* 120 (2015) 39-47. <https://doi.org/10.1016/j.lfs.2014.10.014>.
- [107] K. Yamagata, C. Tsuruta, A. Ohtuski, M. Tagami, Docosahexaenoic acid decreases TNF- α -induced lectin-like oxidized low-density lipoprotein receptor-1 expression in THP-1 cells, *Prostaglandins Leukot. Essent. Fatty Acids* 90(4) (2014) 125-132. <https://doi.org/10.1016/j.plefa.2013.12.011>.

- [108] A. Takashima, D. Fukuda, K. Tanaka, Y. Higashikuni, Y. Hirata, S. Nishimoto, S. Yagi, H. Yamada, T. Soeki, T. Wakatsuki, Y. Taketani, M. Shimabukuro, M. Sata Combination of n-3 polyunsaturated fatty acids reduces atherogenesis in apolipoprotein E-deficient mice by inhibiting macrophage activation, *Atherosclerosis* 254 (2016) 142-150. <https://doi.org/10.1016/j.atherosclerosis.2016.10.002>.
- [109] X. Li, Y. Yu, C.D. Funk, Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4), *FASEB J.* 27(12) (2013) 4987-4997. <https://doi.org/10.1096/fj.13-235333>.
- [110] C. De Pascale, V. Graham, R.C. Fowkes, C.P.D. Wheeler-Jones, K.M. Botham, Suppression of nuclear factor-kappaB activity in macrophages by chylomicron remnants: modulation by the fatty acid composition of the particles, *FEBS J.* 276(19) (2009) 5689-5702. <https://doi.org/10.1111/j.1742-4658.2009.07260.x>.
- [111] T.L. Si, Q. Liu, Y.F. Ren, H. Li, X.Y. Xu, E.H. Li, S.Y. Pan, J.L. Zhang, K.X. Wang, Enhanced anti-inflammatory effects of DHA and quercetin in lipopolysaccharide-induced RAW264.7 macrophages by inhibiting NF- κ B and MAPK activation, *Mol. Med. Rep.* 14(1) (2016) 499-508. <https://doi.org/10.3892/mmr.2016.5259>.
- [112] N. Martinez-Micaelo, N. González-Abuín, X. Terra, C. Richart, A. Ardèvol, M. Pinent, M. Blay, Omega-3 docosahexaenoic acid and procyanidins inhibit cyclo-oxygenase activity and attenuate NF- κ B activation through a p105/p50 regulatory mechanism in macrophage inflammation, *Biochem. J.* 441(2) (2012) 653-663. <https://doi.org/10.1042/BJ20110967>.
- [113] Y. Yu, P.H. Correll, J.P. Vanden Heuvel, Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPAR gamma-dependent mechanism, *Biochim. Biophys. Acta* 1581(3) (2002) 89-99. [https://doi.org/10.1016/s1388-1981\(02\)00126-9](https://doi.org/10.1016/s1388-1981(02)00126-9).
- [114] E. Stachowska, J. Kijowski, V. Dziedziejko, A. Siennicka, D. Chlubek, Conjugated linoleic acid regulates phosphorylation of PPAR γ by modulation of ERK 1/2 and p38 signaling in human macrophages/fatty acid-laden macrophages, *J. Agric. Food Chem.* 59(21) (2011) 11846-11852. <https://doi.org/10.1021/jf2014233>.
- [115] Y. Lee, J.T. Thompson, A.R. de Lera, J.P. Vanden Heuvel, Isomer-specific effects of conjugated linoleic acid on gene expression in RAW 264.7, *J. Nutr. Biochem.* 20(11) (2009) 848-859, 859.e1-5. <https://doi.org/10.1016/j.jnutbio.2008.07.013>.
- [116] C. McCarthy, M.M. Duffy, D. Mooney, W.G. James, M.D. Griffin, D.J. Fitzgerald, O. Belton, IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis, *FASEB J.* 27(2) (2013) 499-510. <https://doi.org/10.1096/fj.12-215442>.

- [117] H.N. Lee, Y.J. Surh, Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis, *Biochem. Pharmacol.* 86(6) (2013) 759-769. <https://doi.org/10.1016/j.bcp.2013.07.002>.
- [118] A. Ryan, C. Godson, Lipoxins: regulators of resolution, *Curr. Opin. Pharmacol.* 10(2) (2010) 166-172. <https://doi.org/10.1016/j.coph.2010.02.005>.
- [119] B.E. Sansbury, M. Spite, Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology. *Circ. Res.* 119(1) (2016) 113-30. <https://doi.org/10.1161/CIRCRESAHA.116.307308>.
- [120] J. Mai, W. Liu, Y. Fang, S. Zhang, Q. Qiu, Y. Yang, X. Wang, T. Huang, H. Zhang, Y. Xie, M. Lin, Y. Chen, J. Wang, The atheroprotective role of lipoxin A₄ prevents oxLDL-induced apoptotic signaling in macrophages via JNK pathway, *Atherosclerosis* 278 (2018) 259-268. <https://doi.org/10.1016/j.atherosclerosis.2018.09.025>.
- [121] Z. Huang, S. Meng, L. Wang, Y. Wang, T. Chen, C. Wang, Suppression of oxLDL-induced MMP-9 and EMMPRIN expression by berberine via inhibition of NF- κ B activation in human THP-1 macrophages, *Anat. Rec. (Hoboken)* 295(1) (2012) 78-86. <https://doi.org/10.1002/ar.21489>.
- [122] L. Lu, J. Huang, X. Xue, T. Wang, Z. Huang, J. Li, 2021. Berberine Regulated miR150-5p to Inhibit P2X7 Receptor, EMMPRIN and MMP-9 Expression in oxLDL Induced Macrophages. *Front. Pharmacol.* 12, 639558. <https://doi.org/10.3389/fphar.2021.639558>.
- [123] J. Li, H.T. Lei, L. Cao, Y.N. Mi, S. Li, Y.X. Cao, Crocin alleviates coronary atherosclerosis via inhibiting lipid synthesis and inducing M2 macrophage polarization, *Int. Immunopharmacol.* 55 (2018) 120-127. <https://doi.org/10.1016/j.intimp.2017.11.037>.
- [124] J. Marcotorchino, B. Romier, E. Gouranton, C. Riollet, B. Gleize, C. Malezet-Desmoulins, J.F. Landrier, Lycopene attenuates LPS-induced TNF- α secretion in macrophages and inflammatory markers in adipocytes exposed to macrophage-conditioned media, *Mol. Nutr. Food Res.* 56(5) (2012) 725-732. <https://doi.org/10.1002/mnfr.201100623>.
- [125] L. Speranza, M. Pesce, A. Patruno, S. Franceschelli, M.A. de Lutiis, A. Grilli, M. Felaco, Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target, *Mar. Drugs* 10(4) (2012) 890-899. <https://doi.org/10.3390/md10040890>.
- [126] E. Bas, M.C. Recio, S. Máñez, R.M. Giner, J.M. Escandell, C. López-Ginés, J.L. Ríos, New insight into the inhibition of the inflammatory response to experimental delayed-type hypersensitivity reactions in mice by scropolioside A, *Eur. J. Pharmacol.* 555(2-3) (2007) 199-210. <https://doi.org/10.1016/j.ejphar.2006.10.012>.

- [127] Y. Zhang, D.Y. Leung, B.N. Richers, Y. Liu, L.K. Remigio, D.W. Riches, E. Goleva, Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1, *J. Immunol.* 188(5) (2012) 2127-2135. <https://doi.org/10.4049/jimmunol.1102412>.
- [128] F. Carbone, N. Satta, F. Burger, A. Roth, S. Lenglet, S. Pagano, P. Lescuyer, M. Bertolotto, G. Spinella, B. Pane, D. Palombo, A. Pende, F. Dallegri, F. Mach, N. Vuilleumier, F. Montecucco, Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages, *Vascul. Pharmacol.* 85 (2016) 57-65. <https://doi.org/10.1016/j.vph.2016.08.004>.
- [129] S. Kumar, R. Nanduri, E. Bhagyaraj, R. Kalra, N. Ahuja, A.P. Chacko, D. Tiwari, K. Sethi, A. Saini, V. Chandra, M. Jain, S. Gupta, D. Bhatt, P. Gupta, Vitamin D3-VDR-PTPN6 axis mediated autophagy contributes to the inhibition of macrophage foam cell formation, *Autophagy* 17(9) (2021) 2273-2289. <https://doi.org/10.1080/15548627.2020.1822088>.
- [130] D.Y. Lee, H. Li, H.J. Lim, H.J. Lee, R. Jeon, J.H. Ryu, Anti-inflammatory activity of sulfur-containing compounds from garlic, *J. Med. Food.* 15(11) (2012) 992-999. <https://doi.org/10.1089/jmf.2012.2275>.
- [131] M. Guo, J. Xiao, X. Sheng, X. Zhang, Y. Tie, L. Wang, L. Zhao, X. Ji, 2018. Ginsenoside Rg3 Mitigates Atherosclerosis Progression in Diabetic apoE^{-/-} Mice by Skewing Macrophages to the M2 Phenotype. *Front. Pharmacol.* 9, 464. <https://doi.org/10.3389/fphar.2018.00464>.
- [132] X. Zhang, M.H. Liu, L. Qiao, X.Y. Zhang, X.L. Liu, M. Dong, H.Y. Dai, M. Ni, X.R. Luan, J. Guan, H.X. Lu, Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages to the M2 phenotype, *J. Cell. Mol. Med.* 22(1) (2018) 409-416. <https://doi.org/10.1111/jcmm.13329>.
- [133] A. Binesh, S.N. Devaraj, H. Devaraj, Inhibition of nuclear translocation of notch intracellular domain (NICD) by diosgenin prevented atherosclerotic disease progression, *Biochimie* 148 (2018) 63-71. <https://doi.org/10.1016/j.biochi.2018.02.011>.
- [134] D.H. Jung, H.J. Park, H.E. Byun, Y.M. Park, T.W. Kim, B.O. Kim, S.H. Um, S. Pyo, Diosgenin inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, NF-kappaB and AP-1 activation, *Int. Immunopharmacol.* 10(9) (2010) 1047-1054. <https://doi.org/10.1016/j.intimp.2010.06.004>.
- [135] B.C. Zhang, C.W. Zhang, C. Wang, D.F. Pan, T.D. Xu, D.Y. Li, Luteolin Attenuates Foam Cell Formation and Apoptosis in Ox-LDL-Stimulated Macrophages by Enhancing Autophagy, *Cell. Physiol. Biochem.* 39(5) (2016) 2065-2076. <https://doi.org/10.1159/000447902>.
- [136] J. Wei, L. Huang, D. Li, J. He, Y. Li, F. He, W. Fang, G. Wei, 2021. Total Flavonoids of *Engelhardia roxburghiana* Wall. Leaves Alleviated Foam Cells Formation through AKT/mTOR-Mediated Autophagy in the Progression of Atherosclerosis. *Chem. Biodivers.* 18(9), e2100308. <https://doi.org/10.1002/cbdv.202100308>.

- [137] S. Jamuna, R. Ashokkumar, M.S. Sakeena Sadullah, S.N. Devaraj, Oligomeric proanthocyanidins and epigallocatechin gallate aggravate autophagy of foam cells through the activation of Class III PI3K/Beclin1-complex mediated cholesterol efflux, *Biofactors* 45(5) (2019) 763-773. <https://doi.org/10.1002/biof.1537>.
- [138] B. Liu, B. Zhang, R. Guo, S. Li, Y. Xu, Enhancement in efferocytosis of oxidized low-density lipoprotein-induced apoptotic RAW264.7 cells through Sirt1-mediated autophagy, *Int. J. Mol. Med.* (2014) 33(3) 523-533. <https://doi.org/10.3892/ijmm.2013.1609>.
- [139] W.J. Duan, Y.F. Li, F.L. Liu, J. Deng, Y.P. Wu, W.L. Yuan, B. Tsoi, J.L. Chen, Q. Wang, S.H. Cai, H. Kurihara, R.R. He, A SIRT3/AMPK/autophagy network orchestrates the protective effects of trans-resveratrol in stressed peritoneal macrophages and RAW 264.7 macrophages, *Free Radic. Biol. Med.* 95 (2016) 230-242. <https://doi.org/10.1016/j.freeradbiomed.2016.03.022>.
- [140] H. Cao, Q. Jia, L. Yan, C. Chen, S. Xing, D. Shen, 2019. Quercetin Suppresses the Progression of Atherosclerosis by Regulating MST1-Mediated Autophagy in ox-LDL-Induced RAW264.7 Macrophage Foam Cells. *Int. J. Mol. Sci.* 20(23), 6093. <https://doi.org/10.3390/ijms20236093>.
- [141] F. Kong, B. Ye, J. Cao, X. Cai, L. Lin, S. Huang, W. Huang, Z. Huang, 2016. Curcumin Represses NLRP3 Inflammasome Activation via TLR4/MyD88/NF- κ B and P2X7R Signaling in PMA-Induced Macrophages. *Front. Pharmacol.* 7, 369. <https://doi.org/10.3389/fphar.2016.00369>.
- [142] P. Chalons, S. Amor, F. Courtaut, E. Cantos-Villar, T. Richard, C. Auger, P. Chabert, V. Schni-Kerth, V. Aires, D. Delmas, 2018. Study of Potential Anti-Inflammatory Effects of Red Wine Extract and Resveratrol through a Modulation of Interleukin-1-Beta in Macrophages. *Nutrients.* 10(12), 1856. <https://doi.org/10.3390/nu10121856>.
- [143] B.C. Zhang, Z. Li, W. Xu, C.H. Xiang, Y.F. Ma, Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells, *Am. J. Transl. Res.* 10(1) (2018) 265-273.
- [144] J.Y. Kou, Y. Li, Z.Y. Zhong, Y.Q. Jiang, X.S. Li, X.B. Han, Z.N. Liu, Y. Tian, L.M. Yang, 2018. Berberine-sonodynamic therapy induces autophagy and lipid unloading in macrophage. *Cell Death Dis.* 8(1), e2558. <https://doi.org/10.1038/cddis.2016.354>.
- [145] X. Fan, J. Wang, J. Hou, C. Lin, A. Bensoussan, D. Chang, J. Liu, B. Wang, 2015. Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway. *J. Transl. Med.* 13, 92. <https://doi.org/10.1186/s12967-015-0450-z>.
- [146] Y. Luo, S. Lu, Y. Gao, K. Yang, D. Wu, X. Xu, G. Sun, X. Sun, Araloside C attenuates atherosclerosis by modulating macrophage polarization via Sirt1-mediated autophagy, *Aging (Albany NY)* 12(2) (2020) 1704-1724. <https://doi.org/10.18632/aging.102708>.

- [147] L. Qiao, X. Zhang, M. Liu, X. Liu, M. Dong, J. Cheng, X. Zhang, C. Zhai, Y. Song, H. Lu, W. Chen, 2017. Ginsenoside Rb1 Enhances Atherosclerotic Plaque Stability by Improving Autophagy and Lipid Metabolism in Macrophage Foam Cells. *Front. Pharmacol.* 8, 727. <https://doi.org/10.3389/fphar.2017.00727>.
- [148] J. Kim, H. Ahn, B.C. Han, S.H. Lee, Y.W. Cho, C.H. Kim, E.J. Hong, B.S. An, E.B. Jeung, G.S. Lee, Korean red ginseng extracts inhibit NLRP3 and AIM2 inflammasome activation, *Immunol. Lett.* 158(1-2) (2014) 143-150. <https://doi.org/10.1016/j.imlet.2013.12.017>.
- [149] S. Leng, S. Iwanowycz, F. Saaoud, J. Wang, Y. Wang, I. Sergin, B. Razani, D. Fan, Ursolic acid enhances macrophage autophagy and attenuates atherogenesis, *J. Lipid Res.* 57(6) (2016) 1006-1016. <https://doi.org/10.1194/jlr.M065888>.
- [150] W. Chen, X. Li, S. Guo, N. Song, J. Wang, L. Jia, A. Zhu, Tanshinone IIA harmonizes the crosstalk of autophagy and polarization in macrophages via miR-375/KLF4 pathway to attenuate atherosclerosis, *Int. Immunopharmacol.* 70 (2019) 486-497. <https://doi.org/10.1016/j.intimp.2019.02.054>.
- [151] T. Zhu, L. Zhang, S. Ling, J. Duan, F. Qian, Y. Li, J.W. Xu, 2014. Scropolioside B inhibits IL-1 β and cytokines expression through NF- κ B and inflammasome NLRP3 pathways. *Mediators Inflamm.* 2014, 819053. <https://doi.org/10.1155/2014/819053>.
- [152] L. Shen, Y. Yang, T. Ou, C.C. Key, S.H. Tong, R.C. Sequeira, J.M. Nelson, Y. Nie, Z. Wang, E. Boudyguina, S.V. Shewale, X. Zhu, Dietary PUFAs attenuate NLRP3 inflammasome activation via enhancing macrophage autophagy, *J. Lipid Res.* 58(9) (2017) 1808-1821. <https://doi.org/10.1194/jlr.M075879>.
- [153] Y. Yan, W. Jiang, T. Spinetti, A. Tardivel, R. Castillo, C. Bourquin, G. Guarda, Z. Tian, J. Tschopp, R. Zhou, Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation, *Immunity* 38(6) (2013) 1154-1163. <https://doi.org/10.1016/j.immuni.2013.05.015>.
- [154] E. Bigagli, L. Cinci, S. Paccosi, A. Parenti, M. D'Ambrosio, C. Luceri, Nutritionally relevant concentrations of resveratrol and hydroxytyrosol mitigate oxidative burst of human granulocytes and monocytes and the production of pro-inflammatory mediators in LPS-stimulated RAW 264.7 macrophages, *Int. Immunopharmacol.* 43 (2017) 147-155. <https://doi.org/10.1016/j.intimp.2016.12.012>.
- [155] G. Pepe, E. Sommella, D. Cianciarulo, C. Ostacolo, M. Manfra, V. Di Sarno, S. Musella, M. Russo, A. Messori, B. Parrino, A. Bertamino, G. Autore, S. Marzocco, P. Campiglia, 2018. Polyphenolic Extract from Tarocco (*Citrus sinensis* L. Osbeck) Clone "Lempso" Exerts Anti-

- Inflammatory and Antioxidant Effects via NF- κ B and Nrf-2 Activation in Murine Macrophages. *Nutrients*. 10(12), 1961. <https://doi.org/10.3390/nu10121961>.
- [156] R. Vari, M. D'Archivio, C. Filesi, S. Carotenuto, B. Scazzocchio, C. Santangelo, C. Giovannini, R. Masella, Protocatechuic acid induces antioxidant/detoxifying enzyme expression through JNK-mediated Nrf2 activation in murine macrophages, *J. Nutr. Biochem.* 22(5) (2011) 409-417. <https://doi.org/10.1016/j.jnutbio.2010.03.008>.
- [157] S.G. Lee, C.R. Brownmiller, S.O. Lee, H.W. Kang, 2020. Anti-Inflammatory and Antioxidant Effects of Anthocyanins of *Trifolium pratense* (Red Clover) in Lipopolysaccharide-Stimulated RAW-267.4 Macrophages. *Nutrients*. 12(4), 1089. <https://doi.org/10.3390/nu12041089>.
- [158] S.J. Chapple, R.C. Siow, G.E. Mann, Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging, *Int. J. Biochem. Cell Biol.* 44(8) (2012) 1315-1320. <https://doi.org/10.1016/j.biocel.2012.04.021>.
- [159] M.K. Kwak, N. Wakabayashi, J.L. Greenlaw, M. Yamamoto, T.W. Kensler, Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway, *Mol. Cell. Biol.* 23(23) (2003) 8786-8794. <https://doi.org/10.1128/MCB.23.23.8786-8794.2003>.
- [160] A.J. Greaney, N.K. Maier, S.H. Leppla, M. Moayeri, Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism, *J. Leukoc. Biol.* 99(1) (2016) 189-199. <https://doi.org/10.1189/jlb.3A0415-155RR>.
- [161] M. Ali, M. Bonay, V. Vanhee, S. Vinit, T.B. Deramautd, 2020. Comparative effectiveness of 4 natural and chemical activators of Nrf2 on inflammation, oxidative stress, macrophage polarization, and bactericidal activity in an in vitro macrophage infection model. *PLoS One*. 15(6), e0234484. <https://doi.org/10.1371/journal.pone.0234484>.
- [162] R.T. Ruhee, S. Ma, K. Suzuki, 2019. Sulforaphane Protects Cells against Lipopolysaccharide-Stimulated Inflammation in Murine Macrophages. *Antioxidants (Basel)*. 8(12), 577. <https://doi.org/10.3390/antiox8120577>.
- [163] A.E. Wagner, C. Boesch-Saadatmandi, J. Dose, G. Schultheiss, G. Rimbach, Anti-inflammatory potential of allyl-isothiocyanate--role of Nrf2, NF-(κ) B and microRNA-155, *J. Cell. Mol. Med.* 16(4) (2012) 836-843. <https://doi.org/10.1111/j.1582-4934.2011.01367.x>.
- [164] S.B. Vasamsetti, S. Karnewar, R. Gopaju, P.N. Gollavilli, S.R. Narra, J.M. Kumar, S. Kotamraju, Resveratrol attenuates monocyte-to-macrophage differentiation and associated inflammation via modulation of intracellular GSH homeostasis: Relevance in atherosclerosis, *Free Radic Biol. Med.* 96 (2016) 392-405. <https://doi.org/10.1016/j.freeradbiomed.2016.05.003>.

- [165] X. Liu, J. Li, X. Peng, B. Lv, P. Wang, X. Zhao, B. Yu, Geraniin Inhibits LPS-Induced THP-1 Macrophages Switching to M1 Phenotype via SOCS1/NF- κ B Pathway, *Inflammation* 39(4) (2016) 1421-1433. <https://doi.org/10.1007/s10753-016-0374-7>.
- [166] S. Qi, Z. Feng, Q. Li, Z. Qi, Y. Zhang, 2017. Myricitrin Modulates NADPH Oxidase-Dependent ROS Production to Inhibit Endotoxin-Mediated Inflammation by Blocking the JAK/STAT1 and NOX2/p47phox Pathways. *Oxid. Med. Cell. Longev.* 2017, 9738745. <https://doi.org/10.1155/2017/9738745>.
- [167] M. Shiner, B. Fuhrman, M. Aviram, Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPAR gamma and AP-1 pathway activation, *Atherosclerosis* 195(2) (2007) 313-321. <https://doi.org/10.1016/j.atherosclerosis.2007.01.007>.
- [168] Y. Manabe, Y. Takii, T. Sugawara, Siphonaxanthin, a carotenoid from green algae, suppresses advanced glycation end product-induced inflammatory responses, *J. Nat. Med.* 74(1) (2020) 127-134. <https://doi.org/10.1007/s11418-019-01354-z>.
- [169] Y. Zhang, C. Wang, Y. Jin, Q. Yang, Q. Meng, Q. Liu, Y. Dai, L. Cai, Z. Liu, K. Liu, H. Sun, 2018. Activating the PGC-1 α /TERT Pathway by Catalpol Ameliorates Atherosclerosis via Modulating ROS Production, DNA Damage, and Telomere Function: Implications on Mitochondria and Telomere Link. *Oxid. Med. Cell. Longev.* 2018, 2876350. <https://doi.org/10.1155/2018/2876350>.
- [170] Q. Chen, X. Qi, W. Zhang, Y. Zhang, Y. Bi, Q. Meng, H. Bian, Y. Li, 2021. Catalpol Inhibits Macrophage Polarization and Prevents Postmenopausal Atherosclerosis Through Regulating Estrogen Receptor Alpha. *Front. Pharmacol.* 12, 655081. <https://doi.org/10.3389/fphar.2021.655081>.
- [171] L.K. Sarna, N. Wu, S.Y. Hwang, Y.L. Siow, K. O, Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages, *Can. J. Physiol. Pharmacol.* 88(3) (2010) 369-378. <https://doi.org/10.1139/Y09-136>.
- [172] M. Vivancos, J.J. Moreno, beta-Sitosterol modulates antioxidant enzyme response in RAW 264.7 macrophages, *Free Radic. Biol. Med.* (2005) 39(1) 91-97. <https://doi.org/10.1016/j.freeradbiomed.2005.02.025>.
- [173] J. Jiang, Z.C. Mo, K. Yin, G.J. Zhao, Y.C. Lv, X.P. Ouyang, Z.S. Jiang, Y. Fu, C.K. Tang, Epigallocatechin-3-gallate prevents TNF- α -induced NF- κ B activation thereby upregulating ABCA1 via the Nrf2/Keap1 pathway in macrophage foam cells, *Int. J. Mol. Med.* 29(5) (2012) 946-956. <https://doi.org/10.3892/ijmm.2012.924>.
- [174] J. Saenz, C. Santa-María, M.E. Reyes-Quiroz, I. Geniz, J. Jiménez, F. Sobrino, G. Alba, Grapefruit Flavonoid Naringenin Regulates the Expression of LXR α in THP-1 Macrophages by

Modulating AMP-Activated Protein Kinase, *Mol. Pharm.* 15(5) (2018) 1735-1745.
<https://doi.org/10.1021/acs.molpharmaceut.7b00797>.

[175] A. Iio, K. Ohguchi, M. Inuma, Y. Nozawa, M. Ito, Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages, *J. Nat. Prod.* (2012) 75(4) 563-566.
<https://doi.org/10.1021/np200696r>.

[176] L. Sun, E. Li, F. Wang, T. Wang, Z. Qin, S. Niu, C. Qiu, 2015. Quercetin increases macrophage cholesterol efflux to inhibit foam cell formation through activating PPARgamma-ABCA1 pathway. *Int. J. Clin. Exp. Pathol.* 8(9), 10854-60.

[177] T.T. Liu, Y. Zeng, K. Tang, X. Chen, W. Zhang, X.L. Xu, Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice, *Atherosclerosis* 262 (2017) 39-50.
<https://doi.org/10.1016/j.atherosclerosis.2017.05.003>.

[178] X.Y. Li, L.X. Kong, J. Li, H.X. He, Y.D. Zhou, Kaempferol suppresses lipid accumulation in macrophages through the downregulation of cluster of differentiation 36 and the upregulation of scavenger receptor class B type I and ATP-binding cassette transporters A1 and G1, *Int. J. Mol. Med.* 31(2) (2013) 331-338. <https://doi.org/10.3892/ijmm.2012.1204>.

[179] G. Ye, G. Chen, H. Gao, Y. Lin, X. Liao, H. Zhang, X. Liu, Y. Chi, Q. Huang, H. Zhu, Y. Fan, S. Dong, Resveratrol inhibits lipid accumulation in the intestine of atherosclerotic mice and macrophages, *J. Cell. Mol. Med.* 23(6) (2019) 4313-4325. <https://doi.org/10.1111/jcmm.14323>.

[180] S. Zhao, J. Li, L. Wang, X. Wu, Pomegranate peel polyphenols inhibit lipid accumulation and enhance cholesterol efflux in raw264.7 macrophages, *Food Funct.* 7(7) (2016) 3201-3210.
<https://doi.org/10.1039/c6fo00347h>.

[181] C. Wu, H. Luan, X. Zhang, S. Wang, X. Zhang, X. Sun, P. Guo, 2014. Chlorogenic acid protects against atherosclerosis in ApoE^{-/-} mice and promotes cholesterol efflux from RAW264.7 macrophages. *PLoS One*, 9(9), e95452. <https://doi.org/10.1371/journal.pone.0095452>.

[182] J.F. Zhao, L.C. Ching, Y.C. Huang, C.Y. Chen, A.N. Chiang, Y.R. Kou, S.K. Shyue, T.S. Lee, Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis, *Mol. Nutr. Food Res.* 56(5) (2012) 691-701.
<https://doi.org/10.1002/mnfr.201100735>.

[183] X.L. Lin, M.H. Liu, H.J. Hu, H.R. Feng, X.J. Fan, W.W. Zou, Y.Q. Pan, X.M. Hu, Z. Wang, Curcumin enhanced cholesterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-LXR α signaling in THP-1 macrophage-derived foam cells, *DNA Cell Biol.* (2015) 34(9) 561-572.
<https://doi.org/10.1089/dna.2015.2866>.

[184] F.Y. Chen, J. Zhou, N. Guo, W.G. Ma, X. Huang, H. Wang, Z.Y. Yuan, Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent

atherosclerosis, *Biochem. Biophys. Res. Commun.* 467(4) (2015) 872-878. <https://doi.org/10.1016/j.bbrc.2015.10.051>.

[185] J.H. Chen, C.W. Tsai, C.P. Wang, H.H. Lin, Anti-atherosclerotic potential of gossypetin via inhibiting LDL oxidation and foam cell formation, *Toxicol. Appl. Pharmacol.* 272(2) (2013) 313-324. <https://doi.org/10.1016/j.taap.2013.06.027>.

[186] W. Dong, X. Wang, S. Bi, Z. Pan, S. Liu, H. Yu, H. Lu, X. Lin, X. Wang, T. Ma, W. Zhang, Inhibitory effects of resveratrol on foam cell formation are mediated through monocyte chemotactic protein-1 and lipid metabolism-related proteins, *Int. J. Mol. Med.* (2014) 33(5) 1161-1168. <https://doi.org/10.3892/ijmm.2014.1680>.

[187] Q. Jia, H. Cao, D. Shen, L. Yan, C. Chen, S. Xing, 2019. Fisetin, via CKIP-1/REGgamma, limits oxidized LDL-induced lipid accumulation and senescence in RAW264.7 macrophage-derived foam cells. *Eur J Pharmacol.* 865, 172748. <https://doi.org/10.1016/j.ejphar.2019.172748>.

[188] J.F. Varghese, R. Patel, M. Singh, U. Chand Singh Yadav, Fisetin prevents oxidized low-density lipoproteins induced macrophage foam cell formation, *J. Cardiovasc. Pharmacol.* 78(5) (2021) e729-e737. <https://doi.org/10.1097/FJC.0000000000001096>.

[189] R.G. Carroll, Z. Zaslona, S. Galván-Peña, E.L. Koppe, D.C. Sévin, S. Angiari, M. Triantafilou, K. Triantafilou, L.K. Modis, L.A. O'Neill, An unexpected link between fatty acid synthase and cholesterol synthesis in proinflammatory macrophage activation, *J. Biol. Chem.* 293(15) (2018) 5509-5521. <https://doi.org/10.1074/jbc.RA118.001921>.

[190] M. Rosenblat, N. Volkova, M. Aviram, Pomegranate phytosterol (beta-sitosterol) and polyphenolic antioxidant (punicalagin) addition to statin, significantly protected against macrophage foam cells formation, *Atherosclerosis* 226(1) (2013) 110-117. <https://doi.org/10.1016/j.atherosclerosis.2012.10.054>.

[191] N.S. Sabeva, C.M. McPhaul, X. Li, T.J. Cory, D.J. Feola, G.A. Graf, Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foamcells, *J. Nutr. Biochem.* 22(8) (2011) 777-783. <https://doi.org/10.1016/j.jnutbio.2010.07.002>.

[192] J.W. Moss, T.S. Davies, I. Garaiova, S.F. Plummer, D.R. Michael, D.P. Ramji, 2016. A Unique Combination of Nutritionally Active Ingredients Can Prevent Several Key Processes Associated with Atherosclerosis In Vitro. *PLoS One.* 11(3), e0151057. <https://doi.org/10.1371/journal.pone.0151057>.

[193] J. Ishiyama, R. Taguchi, Y. Akasaka, S. Shibata, M. Ito, M. Nagasawa, K. Murakami, Unsaturated FAs prevent palmitate-induced LOX-1 induction via inhibition of ER stress in macrophages, *J. Lipid Res.* 52(2) (2011) 299-307. <https://doi.org/10.1194/jlr.M007104>.

- [194] O. Rom, H. Jeries, T. Hayek, M. Aviram, Supplementation with linoleic acid-rich soybean oil stimulates macrophage foam cell formation via increased oxidative stress and diacylglycerol acyltransferase1-mediated triglyceride biosynthesis, *Biofactors* 43(1) (2017) 100-116. <https://doi.org/10.1002/biof.1319>.
- [195] Y. Wang, J.F. Oram, Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1, *J. Biol. Chem.* 277(7) (2002) 5692-5697. <https://doi.org/10.1074/jbc.M109977200>.
- [196] J.E. Kanter, C. Tang, J.F. Oram, K.E. Bornfeldt, Acyl-CoA synthetase 1 is required for oleate and linoleate mediated inhibition of cholesterol efflux through ATP-binding cassette transporter A1 in macrophages, *Biochim. Biophys. Acta* 1821(3) (2012) 358-364. <https://doi.org/10.1016/j.bbaliip.2011.10.008>.
- [197] C.S. Ku, Y. Park, S.L. Coleman, J. Lee, Unsaturated fatty acids repress expression of ATP binding cassette transporter A1 and G1 in RAW 264.7 macrophages, *J. Nutr. Biochem.* (2012) 23(10) 1271-1276. <https://doi.org/10.1016/j.jnutbio.2011.07.007>.
- [198] M. de Gaetano, K. Alghamdi, S. Marcone, O. Belton, 2015. Conjugated linoleic acid induces an atheroprotective macrophage MΦ2 phenotype and limits foam cell formation. *J. Inflamm. (Lond)*. 12, 15. <https://doi.org/10.1186/s12950-015-0060-9>.
- [199] C. McCarthy, N.T. Lieggi, D. Barry, D. Mooney, M. de Gaetano, W.G. James, S. McClelland, M.C. Barry, L. Escoubet-Lozach, A.C. Li, C.K. Glass, D.J. Fitzgerald, O. Belton, Macrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid, *EMBO Mol. Med.* 5(9) (2013) 1443-1457. <https://doi.org/10.1002/emmm.201302587>.
- [200] S. Weldon, S. Mitchell, D. Kelleher, M.J. Gibney, H.M. Roche, Conjugated linoleic acid and atherosclerosis: no effect on molecular markers of cholesterol homeostasis in THP-1 macrophages, *Atherosclerosis* 174(2) (2004) 261-273. <https://doi.org/10.1016/j.atherosclerosis.2004.02.007>.
- [201] J. Ecker, T. Langmann, C. Moehle, G. Schmitz, Isomer specific effects of Conjugated Linoleic Acid on macrophage ABCG1 transcription by a SREBP-1c dependent mechanism, *Biochem. Biophys. Res. Commun.* 352(3) (2007) 805-811. <https://doi.org/10.1016/j.bbrc.2006.11.087>.
- [202] P. Palozza, R. Simone, A. Catalano, N. Parrone, G. Monego, F.O. Ranelletti, Lycopene regulation of cholesterol synthesis and efflux in human macrophages, *J. Nutr. Biochem.* 22(10) (2011) 971-978. <https://doi.org/10.1016/j.jnutbio.2010.08.010>.
- [203] S. Bechor, N. Zolberg Relevy, A. Harari, T. Almog, Y. Kamari, A. Ben-Amotz, D. Harats, A. Shaish, 2016. 9-cis β -Carotene Increased Cholesterol Efflux to HDL in Macrophages. *Nutrients*. 8(7), 435. <https://doi.org/10.3390/nu8070435>.

- [204] J. Liu, Y. Wei, Y. Lin, P. Zhang, Z. Zhang, H. Huang, H. Wu, T. Zou, 2021. Expression of the circular RNAs in astaxanthin promotes cholesterol efflux from THP-1 cells based on RNA-seq. *Genes Nutr.* 16(1), 13. <https://doi.org/10.1186/s12263-021-00693-5>.
- [205] Y.C. Lv, J. Yang, F. Yao, W. Xie, Y.Y. Tang, X.P. Ouyang, P.P. He, Y.L. Tan, L. Li, M. Zhang, D. Liu, F.S. Cayabyab, X.L. Zheng, C.K. Tang, Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATP-binding cassette transporter A1, *Atherosclerosis* 240(1) (2015) 80-89. <https://doi.org/10.1016/j.atherosclerosis.2015.02.044>.
- [206] X.L. Lin, H.J. Hu, Y.B. Liu, X.M. Hu, X.J. Fan, W.W. Zou, Y.Q. Pan, W.Q. Zhou, M.W. Peng, C.H. Gu, Allicin induces the upregulation of ABCA1 expression via PPARgamma/LXRalpha signaling in THP-1 macrophage-derived foam cells, *Int. J. Mol. Med.* 39(6) (2017) 1452-1460. <https://doi.org/10.3892/ijmm.2017.2949>.
- [207] K. Yin, Y. You, V. Swier, L. Tang, M.M. Radwan, A.N. Pandya, D.K. Agrawal, Vitamin D Protects Against Atherosclerosis via Regulation of Cholesterol Efflux and Macrophage Polarization in Hypercholesterolemic Swine, *Arterioscler. Thromb. Vasc. Biol.* (2015) 35(11) 2432-2442. <https://doi.org/10.1161/ATVBAHA.115.306132>.
- [208] Z. Huang, F. Dong, S. Li, M. Chu, H. Zhou, Z. Lu, W. Huang, Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages, *Eur. J. Pharmacol.* 690(1-3) (2012) 164-169. <https://doi.org/10.1016/j.ejphar.2012.07.009>.
- [209] X.J. Yang, F. Liu, N. Feng, X.S. Ding, Y. Chen, S.X. Zhu, L.C. Yang, X.F. Feng, Berberine Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and Activation of the Nrf2/HO-1 Pathway, *J. Cardiovasc. Pharmacol.* 75(1) (2020) 45-53. <https://doi.org/10.1097/FJC.0000000000000769>
- [210] L. Chi, L. Peng, N. Pan, X. Hu, Y. Zhang, The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1, *Int. J. Mol. Med.* 34(4) (2014) 1087-1093. <https://doi.org/10.3892/ijmm.2014.1868>.
- [211] F. Zimetti, M.P. Adorni, N. Ronda, R. Gatti, F. Bernini, E. Favari, The natural compound berberine positively affects macrophage functions involved in atherogenesis, *Nutr. Metab. Cardiovasc. Dis.* 25(2) (2015) 195-201. [10.1016/j.numecd.2014.08.004](https://doi.org/10.1016/j.numecd.2014.08.004).
- [212] J.E. McLaren, D.R. Michael, I.A. Guschina, J.L. Harwood, DP. Ramji, Eicosapentaenoic acid and docosahexaenoic acid regulate modified LDL uptake and macropinocytosis in human macrophages, *Lipids* 46(11) (2011) 1053-1061. <https://doi.org/10.1007/s11745-011-3598-1>.

- [213] Z. Liu, J. Wang, E. Huang, S. Gao, H. Li, J. Lu, K. Tian, P.J. Little, X. Shen, S. Xu, P. Liu, Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1, *J. Lipid Res.* 55(2) (2014) 201-213. <https://doi.org/10.1194/jlr.M040394>.
- [214] L. Dugo, M.G. Belluomo, C. Fanali, M. Russo, F. Cacciola, M. Maccarrone, A.M. Sardanelli, 2017. Effect of Cocoa Polyphenolic Extract on Macrophage Polarization from Proinflammatory M1 to Anti-Inflammatory M2 State. *Oxid. Med. Cell. Longev.* 2017, 6293740. <https://doi.org/10.1155/2017/6293740>.
- [215] G. Caruso, C.G. Fresta, A. Fidilio, F. O'Donnell, N. Musso, G. Lazzarino, M. Grasso, A.M. Amorini, F. Tascetta, C. Bucolo, F. Drago, B. Tavazzi, G. Lazzarino, S.M. Lunte, F. Caraci, 2019. Carnosine Decreases PMA-Induced Oxidative Stress and Inflammation in Murine Macrophages. *Antioxidants (Basel)*. 8(8), 281. <https://doi.org/10.3390/antiox8080281>.
- [216] C.G. Fresta, A. Fidilio, G. Lazzarino, N. Musso, M. Grasso, S. Merlo, A.M. Amorini, C. Bucolo, B. Tavazzi, G. Lazzarino, S.M. Lunte, F. Caraci, G. Caruso, 2020. Modulation of Pro-Oxidant and Pro-Inflammatory Activities of M1 Macrophages by the Natural Dipeptide Carnosine. *Int. J. Mol. Sci.* 21(3), 776. <https://doi.org/10.3390/ijms21030776>.
- [217] R. Bahramsoltani, F. Ebrahimi, M.H. Farzaei, A. Baratpournoghaddam, P. Ahmadi, P. Rostamiasrabadi, A.H. Rasouli Amirabadi, R. Rahimi, Dietary polyphenols for atherosclerosis: A comprehensive review and future perspectives, *Crit. Rev. Food Sci. Nutr.* 59(1) (2019) 114-132. <https://doi.org/10.1080/10408398.2017.1360244>.
- [218] R. Casas, R. Estruch, E. Sacanella, 2018. Influence of Bioactive Nutrients on the Atherosclerotic Process: A Review. *Nutrients*. 10(11), 1630. <https://doi.org/10.3390/nu10111630>.
- [219] M. Urpi-Sarda, R. Casas, E. Sacanella, D. Corella, C. Andrés-Lacueva, R. Llorach, G. Garrabou, F. Cardellach, A. Sala-Vila, E. Ros, M. Ruiz-Canela, M. Fitó, J. Salas-Salvadó, R. Estruch, 2021. The 3-Year Effect of the Mediterranean Diet Intervention on Inflammatory Biomarkers Related to Cardiovascular Disease. *Biomedicines*. 9(8), 862. <https://doi.org/10.3390/biomedicines9080862>.
- [220] A. Medina-Remón, R. Casas, A. Tresserra-Rimbau, E. Ros, M.A. Martínez-González, M. Fitó, D. Corella, J. Salas-Salvadó, R.M. Lamuela-Raventos, R. Estruch; PREDIMED Study Investigators, Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers related to atherosclerosis: a substudy of the PREDIMED trial, *Br. J. Clin. Pharmacol.* 83(1) (2017) 114-128. <https://doi.org/10.1111/bcp.12986>.
- [221] M.A. Martínez-González, J. Salas-Salvadó, R. Estruch, D. Corella, M. Fitó, E. Ros; PREDIMED INVESTIGATORS, Benefits of the Mediterranean Diet: Insights From the PREDIMED Study, *Prog. Cardiovasc. Dis.* 58(1) (2015) 50-60. <https://doi.org/10.1016/j.pcad.2015.04.003>.

- [222] R. Casas, E. Sacanella, M. Urpí-Sardà, G. Chiva-Blanch, E. Ros, M.A. Martínez-González, M.I. Covas, R.M. Lamuela-Raventós, J. Salas-Salvadó, M. Fiol, F. Arós, R. Estruch, 2014. The effects of the mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial. *PLoS One*. 9(6), e100084. doi: <https://doi.org/10.1371/journal.pone.0100084>.
- [223] M. Uрпи-Sarda, R. Casas, G. Chiva-Blanch, E.S. Romero-Mamani, P. Valderas-Martínez, S. Arranz, C. Andres-Lacueva, R. Llorach, A. Medina-Remón, R.M. Lamuela-Raventós, R. Estruch, Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomarkers related to atherosclerosis, *Pharmacol. Res.* 65(6) (2012) 577-583. <https://doi.org/10.1016/j.phrs.2012.03.006>.
- [224] V. Konstantinidou, M.I. Covas, R. Sola, M. Fitó, Up-to date knowledge on the in vivo transcriptomic effect of the Mediterranean diet in humans, *Mol. Nutr. Food Res.* 57(5) (2013) 772-783. <https://doi.org/10.1002/mnfr.201200613>.
- [225] N. Khan, O. Khymenets, M. Urpí-Sardà, S. Tulipani, M. Garcia-Aloy, M. Monagas, X. Mora-Cubillos, R. Llorach, C. Andres-Lacueva, Cocoa polyphenols and inflammatory markers of cardiovascular disease, *Nutrients* 6(2) (2014) 844-880. <https://doi.org/10.3390/nu6020844>.
- [226] M. Monagas, N. Khan, C. Andres-Lacueva, R. Casas, M. Urpí-Sardà, R. Llorach, R.M. Lamuela-Raventós, R. Estruch, Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease, *Am. J. Clin. Nutr.* 90(5) (2009) 1144-1150. <https://doi.org/10.3945/ajcn.2009.27716>.
- [227] N. Khan, H. Mukhtar, Tea and health: studies in humans, *Curr. Pharm. Des.* 19(34) (2013) 6141-6147. <https://doi.org/10.2174/1381612811319340008>.
- [228] M. Massaro, E. Scoditti, M.A. Carluccio, R. De Caterina, 2010. Nutraceuticals and prevention of atherosclerosis: focus on omega-3 polyunsaturated fatty acids and Mediterranean diet polyphenols. *Cardiovasc. Ther.* 28(4), e13-9. <https://doi.org/10.1111/j.1755-5922.2010.00211.x>.
- [229] P. Ditano-Vázquez, J.D. Torres-Peña, F. Galeano-Valle, A.I. Pérez-Caballero, P. Demelo-Rodríguez, J. Lopez-Miranda, N. Katsiki, J. Delgado-Lista, L.A. Alvarez-Sala-Walther, 2019. The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. *Nutrients*. 11(11), 2833. <https://doi.org/10.3390/nu11112833>.
- [230] J. Tomé-Carneiro, M. González, M. Larrosa, M.J. Yáñez-Gascón, F.J. García-Almagro, J.A. Ruiz-Ros, F.A. Tomás-Barberán, M.T. García-Conesa, J.C. Espín, Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-

blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease, *Cardiovasc. Drugs Ther.* 27(1) (2013) 37-48. <https://doi.org/10.1007/s10557-012-6427-8>.

[231] J. Tomé-Carneiro, M. Larrosa, M.J. Yáñez-Gascón, A. Dávalos, J. Gil-Zamorano, M. González, F.J. García-Almagro, J.A. Ruiz Ros, F.A. Tomás-Barberán, J.C. Espín, M.T. García-Conesa, One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease, *Pharmacol. Res.* 72 (2013) 69-82. <https://doi.org/10.1016/j.phrs.2013.03.011>.

[232] A. Camargo, J. Delgado-Lista, A. Garcia-Rios, C. Cruz-Teno, E.M. Yubero-Serrano, P. Perez-Martinez, F.M. Gutierrez-Mariscal, P. Lora-Aguilar, F. Rodriguez-Cantalejo, F. Fuentes-Jimenez, F.J. Tinahones, M.M. Malagon, F. Perez-Jimenez, J. Lopez-Miranda, Expression of proinflammatory, proatherogenic genes is reduced by the Mediterranean diet in elderly people, *Br. J. Nutr.* 108(3) (2012) 500-508. <https://doi: 10.1017/S0007114511005812>.

[233] G.M. Quintana-Navarro, J.F. Alcalá-Díaz, J. Lopez-Moreno, I. Perez-Corral, A. Leon-Acuña, J.D. Torres-Peña, O.A. Rangel-Zuñiga, A.P. Arenas de Larriva, A. Corina, A. Camargo, E.M. Yubero-Serrano, F. Rodriguez-Cantalejo, A. Garcia-Rios, R.M. Luque, J.M. Ordoñas, P. Perez-Martinez, J. Lopez-Miranda, J. Delgado-Lista, Long-term dietary adherence and changes in dietary intake in coronary patients after intervention with a Mediterranean diet or a low-fat diet: the CORDIOPREV randomized trial, *Eur. J. Nutr.* 59(5) (2020) 2099-2110. <https://doi.org/10.1007/s00394-019-02059-5>.

[234] J. Jimenez-Torres, J.F. Alcalá-Díaz, J.D. Torres-Peña, F.M. Gutierrez-Mariscal, A. Leon-Acuña, P. Gómez-Luna, C. Fernández-Gandara, G.M. Quintana-Navarro, J.C. Fernandez-Garcia, P. Perez-Martinez, J.M. Ordoñas, J. Delgado-Lista, E.M. Yubero-Serrano, J. Lopez-Miranda, Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial, *Stroke* 52(11) (2021) 3440-3449. <https://doi.org/10.1161/STROKEAHA.120.033214>.

[235] Y. Hu, F.B. Hu, J.E. Manson, 2019. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. *J. Am. Heart Assoc.* 8(19), e013543. <https://doi.org/10.1161/JAHA.119.013543>.

[236] A.S. Abdelhamid, T.J. Brown, J.S. Brainard, P. Biswas, G.C. Thorpe, H.J. Moore, K.H. Deane, C.D. Summerbell, H.V. Worthington, F. Song, L. Hooper, 2020. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst. Rev.* 3(2), CD003177. <https://doi.org/10.1002/14651858.CD003177.pub5>.

- [237] C. Skarke, N. Alamuddin, J.A. Lawson, X. Li, J.F. Ferguson, M.P. Reilly, G.A. FitzGerald, Bioactive products formed in humans from fish oils, *J. Lipid Res.* 56(9) (2015) 1808-1820. <https://doi.org/10.1194/jlr.M060392>.
- [238] J. So, D. Wu, A.H. Lichtenstein, A.K. Tai, N.R. Matthan, K.R. Maddipati, S. Lamon-Fava, EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study, *Atherosclerosis* 316 (2021) 90-98. <https://doi.org/10.1016/j.atherosclerosis.2020.11.018>.
- [239] M.S. Schaller, M. Chen, R.A. Colas, T.A. Sorrentino, A.A. Lazar, S.M. Grenon, J. Dalli, M.S. Conte, 2020. Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease. *J. Am. Heart Assoc.* 9(15), e016113. <https://doi.org/10.1161/JAHA.120.016113>.
- [240] T. Niki, T. Wakatsuki, K. Yamaguchi, Y. Taketani, H. Oeduka, K. Kusunose, T. Ise, T. Iwase, H. Yamada, T. Soeki, M. Sata, Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound, *Circ. J.* 80(2) (2016) 450-460. <https://doi.org/10.1253/circj.CJ-15-0813>.
- [241] A.L. Cawood, R. Ding, F.L. Napper, R.H. Young, J.A. Williams, M.J. Ward, O. Gudmundsen, R. Vige, S.P. Payne, S. Ye, C.P. Shearman, P.J. Gallagher, R.F. Grimble, P.C. Calder, Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability, *Atherosclerosis* 212(1) (2010) 252-259. <https://doi.org/10.1016/j.atherosclerosis.2010.05.022>.
- [242] F. Thies, J.M. Garry, P. Yaqoob, K. Rerkasem, J. Williams, C.P. Shearman, P.J. Gallagher, P.C. Calder, R.F. Grimble, Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial, *Lancet* 361(9356) (2003) 477-485. [https://doi.org/10.1016/S0140-6736\(03\)12468-3](https://doi.org/10.1016/S0140-6736(03)12468-3).
- [243] Y. Yao, H.M. Goh, J.E. Kim, The Roles of Carotenoid Consumption and Bioavailability in Cardiovascular Health, *Antioxidants (Basel)* 10(12) (2021) 1978. <https://doi.org/10.3390/antiox10121978>.
- [244] J. Huang, S.J. Weinstein, K. Yu, S. Männistö, D. Albanes, Serum Beta Carotene and Overall and Cause-Specific Mortality, *Circ. Res.* 123(12) (2018) 1339-1349. <https://doi.org/10.1161/CIRCRESAHA.118.313409>.

- [245] G. Bjelakovic, D. Nikolova, L.L. Gluud, R.G. Simonetti, C. Gluud, 2012. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst. Rev.* 2012(3), CD007176. <https://doi.org/10.1002/14651858.CD007176.pub2>.
- [246] V.A. Moyer, Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. preventive services task force recommendation statement, *Ann. Intern. Med.* 160(8) (2014) 558-564. <https://doi.org/10.7326/M14-0198>.
- [247] H.M. Cheng, G. Koutsidis, J.K. Lodge, A. Ashor, M. Siervo, J. Lara, Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis, *Atherosclerosis* 257 (2017) 100-108. <https://doi.org/10.1016/j.atherosclerosis.2017.01.009>.
- [248] Z.Y. Zou, X.R. Xu, X.M. Lin, H.B. Zhang, X. Xiao, L. Ouyang, Y.M. Huang, X. Wang, Y.Q. Liu, Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial, *Br. J. Nutr.* 111(3) (2014) 474-480. <https://doi.org/10.1017/S0007114513002730>.
- [249] M. Colmán-Martínez, M. Martínez-Huélamo, P. Valderas-Martínez, S. Arranz-Martínez, E. Almanza-Aguilera, D. Corella, R. Estruch, R.M. Lamuela-Raventós, 2017. trans-Lycopene from tomato juice attenuates inflammatory biomarkers in human plasma samples: An intervention trial. *Mol. Nutr. Food Res.* 61(11). <https://doi.org/10.1002/mnfr.201600993>.
- [250] F. Thies, L.F. Masson, A. Rudd, N. Vaughan, C. Tsang, J. Brittenden, W.G. Simpson, S. Duthie, G.W. Horgan, G. Duthie, Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial, *Am. J. Clin. Nutr.* 95(5) (2012) 1013-1022. <https://doi.org/10.3945/ajcn.111.026286>.
- [251] P.R. Gajendragadkar, A. Hubsch, K.M. Mäki-Petäjä, M. Serg, I.B. Wilkinson, J. Cheriyan, 2014. Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. *PLoS One.* 9(6), e99070. <https://doi.org/10.1371/journal.pone.0099070>.
- [252] S. Devaraj, I. Jialal, J. Rockwood, D. Zak, Effect of orange juice and beverage with phytosterols on cytokines and PAI-1 activity, *Clin. Nutr.* 30(5) (2011) 668-671. <https://doi.org/10.1016/j.clnu.2011.03.009>.
- [253] V.Z. Rocha, R.T. Ras, A.C. Gagliardi, L.C. Mangili, E.A. Trautwein, R.D. Santos, Effects of phytosterols on markers of inflammation: A systematic review and meta-analysis, *Atherosclerosis* 248 (2016) 76-83. <https://doi.org/10.1016/j.atherosclerosis.2016.01.035>
- [254] Z. Luo, Y. Liu, Z. Zhao, X. Yan, D. Wang, Q. Liu, 2020. Effects of Astragalus injection and Salvia Miltiorrhiza injection on serum inflammatory markers in patients with stable coronary heart

disease: a randomized controlled trial protocol. *Trials*. 21(1), 267. <https://doi.org/10.1186/s13063-020-4109-6>.

[255] K. Gul, A.K. Singh, R. Jabeen, *Nutraceuticals and Functional Foods: The Foods for the Future World*, *Crit. Rev. Food Sci. Nutr.* (2016) 56(16) 2617-2627. <https://doi.org/10.1080/10408398.2014.903384>.

[256] A.M. Ruiz-León, M. Lapuente, R. Estruch, R. Casas, 2019. *Clinical Advances in Immunonutrition and Atherosclerosis: A Review*. *Front. Immunol.* 10, 837. <https://doi.org/10.3389/fimmu.2019.00837>.

[257] A.F.G. Cicero, F. Fogacci, A. Colletti, *Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach*, *Food Funct.* 8(6) (2017) 2076-2088. <https://doi.org/10.1039/c7fo00178a>.

[258] B. Scolaro, H. Soo Jin Kim, I.A. de Castro, *Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention*, *Crit. Rev. Food Sci. Nutr.* 58(6) (2018) 958-971. <https://doi.org/10.1080/10408398.2016.1235546>.

Fig. 1. Different macrophage subtypes found in atherosclerotic lesion. Stimuli present in atherosclerotic lesions direct macrophage polarization towards different phenotypes characterized by specific expression and function profiles.

Fig. 2. Nutraceutical modulation of the most relevant macrophage signaling pathways and the relative beneficial effects against atheroma progression.